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Abstract 	   The gut microbiota is a complex community that consists of 1011-1012 
organisms per gram of colonic contents and over 150-fold more genes than the 
human genome. This community has evolved with its eukaryotic host to form a 
mutualistic relationship. It has been known that the microbiota is involved in the 
production of vitamins, the breakdown of dietary substances and the maturation of 
the immune system. Recent work has expanded the role of the microbiota in human 
health. The microbiota has been implicated in the regulation of fat storage and 
diseases such as ulcers, diabetes, obesity, cardiovascular disease, and 
inflammatory bowel disease (IBD). 
 The work in this dissertation focuses on the role of the microbiota in IBD, a 
disease of unknown etiology. Several factors contribute to the development of 
disease, including environmental factors, host genetics, the immune response, and 
the gut microbiota. An environmental factor that has become increasingly recognized 
as a critical component in shaping the microbiota is the use of antibiotics and the 
potential link to IBD. The research summarized in chapter 2 reveals the effects that 
antibiotics have on a limited microbiota, the altered Schaedler flora (ASF). Use of a 
limited microbiota affords the ability to monitor effects of antibiotics on the entire 
community that would be missed when using a conventional microbiota. Following 
treatment with ampicillin, mice harboring the ASF developed more severe disease in 
response to a colitic insult than did mice bearing a conventional microbiota, 
indicating a central role for the microbiota in reducing disease severity. Those 
conventional mice that received ampicillin prior to colitic insult revealed that the ASF 
	   viii	  
in a more complex community was less affected by the administration of antibiotics. 
However, conventionally-reared mice harboring a complex microbiota did exhibit low 
grade inflammation following colitic insult and eventually developed a physiological 
profile consistent with the onset of metabolic syndrome.  
 The research summarized in chapter 3, evaluated the immunomodulatory and 
anti-bacterial properties of ethanolic extracts of Prunella vulgaris and Hypericum 
gentianoides, which have the potential to be used as complementary and alternative 
treatments for gastrointestinal diseases including IBD. There is no cure for ulcerative 
colitis or Crohn’s disease, and many of the treatments have severe side effects. This 
has caused some patients to seek alternative therapies to manage their disease. In 
chapter 3, herbal therapies were administered prophylactically to mice harboring the 
ASF to assess their ability to prevent or attenuate DSS-induced colitis. The results 
revealed that one of the herbal therapies, P. vulgaris, was actually pro-inflammatory 
in the ASF mice as evidenced by the increased production of pro-inflammatory 
cytokines/chemokines. The other botanical extract, H. gentianoides, seemed to exert 
both anti-inflammatory and anti-bacterial effects in this murine model of colitis 
indicating a possible role for H. gentianoides as a therapy for IBD. 
 One of the consistent observations noted in IBD patients is that their 
microbiota is abnormal (i.e., dysbiotic) compared to healthy controls. Whether this 
change in the microbiota occurs post-inflammation, or if dysbiosis initiates the 
inflammation, is still up for debate. Summarized in chapter 4 are the results of a 
temporal study that chronologically evaluated changes in the microbiota and the 
host’s inflammatory response over the course of disease using a spontaneous 
	   ix	  
model of murine colitis. The results revealed that in this model, the mucosal 
inflammation occurs early, before the changes in the microbiota. This indicates that 
the inflammation is what drives the microbial changes seen in the diseased mice. In 
summary, studies described herein indicate that the microbiota plays a large role in 
the inflammatory processes of murine models of colitis. 
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1. An Introduction to the Microbiota  
 Antony van Leeuwenhoek’s observation of “animalcules” in the tarter of teeth 
in 1683 marked the beginning of humans trying to understand their relationship with 
microbes. Now commonly referred to as “bacteria” or the “microbiota” we share our 
inner and outer space with these single-celled organisms. They are present all 
around us-in the oceans, soil, leaves, and even air [1]. One of the microbial niches 
that has recently garnered much attention is the human body. In this niche, we share 
the table with 1014 microbial cells, which outnumber our eukaryotic cells ten to one [1, 
2]. These organisms colonize most body sites, including the skin, oral cavity, 
gastrointestinal, urogenital and respiratory tracts. Additionally, there is 150 times 
more genetic material associated with our resident bacteria when compared to our 
own DNA and comprises what is known as our body’s “second genome,” a concept 
recently reviewed by Zhu et al. [3]. In an effort to understand the role that these 
organisms have in human development, health and disease, the National Institutes 
of Health launched the “Human Microbiome Project” in 2007 in an effort to elucidate 
this host-microbe interaction [4-6].  
The role of bacteria is most obvious in the gastrointestinal tract (GIT). 
Bacteria in this niche have the ability to break down substances that otherwise could 
not be digested by GIT cells; they also produce metabolites needed by the body 
such as vitamin K (menaquinones), folate, B12, and riboflavin [7-12]. The GIT has a 
surface area the size of a tennis court and is home to 1011-1012 organisms per gram 
of colonic content [1, 13]. The predominant bacterial phyla present in the GIT include 
the Firmicutes and Bacteroidetes with low levels of Proteobacteria, Actinobacteria, 
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Fusobacteria, and Verrucomicrobia [14-16]. It has been noted that members of the 
predominant factions (the Firmicutes and Bacteroidetes) belong to only three groups, 
Bacteroides, Clostridium coccoides (cluster XIVa) and Clostridium leptum (cluster 
IV) [15, 17, 18]. There are also Archaea present in the GIT and have been found to 
belong to one phylotype, Methanobrevibacter smithii [14, 19].  
 
1. a. Initial Colonization of the Gastrointestinal Tract 
Infants are born sterile and establishment of the GI microbiota begins shortly 
thereafter. Studies in mice have revealed that the first organisms to colonize include 
lactobacilli, flavobacteria and Group N streptococci [20]. These three groups were 
found in the stomach, and small and large intestine. When the mice were 12 days of 
age, the flavobacteria disappeared from all three sites. Concurrently, there was a 
rapid increase in the presence of enterococci and slow lactose fermenting coliform 
bacilli reaching 109 bacteria per gram of tissue in the large intestine. This spike was 
transient however, and as the mice aged, a shift toward a more strict anaerobic 
population occurred in the large intestine. This ordered colonization occurs because 
aerotolerant organisms are able to colonize the GIT early in the presence of oxygen. 
Through their metabolism, they reduce the redox potential and allow for the later 
colonization by and replication of strict anaerobes [21].   
 
1. b. Impact of the Method of Delivery on Colonization 
In humans, the method of delivery impacts the initial microbiota of the infant 
[22-24]. In a study of Venezuelan women, vaginal delivery was associated with initial 
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colonization by Lactobacillus, Prevotella, Atopobium, and Sneathia spp.; in contrast 
Cesarean delivery was associated with colonization of Staphylococcus, 
Propionibacterium, and Corynebacterium spp. (organisms typically found on skin). It 
was also noted that the initial bacteria present in infants born vaginally were 
vertically transferred from the mother. This was not the case for those born via 
Cesarean. A Finnish study analyzed infant fecal samples collected between three 
days of age and six months of age to evaluate temporal colonization [23]. The 
results revealed that at three days of age, all but one infant, regardless of the 
delivery method, was colonized with aerobic bacteria. However, a higher percentage 
of vaginally delivered infants were colonized with Bifidobacterium-like (BLB) and 
Lactobacillus-like (LBB) bacteria as compared to Cesarean delivered infants. These 
differential colonization patterns were corrected by day ten for LBB and by day 30 for 
BLB. Additional characterization of the fecal microbiota revealed that at one month 
of age, infants born via Cesarean had a significant increase in Clostridium 
perfringens (25 % to 56 %); an increase not seen in vaginally delivered infants. This 
is an important observation, as C. perfringens has been thought to play a role in 
sudden infant death syndrome (SIDS) [25]. Also of note, significant differences in the 
numbers of Bacteroides fragilis were observed between the two methods of delivery 
[23]. Specifically, this bacterium was present at statistically higher numbers in 
vaginally delivered infants as compared to Cesarean delivered infants at all time 
points throughout the six months of the study. 
These differences in initial colonizers have been associated with adverse 
effects, as infants born via Cesarean are more susceptible to skin infections with 
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methicillin resistant Staphylococcus aureus (MRSA). A 2004 report indicated that 
82 % of infant MRSA cases in Chicago and 64 % in Los Angeles were delivered via 
Cesarean, all of which involved healthy, full-term infants [26]. An additional 
prospective cohort study indicated a link between Cesarean delivery and Clostridium 
difficile infection, which was further associated with the development of wheeze, 
asthma, eczema, and food allergies throughout the first seven years of life [27]. 
Consistent with these findings, a Norwegian study documented an association 
between asthma and Cesarean delivered children [28]. Although the epidemiological 
connections among Cesarean delivery, the composition of the microbiota, and 
disease are still being studied, strong evidence exists that early colonization of the 
intestines with aerobic skin microbes is associated with health risks. 
 
1. c. Impact of Feeding Method on Colonization 
Another factor affecting early colonization of the human gut is determined by 
feeding method [29]. In one study of vaginally delivered infants, the fecal microbiota 
of breast-fed compared to formula-fed infants within the first month of life was 
analyzed using fluorescence in situ hybridization (FISH) to evaluate 11 separate 
groups of organisms [29]. Bifidobacterium spp. were the most prominent organisms 
found to colonize infants fed breast milk, comprising 69 % of the bacterial population, 
with the next most prevalent group being the Bacteroides and Prevotella spp. 
making up 12 %. With respect to the fecal microbiota of formula-fed infants, the 
microbiota was actually more diverse than that found in the breast-fed babies. 
Formula-fed infants had Bifidobacterium spp. as the most predominant group; 
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however, they only comprised 32 % of the bacterial population while Bacteroides 
and Prevotella spp. comprised 29 % of the composition. Additionally, Atopbium spp. 
were found to account for 8 % of the microbiota in formula-fed infants, but comprised 
only 1 % of the community in the breast-fed infants.  
 
1. d. Microbial Changes that Occur After Weaning 
The next major shift in the microbial population occurs during weaning. In a 
study consisting of infants from five European countries, the composition of the fecal 
microbiota at four weeks post-weaning was analyzed via FISH using 10 different 
probes [30].  When considering the results from all of the infants, it was noted that 
the microbial communities consisted primarily of Bifidobacterium spp. (37 %), C. 
coccoides (14 %) and Bacteroides spp. (14 %). When samples were obtained from 
infants that were separated by geographic location, differences among the groups 
were noticeable. Infants from Spain had significantly greater populations of 
Lactobacillus spp. and fewer Bifidobacterium spp. as compared to infants from the 
UK, Sweden, Germany, and Italy. The Spanish fecal samples also had significantly 
greater presence of Bacteroides spp. and C. leptum compared to those from the UK, 
Sweden, or Italy. The numbers of C. leptum was highest in samples obtained from 
German infants. The microbiota of infants from Spain also had significantly greater 
numbers of enterobacteria when compared to those from the UK, Sweden, or 
Germany, and higher numbers of Streptococcus spp. compared to those from 
Germany. The infants with the highest numbers of Bifidobacterium spp. were from 
Sweden and the UK. Further separation of the data revealed that breast-fed infants 
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had an increased percentage of Bifidobacterium spp. while Bacteroides spp. and C. 
coccoides were reduced post-weaning. Additionally, delivery method also influenced 
the microbiota composition, with vaginally delivered infants having higher numbers 
of Bacteroides present.  
This study also reported results from infants who provided samples before (at 
six weeks of age) and four weeks after weaning [30]. Switching to solid food during 
this time caused a significant reduction in the presence of bifidobacteria, 
enterobacteria and C. difficile/C. perfringens proportions. These reductions were 
accompanied by significant increases in both C. leptum and C. coccoides clusters. 
Again, location also played a significant role in the microbial differences at weaning. 
Spanish infants had the greatest increase in both C. coccoides and C. leptum post-
weaning compared to the other four countries, while enterobacteria numbers were  
significantly decreased in the Spanish samples compared to those from the other 
countries. The samples from Spanish infants also had significant increases in 
Atopobium spp. compared to those from Sweden and Germany and Streptococcus 
spp. compared to Germany and Italy. The authors also reported significant 
decreases post-weaning in the enterobacteria present in the Italian infant samples 
as compared to samples from Sweden and the UK. As mentioned previously, 
feeding and delivery method alter the composition of the microbiota at birth; this is 
also true after weaning. Formula-fed infants had higher proportions of C. leptum in 
their feces compared to breast-fed infants post-weaning. Infants born via Cesarean 
possessed increased levels of Bacteroides spp. after weaning, whereas there was 
no change in the abundance of this group in vaginally delivered infants. Additionally, 
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Atopobium spp. decreased in vaginally delivered children but increased in Cesarean 
delivered children post-weaning [30].  
Studies describing development or maturation of the human microbiota reveal 
that as an individual ages, the microbiota shifts from predominantly facultative 
anaerobes to strict anaerobes, just as previously observed in rodents [20]. Notably, 
variations in initial colonization associated with different delivery and feeding 
methods seems to profoundly impact the microbial community post-weaning. 
Additionally, geographic location plays an important role in the initial colonization of 
the GIT. In spite of all these variables, several themes for colonization can be 
described. Initially, Bifidobacterium spp. are the primary colonizers of the infant GIT 
along with other species such as Bacteroides, Lactobacillus, Prevotella, and 
Atopobium. As the infant matures, the oxygen presence in the gut is reduced and 
the infant begins eating solid food, which promotes a transition towards the growth 
and maintenance of the anaerobes found in the C. coccoides and C. leptum clusters.  
 
1. e. The Microbiota and Gastrointestinal Homeostasis 
The commensal microbiota has a tremendous influence on the development 
and functional capabilities of the GIT of its host. Numerous studies have 
documented the effects that the microbiota has on GIT development in mice. 
Specifically, the morphology of the intestines differs significantly in animals devoid of 
microbes (i.e., germfree) compared to conventionally-reared (CONVR) mice [31]. 
The mucus layer is thinner and epithelial cells have a slower rate of turnover 
compared to those from conventional animals, primarily because of extended time in 
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the S and G1 phases of the cell cycle [32]. This can be corrected by bacterial 
colonization. In Figure 1, panel A shows intestinal tissue from germfree (GF) mice 
and panel B shows tissue from a mouse colonized with Brachyspira hyodysenteriae. 
Colonization with B. hyodysenteriae elicits the production of goblet cells and 
increases the heights of the mucosa, resembling what is seen in CONVR mice. 
 
 
 
 
 
 
 
 
In the small intestine, this change in epithelial cell transit time is doubled, 
going from 53 hours in a CONVR mouse to 115 hours in a GF mouse [33]. The most 
noticeable gross change in GF mice is the enlargement of the cecum, which can 
comprise up to 19 % of the mouse’s body weight [34]. The cecum of a GF mouse 
can assume a more normal size (4.5 % body weight) following colonization with a 
mixture of Lactobacillus spp., Group N streptococci, Bacteroides spp., enterococci 
and coliform bacilli recovered from CONVR mice [34]. As shown in Figure 2, 
monoassociation with B. hyodysenteriae also returns the cecum to a more normal 
size.   
Figure 1. Photomicrographs of cecal tissue from a germfree mouse (Panel A) and a mouse 
monoassociated with Brachyspira hyodysenteriae (Panel B). Note the changes in the 
cellularity, presence of goblet cells, and height of the mucosa in the ceca from the 
monoassociated mouse 28 days after colonization with B. hyodysenteriae.   	  
A B A B 
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Of interest, not all bacteria tested were able to return the cecum to a normal size. It 
was noted that colonizing mice with Lactobacillus spp. and Group N streptococci 
only was not sufficient to change the morphology of the cecum. However, when 
Bacteroides spp. colonized, the mice the morphology assumed a more normal size. 
Other differences between GF and CONVR mice include the consistency of the 
cecal contents, with the contents from a GF mouse being more liquid, hypotonic and 
alkaline than in a CONVR mouse [35]. Additionally, GI transit time is slower in GF 
mice, which are also prone to vitamin deficiency due to a lack of bacterial 
metabolism [36-38]. In GF rats, monoassociation with either a rat-derived 
Escherichia coli strain or a sarcina-like micrococcus was able to reverse the vitamin 
K deficiency. Research identifying the response to Salmonella Typhimurium 
challenge indicated that there was a 50-fold greater translocation of bacteria to the 
mesenteric lymph node, and organisms were present in the blood of GF mice, 
something not seen in CONVR mice [37]. This phenomenon occurred due to the 
Figure 2.  Physical and 
morphological changes associated 
with microbial colonization. Shown 
here are ceca from a germfree 
mouse (left), monoassociated 
mouse (center), and conventional 
microbiota mouse (right). Note the 
increased size of the cecum from 
the GF mouse. The distal end of the 
cecum (appendix) of the 
monoassociated mouse has begun 
to undergo morphological changes, 
including the development of a 
lymphoid tissue known as a cecal 
tonsil.  	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decreased transit time in the small intestine of GF mice, thereby allowing the 
Salmonella to multiply in the host and translocate to other tissue sites. 
 
1. f. Effect of Bacterial Colonization on Immune Development  
In addition to its importance in maintaining gut homeostasis, the GI microbiota 
is also critical for normal priming and development of the immune system [39-41]. 
GF mice have reduced numbers of immune cells in the lamina propria and have 
smaller Peyer’s patches compared to CONVR mice. They also have a diminished 
capacity for antibody production, fewer plasma cells, smaller mesenteric lymph 
nodes, and reduced numbers of germinal centers compared to CONVR mice [39]. 
However, this underdeveloped immune system is fully capable of mounting a 
response comparable to that of a CONVR mouse when stimulated with bacterial 
antigen or protein [40, 41]. Macrophages from CONVR mice process antigen faster 
than those from GF mice, likely because the continued exposure of CONVR 
macrophages to bacterial antigen allows them to be “primed” for antigen degradation, 
a phenomenon that does not occur in GF mice [41]. The presence of bacteria in the 
GIT promotes decreased immunoreactivity towards commensal organisms. The 
barrier between the gut microbiota and the underlying gastrointestinal-associated 
lymphoid tissue consists of a single layer of epithelial cells covered by two layers of 
mucus [42, 43]. The inner layer of mucus is approximately 100 µm thick while the 
outer layer is approximately 700 µm in the rat colon [43]. The inner layer is firmly 
attached to the epithelial cells and devoid of bacteria, while the outer layer is “loose” 
and contains commensal organisms [44]. The major constituent of these layers is a 
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protein known as Muc2 [42]. The importance of Muc2 has been highlighted by the 
development of Muc2-/- mice. These mice fail to gain weight, have diarrhea by seven 
weeks of age, occult blood present in their feces by eight weeks of age, and the 
majority had gross bleeding and reversible rectal prolapse by nine weeks of age [45]. 
These mice also developed microscopic evidence of colitis as early as five weeks of 
age. 
Underneath the mucus layers lie the intestinal epithelial cells, which are held 
together by tight junction proteins such as occludins, claudins, and junctional 
adhesion molecules [46]. These proteins seal the paracellular junction between the 
cells and regulate the entry of nutrients, ions and water. They also act as a barrier 
against bacterial entry. Loss of epithelial barrier function promotes a break in 
immunological tolerance and facilitates immunoreactivity towards the normal 
commensal microbiota (Figure 3). This phenomenon has been demonstrated in 
mouse studies employing 2,4,6 trinitrobenzensulfonic acid (TNBS), a chemical that 
disrupts the epithelial barrier to allow translocation of bacteria, resulting in the 
induction of both innate inflammatory responses and antigen-specific immune 
responses [47]. Subsequent to the loss of epithelial barrier function, these mice 
develop severe gastrointestinal inflammation, which can be ameliorated by 
pretreating with antibiotics to reduce the microbial load [47]. 
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The role of the commensal bacteria in regulating the immune response was 
elegantly demonstrated in a study by Wlodarska et al. [48]. Mice administered 
metronidazole were more susceptible to subsequent infection with the pathogen, 
Citrobacter rodentium. Metronidazole-treated mice had increased submucosal 
edema, ulcerations, mucosal hyperplasia and decreased numbers of goblet cells. 
The authors also noted enhanced expression of IL-25 and Reg3γ mRNA and an 
increased presence of NK cells and macrophages in the lamina propria of these 
mice, indicating an increase in microbial stimulation. The inner mucous layer of 
metronidazole-treated mice was significantly thinner and mRNA expression of genes 
encoding for the goblet-cell specific proteins Muc2, TFF3, and RelmB was also 
decreased in these mice [49, 50]. The thinning of the inner mucous layer following 
B
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Figure 3 Panel A shows normal mucosal homeostasis. The epithelial cells provide a barrier 
between the commensal bacteria and the underlying immune cells. Panel B depicts acute 
inflammation. The epithelial cell barrier has been breached, allowing bacteria to be readily 
detected by the immune system and promote a pro-inflammatory immune response. 
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metronidazole treatment allowed for C. rodentium to closely associate with the 
epithelium and promote production of the pro-inflammatory cytokines and 
chemokines TNF-α, IFN-γ, and MCP-1. This study highlights the contribution of the 
commensal microbiota in the production of the mucus barrier and subsequently in 
maintaining mucosal homeostasis [48]. 
It has also been noted that specific members of the resident microbiota are 
able to elicit specific immune functions. Colonization with Bacteroides fragilis 
expressing polysaccharide A (PSA) suppressed development of T helper 17 (Th17) 
CD4+ T cells by promoting the development of Foxp3+ T regulatory (Treg) CD4+ T 
cells and inducing IL-10 expression via TLR2 signaling [51]. Additional studies have 
demonstrated that purified PSA is sufficient to expand the numbers of Foxp3+ Treg 
cells [52]. B. fragilis inhabits colonic crypts. This niche puts the organism in close 
contact with the immune system but its production of PSA ensures that no 
inflammatory response is induced. Both prophylactic and therapeutic treatment of 
mice with PSA ameliorate TNBS-induced colitis in mice [52]. More recently, work 
from Atarashi et al., elegantly demonstrated a role for indigenous Clostridium 
species in the induction of colonic Treg cells [53]. Colonization of GF mice with a 
cocktail of 46 Clostridium strains enriched for clusters IV and XIVa promoted TGF-β 
production from intestinal epithelial cells and increased the number of Foxp3+ Treg 
cells in the colon. Furthermore, inoculation of young CONVR mice with Clostridium 
species facilitated resistance to both dextran sodium sulfate (DSS)- and oxazolone-
induced colitis as well as increased systemic Immunoglobuin E (IgE) production as 
adults. 
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The segmented filamentous bacteria (SFB) is another microorganism of 
interest that has been implicated in the induction of Th17 responses [54]. Ivanov et al. 
found that C57BL/6 mice purchased from the Jackson Laboratory had significantly 
less IL-17-producing CD4+ T cells in the small intestine compared to those from 
Taconic Farms. This discrepancy could be corrected via gavage of the Jackson mice 
with contents from the small intestines of the Taconic mice. Using a 16S ribosomal 
RNA PhyloChip analysis, SFB were identified in the microbiota of mice from Taconic 
Farms but not in those from the Jackson Laboratory. Monoassociation of mice with 
SFB induced the production of Th17 cells and up-regulated genes encoding 
antimicrobial peptides and serum amyloid A (SAA). SAA co-cultured with naive CD4+ 
T cells and lamina propria derived dendritic cells induced Th17 cell differentiation in 
vitro. The authors concluded that SFB, which tightly adheres to and imbeds itself 
among the microvilli on the epithelial cell surface, induces the production of SAA by 
intestinal epithelial cells. In turn, the SAA acts on lamina propria dendritic cells to 
stimulate the induction of Th17 cells. Colonization with SFB protects against C. 
rodentium infection. Th17 cytokines such as IL-22 likely stimulate intestinal epithelial 
cells to secrete antimicrobial peptides to limit the growth of the pathogen and its 
infiltration into the colonic wall [54].  
 
1. g. Effect of Bacterial Colonization on Other Aspects of the Body  
In addition to promoting immune maturation, the commensal microbiota also 
helps to regulate fat storage. GF mice eat 29 % more food than conventional mice 
yet have 42 % less body fat and a decreased metabolic rate [55]. Colonization of GF 
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mice with cecal contents from conventional mice for 14 days caused a 57 % 
increase in total body fat with a concomitant 27 % reduction in food intake. These 
“conventionalized” mice also had increases in leptin, fasting glucose, and insulin 
levels compared to GF mice; they also developed insulin resistance. Levels of 
mRNAs specific for transcription factors SREBP-1 and ChREBP were also elevated 
leading to increased production of lipogenic enzymes. Fat formation is aided by the 
regulator lipoprotein lipase (LPL) and is inhibited by the fiaf gene product whose 
expression is suppressed in microbiota-bearing conventional mice. The authors 
suggest that the bacteria in the gut breakdown dietary polysaccharide into 
monosaccharaides that are then transported to the liver to activate lipogenic 
enzymes. This process promotes fat formation in the peripheral tissues due to the 
suppression of fiaf. In addition to the production of white adipose tissue, the 
microbiota may also play a role in eye health [56]. A recent study revealed 
differences in the lipid profiles in the lens and retinas of GF mice as compared to 
CONVR mice. The CONVR mice had reduced concentrations of multiple 
phosphatidylcholines and an overall reduced presence of phospholipids in the lens. 
The authors postulate these changes may be due to the increased exposure of the 
CONVR mice to more oxidative stress than their GF counterparts [56]. Together, 
these studies help us realize the effects that the gut microbiota may have on host 
systems that, at the surface, seem to have limited or no connection to the GIT. 
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1. h. Bacterial Production of Short Chain Fatty Acids 
Another health benefit that the microbiota provides its host revolves around 
the production of short-chain fatty acids (SCFA) such as acetate, propionate, and 
butyrate as end products of anaerobic fermentation [57]. These SCFA 
(predominantly butyrate) can be utilized as energy sources by eukaryotic cells. 
Members of the Clostridium clusters IV (e.g., Faecalibacterium prausnitzii) and XIVa 
(e.g., Roseburia spp. and Eubacterium rectale) are the primary butyrate producers in 
the GIT, and they comprise approximately 2-15 % of the total gut microbiota [14, 58-
61]. Butyrate, a four-carbon fatty acid, is produced by bacteria via one of two 
metabolic pathways. The first pathway utilizes the enzymes phosphotransbutyrylase 
and butyrate kinase to form butyrate from butyryl-CoA to yield one ATP per one 
molecule of butyrate produced [62, 63]. The second pathway, which is utilized by 
most organisms in the gut, uses butyryl-CoA acetate CoA transferase to form 
butyrate and acetyl-CoA from butyryl-CoA [64, 65].   
 Once produced, butyrate has multiple effects on gut health. A primary use is 
as a preferred energy source for colonocytes, and the mechanisms by which 
butyrate is utilized in the GIT is summarized in Figure 4 [66-69].  Two biomarkers of 
energy homeostasis, ATP and NADH/NAD+ levels, are both significantly reduced in 
only the colonic tissues of GF mice as compared to CONVR mice [70]. This 
observation indicates that GF mice have a reduction in TCA cycle activity, and 
subsequently less ATP is generated for cellular energy.  
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Figure 4. Microbial regulation of colonocyte metabolism.  Schematic depicting 
how dietary fiber is fermented by microbes into butyrate in the lumen of the colon, 
which is then transported into the colonocyte. In the colonocyte, butyrate 
promotes oxidative metabolism and inhibits autophagy. Based on transcriptome 
and proteome experiments, enzymes regulated by microbes are shown in boxes. 
In all cases, boxed enzymes that function in β-oxidation and the TCA cycle are 
downregulated in GF colonocytes, revealing that microbes positively regulate their 
expression. Diminished ATP results in phosphorylation of AMPK and p27, which 
culminates in autophagy. (Cell Metab. 2011 May 4;13(5):517-5)  Reprinted with 
permission from the publisher license number 2977121495018  
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Moreover, this reduction in ATP was correlated with increased signs of energetic 
stress in colonocytes, including increased expression of 5’-adenosine 
monophosphate-activated protein kinase (AMPK). Consistent with previous reports 
describing a role for AMPK in inducing autophagy [71], GF coloncytes also 
expressed elevated levels of the autophagosome marker LC3-11. Transmission 
election microscopic analysis revealed that significantly more GF colonocytes were 
undergoing autophagy than colonocytes from CONVR mice. Colonizing GF mice 
with a conventional microbiota reversed these effects, as did incubation of isolated 
colonocytes with butyrate. Additional experiments employing the fatty-acid oxidation 
blocker, etomoxir, demonstrated that colonocytes consume butyrate as an energy 
source and not as a histone deacetylase (HDAC) inhibitor, another known function of 
butyrate [72, 73]. 
Butyrate functions as an HDAC inhibitor by blocking cellular deacetylase 
activity and allowing histone acetylation [72, 73]. Histone modification causes 
changes in cellular gene expression patterns; compounds and molecules that can 
elicit these modifications are being studied as potential anti-cancer therapeutics [74]. 
A comparative study of gene expression patterns in HT-29 cells (a colon carcinoma-
derived cell line) treated with either butyrate or trichostain A (a known HDAC 
inhibitor) revealed that both substances had similar effects on gene expression [75]. 
Upregulated genes (21 total) were found to regulate the cell cycle, signal 
transduction, DNA repair and genome transcription. Only two genes were down-
regulated—lactoferrin δ and MAPKAP kinase. It is also important to note that both 
butyrate and trichostain A inhibited the growth of HT-29 cells by creating an arrest in 
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the G1 phase of the cell cycle [76]. Butyrate may also down-regulate pro-
inflammatory responses via its HDAC activity, as incubation of butyrate with inflamed 
biopsy samples or LPS-induced peripheral blood mononuclear cells (PBMCs) 
reduced the mRNA expression of IL-6, TNF-α, TNF-β, and IL-1β Additionally, in 
murine studies of TNBS- and DSS-induced colitis, and in ulcerative colitis (UC) 
patients, administration of butyrate enemas ameliorates disease activity via NFkΒ 
inhibition [77-79]. Butyrate decreases both COX-2 and PGE2 expression in HT-29 
cells stimulated with TNF-α [80].  
 The information presented in this section clearly defines a central role for the 
gut microbiota in many physiological processes; the microbiota has a tremendous 
impact on the host’s health status. Causal links likely exist between the methods by 
which infants are delivered, their gut microbial colonization patterns and subsequent 
health concerns, including asthma, eczema and food allergies. Associations 
between gut bacterial communities and obesity, diabetes and cardiovascular 
disease have also been documented [81-83]. A significant body of literature also 
links changes in the composition of the gut microbiota with inflammatory bowel 
diseases (IBD), which is discussed in detail in the following section [84-89]. 
 
2. Introduction to Inflammatory Bowel Disease  
In 1932, three physicians, Burrill Crohn, Leon Ginzburg, and Gordon 
Oppenheimer described a disease of unknown etiology in the terminal ileum of 
young adults [90]. The disease was characterized as being similar to UC (fever, 
diarrhea and weight loss) and having ulcerations of the mucosa that would 
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eventually lead to stenosis of the lumen and formation of multiple fistulas. Eventually, 
surgical intervention was used to resect the affected portion of the intestinal tract 
and patients recovered with little signs of the disease persisting. In their 1932 report, 
Crohn and colleagues discuss observations from other physicians regarding 
observations of granulomas in the small and large intestine of unknown etiology 
being classified under the umbrella term “benign granulomas.” Still today Crohn’s 
disease (CD) and UC are both included under the umbrella term “inflammatory 
bowel disease.” Crohn and colleagues described the disease as beginning at the 
ileocecal junction with lesions separated by normal mucosa [90]. They described 
inflammation of the submucosa and the muscularis resulting in a markedly thickened 
bowel wall. The presence of “giant cells” was also noted, which they attributed to 
vegetable matter becoming entrapped in the ulcers and becoming encapsulated 
during healing. The authors concluded that the presence of these giant cells in the 
granulomatous lesion led others to believe that the inflammation was due to an 
unusual form of tuberculosis. However, the authors could not find any evidence of 
tuberculosis in their 14 patients.  
Clinically, the patients with IBD were characterized as young adults with fever, 
diarrhea, dull abdominal pain, and vomiting; they were also weak, anemic and had 
poor appetite. Upon physical examination, the author noted five commonalties: 1) a 
mass in the right iliac region, 2) evidence of fistula formation, 3) emaciation and 
anemia, 4) approximately half of the subjects had undergone an appendectomy, and 
5) evidence of intestinal obstruction. Treatment was supportive and surgical 
resection of the affected portion of the intestinal tract was recommended; 13 of the 
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14 patients had no symptoms post-operatively. For the one patient that developed 
recurrent symptoms, it was later determined that not all of the affected intestinal 
tissue had been resected during the first surgery. 
 Eighty years after the first published article of what would become known as 
“Crohn’s disease,” there is still no cure for this disease nor do we fully understand its 
etiology. Unfortunately, the number of people being diagnosed with IBD is increasing 
yearly [91]. There is not one specific, causative agent of IBD; instead the etiology is 
thought to be multifactorial in nature, with host genetics, environmental factors, the 
induction of aberrant immune responses, and the gastrointestinal microbiota 
contributing to disease pathogenesis.  
 
2. a. Genetic Factors Affecting IBD 
 As of 2011, genome-wide meta-analyses had identified 71 susceptibility loci 
associated with CD, 47 with UC and 28 associated with both, some of which are 
shown in Figure 5 [92-95]. Here, we focus on genetic variants within specific genes 
involved in mediating host responses to microbial components 
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2. a. I. Nod2 
One of the first candidate genes linked to IBD susceptibility was Nod2. 
Located on chromosome 16, the defective allele affects the activation of the 
transcription factor NF-κΒ NOD2 is expressed in antigen-presenting cells, 
macrophages, lymphocytes, ileal Paneth cells, and intestinal epithelial cells and 
functions as an intracellular microbial recognition molecule [96-100]. NOD2 senses 
muramyl dipeptide (MDP), a minimally bioactive motif of peptidoglycan from both 
Gram-negative and Gram-positive bacteria. Once activated by its ligand, NOD2 
undergoes a conformational change to expose its CARD domains and recruits the 
kinase RIP2 to the complex. RIP2 associates with NOD2 via homophillic CARD-
Inflammatory bowel disease susceptibility loci. 
Lees C W et al. Gut 2011;60:1739-1753 
Figure 5 Inflammatory bowel disease susceptibility loci. The loci (depicted by 
lead gene name) attaining genome wide significance (p < 5x10-8) are shown for 
Crohn’s disease (CD, red), ulcerative colitis (UC, blue) and IBD (black where p < 
5x10-8 in CD and UC; red were p < 5x10-8 in CD and p < 5x10-4 in UC; blue where 
p < 5x10-8 in UC and p < 5x10-4 in CD. Reprinted with permission from the 
publisher license number: 2977121069437 
	   24	  
CARD interactions [97]. This process leads to the activation of IKK and the 
subsequent degradation of IκΒ and ultimately results in the translocation of NF-κΒ to 
the nucleus [96, 101].  
Petnicki-Ocwieja et al. demonstrated that MDP stimulation of ileal crypts 
induced bactericidal secretions capable of killing E. coli [102]. Moreover, the same 
authors showed that NOD2 was required for the bactericidal activity of crypt 
secretions of the terminal ileum. The composition of the ileal microbiota of the 
NOD2-/- mice was significantly altered in comparison to their WT counterparts. 
Specifically, NOD2-/- mice had increased numbers of Firmicutes, specifically Bacillus 
species and Bacteroides species. Wild-type mice were able to clear an infection of 
Helicobacter hepaticus, an opportunistic mouse pathogen, within seven days while 
NOD2-/- mice remained colonized with H. hepaticus for at least 14 days post-
infection [102]. Also of note, the presence of a gut microbiota was required for the 
expression of NOD2. GF mice possessed decreased levels of NOD2—a phenotype 
that could be reversed following monoassociation with either Gram-negative or 
Gram-positive organisms. Together, these results outline a reciprocal regulatory 
relationship between NOD2 expression and the gut microbiota. 
 
2. a. II. ATG16L1 
Another gene implicated in the pathogenesis of IBD that regulates cellular 
autophagy and is known as ATG16L1 [95, 103]. ]. Autophagy is a process utilized by 
cells to recycle cellular components. This process may also be utilized by cells as a 
non-apoptotic method of programmed cell death [104]. ATG16L1 is expressed by 
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CD4+ and CD8+ T cells, CD19+ B cells, epithelial cells, and macrophages [105, 106]. 
Studies by Caldwell et al. utilizing mice engineered to express low or hypomorphic 
levels of ATG16L1 revealed that this gene is indeed an autophagy-related protein. 
Elevated levels of cytosolic proteins normally degraded by a rapamycin-induced 
degradation pathway were found in the cells of the ATG16L1 hypomorphic 
(ATG16L1HM) mice [95]. Additionally, cells from ATG16L1HM mice possessed fewer 
autophagosomes following rapamycin treatment or nutrient deprivation. The small 
intestines and colons of ATG16L1HM mice had no morphological defects in crypt 
height or villus length, but did possess abnormalities in their Paneth cells. 
Specifically, lysozyme within Paneth cells was either depleted/absent or diffuse, 
which is in contrast to the normal and orderly packaging of lysozyme within granules. 
Decreased levels of lysozyme were also observed in the ileal mucus layer of 
ATG16L1HM mice. However, intact granules were observed in the crypt lumen, 
indicating a potential role of ATG16L1 in the maintenance of the Paneth cell granule 
exocytosis pathway. The authors observed no differences between WT and 
ATG16L1HM mice in terms of resistance to a challenge with Listeria monocytogenes. 
However, others have reported a reduction in intracellular bacteria targeted to 
autophagic vacuoles following in vitro infections of HeLa or Caco-2 cells with S. 
typhimurium in conjunction with siRNA to reduce the expression of ATG16L1 [105, 
107]. Additional work by Caldwell et al. revealed that 100 % of ileocolic resection 
specimens obtained from humans with the ATG16L1 risk allele had abnormal 
Paneth cells that looked similar to those found in the ATG16L1HM mice [95].  
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Using siRNA to reduce ATG16L1 expression in THP-1 macrophages revealed 
an increase in intracellular adherent and invasive E. coli (AIEC) as compared to 
normal THP-1 infected macrophages [106]. AIEC promote enhanced production of 
TNF-α and IL-6 from macrophages. Silencing of ATG16L1 expression resulted in 
significant increases in both cytokines. The authors postulate that bacterial 
clearance is less efficient in individuals with the risk alleles for ATG16L1. When 
AIEC are present, this reduction in bacterial clearance likely leads to increased 
production of pro-inflammatory cytokines, which could tip the immune balance to an 
inflammatory state. Thus, it appears that the presence of bacterial provocateurs (e.g., 
AIEC) in the microbiota increases the risk of developing IBD in individuals 
possessing polymorphisms in genes such as ATG16L or NOD2. 
 
2. b. The Immune Response and IBD  
The mucosal immune system is charged with the monumental task of 
balancing responsiveness and tolerance to a tremendous number of environmental 
antigens, including those from food and bacteria. Although the exact cause of IBD 
remains elusive, significant evidence supports the hypothesis that GIT inflammation 
is initiated and perpetuated by a dysregulated immune response directed against the 
gut microbiota resulting in deleterious responses in genetically susceptible 
individuals following an environmental trigger. The host with a genetic predisposition 
for IBD may possess defects in epithelial permeability and/or altered regulation (i.e., 
NOD2 deficiency) of commensal bacteria. Potential environmental triggers may 
include smoking, certain medications, or a gastrointestinal illness that induces a 
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break in homeostasis. Regardless of the specific genetic or environmental trigger, 
what ensues is an exaggerated, inappropriate mucosal immune response 
characterized by chronic activation of T cells and the production of cytokines and 
other inflammatory mediators. 
The success of cytokine-targeted immunotherapies for a subset of IBD 
patients supports the idea that these chemical messengers of the immune system 
play an important role in disease pathogenesis. However, the nature of the immune 
phenotypes observed in CD and UC patients do differ [108]. The immune response 
of CD is typically associated with a T helper 1 (Th1) phenotype while UC is 
characterized by a T helper 2 (Th2) phenotype [108]. Isolated lamina propria (LP) 
CD4+ T cells from CD patients produce IFN-γ when stimulated via the CD2/CD28 
pathway; in contrast, LP CD4+ T cells from UC patients secreted mostly IL-5 [109]. 
Another cytokine with a strong link to CD is IL-12 [110]. Messenger RNA for IL-
12p40 in LP mononuclear cells (LPMC) was found in 85 % of CD patients, a 
percentage significantly higher than that found in healthy and UC GIT tissue 
samples. Similarly, IL-12p35 mRNA was detectable in the LPMC of 92 % of CD 
patients; expression was again significantly higher than for healthy and UC patients. 
Elevated levels of IL-12 were also detectable in the serum of CD patients [110], and 
this potent Th1-promoting cytokine is able to induce IFN-γ production from LP 
lymphocytes (LPL) isolated from CD patients [111]. Additionally, studies employing a 
murine model of TNBS-induced colitis have revealed that administration of anti-IL-12 
antibodies ameliorates disease severity, presumably by decreasing IFN-γ secretion 
from LP CD4+ T cells[112]. 
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 In UC, production of the cytokines IL-5 and IL-13 appears to mediate the 
disease process. Using LPMC from IBD patients, those with UC produced increased 
amounts of IL-13 and IL-5 upon in vitro restimulation as compared to LPMCs 
recovered from CD patients or healthy individuals [113]. Levels of IFN-γ produced by 
LPMC from UC patients were similar to those produced by cells from healthy 
controls. The authors specifically identified CD4+ CD161+ NK T cells as the primary 
source of IL-13 in UC patients, as these cells produced 30-fold more IL-13 than NK 
T cells from CD patients following in vitro restimulation. 
More recent work has implicated the T helper 17 (Th17) lineage of CD4+ T 
cells in the chronic inflammation observed in IBD [114, 115]. The development of 
Th17 T cells is dependent upon the presence of both IL-6 and TGF-β [115]. Colonic 
biopsies from UC and CD patients expressed higher levels of IL-17A mRNA as 
compared to those from healthy controls [115-117]. Immunohistochemical analysis 
of these tissues identified increased numbers of IL-17A+ cells in both the LP and the 
epithelium of UC and CD patients as compared to controls [116]. Additional work 
also noted the presence of IL-17+ cells in patients with active IBD [114]. However, 
the IL-17+ cells were found predominantly in the LP of UC patients but in the 
submucosa and muscularis propria of CD patients [114]. These different locations of 
IL-17+ cells complements prior observations that CD lesions often present as 
transmural while those in UC are superficial. Also of note, a comparison of biopsies 
from patients with active versus inactive disease revealed that IL-17+ cells were only 
increased in numbers during active disease. The authors also determined that both 
T cells and monocytes/macrophages are a source of IL-17, and that IBD patients 
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have elevated levels of IL-17 in their sera as compared to undetectable levels of this 
cytokine in the sera of healthy individuals. 
The maintenance of Th17 T cells requires the presence of IL-23 [115]. Of 
interest, a gene variant significantly associated with CD encodes for the IL-23R, 
which, along with IL-12Rβ1, comprises the IL-23 receptor complex [118, 119]. This 
receptor complex interacts with IL-23 (a heterodimer of IL-12p40 and IL-23p19) to 
direct the production of a TH17 immune response [120-122]. Anti-IL-23 antibodies 
have been shown to both prevent and ameliorate established disease in a T-cell 
transfer model of murine colitis [123]. Studies of human tissues demonstrate that IL-
23R expression is upregulated not only on IL-17 producing CD4+ T cells, but also on 
IFN-γ+ T cells in both UC and CD patients [115]. Stimulation of LP CD4+ T cells from 
UC patients with IL-23 significantly increased IL-17 production; in contrast, IL-23 
stimulation of LP CD4+ T cells from CD patients resulted in enhanced IFN-γ 
secretion [115]. In addition to promoting the production of TH17 cells, IL-23 also 
inhibits the production of Foxp3+ Treg cells [124] and suppresses production of IL-10, 
a key regulatory cytokine [125]. 
Another hallmark of the immune response observed in IBD is the production 
of IgG antibodies against the normal commensal microbiota [126]. Increased 
intestinal permeability, be it through genetic predisposition or environmental trigger, 
promotes enhanced immunoreactivity to bacterial antigens. The mucosal 
immunoglobulin profile of healthy adults consists predominantly of IgA with only a 
small amount of IgG. In contrast, patients with active IBD presented with significantly 
higher amounts of IgG in their mucosal secretions, but with no difference in amounts 
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of IgA, as compared to controls. IgG antibodies present in IBD patients were found 
to bind to non-pathogenic bacterial commensals, including E. coli, B. fragilis, C. 
perfringens, Klebsiella aerogenes, and Enterobacter faecalis. Patients with CD had 
significantly higher titers than UC patients, while antibody titers to these commensal 
bacteria were at or below the limit of detection in serum samples from healthy 
controls. Notable differences were also observed in the isotypes of IgG present in 
UC versus CD patients. Specifically, UC patients produced predominantly IgG1 and 
IgG3 antibodies to bacterial antigens, while IgG1, IgG2, IgG3 were the predominant 
isotypes reacting with the bacterial antigens in serum samples from CD patients 
[126]. Conversely, other reports have described an increase in IgG1 antibodies in UC 
patients and an increased in IgG2 antibodies in CD patients [127-130]. Additional 
analyses have determined that IgG antibodies in CD patients are primarily directed 
toward bacterial cytoplasmic proteins rather than membrane associated proteins 
[126]. Despite the presence of many types of antibodies in both the mucosal 
secretions and serum of IBD patients, no direct evidence for their involvement in IBD 
immunopathogenesis has been reported, indicating that they may simply be a 
marker for immune responsiveness and/or dysregulation [131]. 
 
2. c. Environmental Factors Affecting IBD   
Although there are allelic differences in many people with IBD, genetics alone 
cannot completely account for the development of IBD nor for the increase in the 
incidence of IBD worldwide. Studies of monozygotic twins best highlight this concept, 
as there are disease concordance rates of only 50 % for CD and only 20 % for UC 
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[132, 133]. Of interest, a British study assessing discordant twins with CD found an 
association with mumps infection, smoking, and oral contraceptive usage with the 
development of CD [134]. Additionally, the twin(s) with CD had suffered both a 
medical illness, more episodes of gastroenteritis, and spent more time with animals. 
Smoking is one confounding environmental factor that is of special interest, because 
it appears to have a protective effect against UC, but increases the risk of CD [132, 
135-137]. Another factor that appears to protect against UC is an appendectomy; its 
effect on CD is not as evident [138-140]. The equivalent procedure performed in 
mice ameliorates colitis in both chemically-induced and genetically-engineered 
murine colitis models [141, 142]. Modest associations between oral contraceptive 
use and IBD have been documented, while others have found breast-feeding to be 
protective against both UC and CD [143, 144]. A meta-analysis performed by 
investigators in New Zealand identified other potential environmental factors, 
including being an only child, using antibiotics prior to and during adolescence (four 
or more courses in year), and having a pet in the house during childhood [145]. IBD 
also tends to occur in extended families as first and second degree relatives of IBD 
patients reported the occurrence of disease with a significantly higher frequency 
than the general population [146]. These findings strengthen the interconnection 
between genetics, environmental factors, and the incidence of IBD. 
 
2. c. I. Antibiotic Usage  
Antibiotics are used in the treatment of IBD to reduce microbial load and 
dampen inflammatory immune responses. However, their use prior to disease 
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diagnosis is now being identified as a risk factor for developing IBD. A Danish study 
of IBD patients revealed that antibiotic users were 1.84 times more likely to develop 
IBD, which correlated with a 12 % increase in disease risk for each course of 
antibiotics taken [147]. Further analysis revealed that antibiotic users were 3.41 
times more likely to develop CD than UC, which correlated to an increased risk of 
18 % per course of antibiotics used. Specifically, use of penicillin V and extended 
spectrum penicillins were associated with the greatest disease risks. A Swedish 
study focused on the use of antibiotics from birth to age 5, a time when the 
microbiota and immune response are still developing and/or maturing, as a risk 
factor for IBD. They reported an association between a diagnosis of pneumonia, 
subsequent antibiotic treatment and the onset of both pediatric and adult CD [148]. 
Another study by Card et al. revealed a statistically significant association between 
antibiotic usage 2 to 5 years prior to diagnosis of CD in patients from the United 
Kingdom [149]. This finding was confirmed in a Canadian study, which reported that 
the more antibiotics taken within 2 to 5 years of diagnosis, the greater the risk of 
developing IBD [150]. That same study found that disease risk was weakly 
associated with penicillin use and greatly associated with metronidazole use, which 
was prescribed primarily for “non-infectious gastroenteritis.” This association with 
antibiotic usage may be explained by the failure of the gut microbiota to reestablish 
its normal community structure and function following a course of antibiotics [151]. 
This dysbiosis or alteration in the microbiota may be a predisposing factor to the 
onset of IBD in a susceptible individual. 
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2. c. II. MAP 
Another potential environmental risk factor for the development of IBD is a 
chronic infection in the GIT. To date, no one particular organism has been found to 
be the causative agent of IBD. Although many microbial pathogens have been 
implicated as causative, only two have been significantly investigated. The first 
organism hypothesized to be associated with IBD was Mycobacterium avium subsp. 
paratuberculosis, which causes Johne’s disease in cattle [152, 153]. The 
granulomatous inflammation observed in CD patients led many early researchers to 
investigate various types of Mycobacterium spp. in CD pathogenesis but 
confirmation was never achieved (reviewed in [154]). The first report of M. 
paratuberculosis-like organisms isolated from patients with CD in was published 
1984. Now known as M. avium subsp. paratuberculosis (MAP), there is still no 
consensus as to whether or not it plays a role in the onset of IBD in a subset of 
genetically susceptible patients [155]. Using PCR to amplify the DNA insertion 
element, IS900, (which is specific to MAP) in biopsy sections, Sanderson et al., 
reported that 65 % of adult CD patients examined were PCR positive [156]. 
Dell’Isola et al. reported that 72 % of pediatric CD patients examined were PCR 
positive for MAP [156, 157]. While many studies have reported MAP DNA in CD 
patients, just as many have found MAP DNA in samples from healthy individuals and 
UC patients [156-162]. Moreover, multiple studies have failed to detect MAP-specific 
DNA in any CD patient sample examined [163-169]. The ability to detect MAP in 
some tissue samples and not others may be due, in part, to the organism’s 
fastidiousness, slow growth, and/or the presence of PCR inhibitors in fecal/tissue 
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samples that inhibit the detection of IS900. Serological evidence also fails to provide 
definitive answers for the involvement of MAP in the pathogenesis of IBD. Some 
studies assessing the presence of serum antibody titers against MAP-derived 
antigens have found an association with IBD [170-176] while others have not [177-
182]. More recent work has identified a possible link between variants in the Nod2 
gene and the presence of MAP [183]. In this study, 68 % of CD patients were 
positive for MAP DNA based on PCR analysis as compared to 21 % of the healthy 
individuals. Fifty-one percent of the CD patients were carriers of NOD2 
polymorphisms as compared to 21 % of healthy individuals, and 74 % of the CD 
patients possessing one of the mutated NOD2 alleles were positive for MAP DNA. 
Even with of all of the data collected, the debate continues as to whether or not MAP 
plays an important role in the pathogenesis of CD [184, 185].  
 
2. c. III. Adherent-invasive Escherichia coli 
 Another organism implicated in IBD pathogenesis is adherent-invasive 
Escherichia coli (AIEC). First described in 1998, AIEC isolates were recovered from 
the ileal mucosa of CD patients [186]. These organisms are found in higher numbers 
in CD patients (22 %) as compared to healthy controls (6 %) [187]. They adhere to 
Caco-2 cells and do not posses any of the virulence genes associated with known E. 
coli pathotypes (e.g., ETEC, EHEC) [186]. A characterization of expressed adhesins 
in AIEC strains revealed the Pap and Sfa adhesin as colonization factors, both of 
which are found in uropathogenic E. coli; however, many of the AIEC strains did not 
possess any of the known adhesins associated with pathogenic E. coli (e.g., intimin). 
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Some of the cytotoxic strains expressed the hly operon, and it was subsequently 
demonstrated that these organisms produce a type 1 pilus similar in sequence to 
that of an E. coli strain associated with avian colisepticemia and meningitis [188]. 
Type 1 pili are involved in both the adherence and internalization of E. coli into host 
cells. They specifically bind to the CEACAM6 receptor on ileal enterocytes, which is 
expressed at significantly higher levels in the inflamed small intestinal epithelium of 
CD patients as compared to healthy controls [189].  
 Further research involving the prototypic AIEC strain, LF82, has shown that 
these pathogenic E. coli strains invade epithelial cells via engagement of actin 
microtubules and microfilaments and replicate intracellularly even without 
possessing any of the known invasive determinants found in other invasive E. coli 
strains [190]. AIEC strains are able to survive and replicate within macrophages 
without causing apoptosis and induce production of the pro-inflammatory cytokine 
TNF-α [191]. LF82 is also able to induce in vitro aggregation of peripheral blood 
mononuclear cells (PBMCs), an observation reminiscent of the granulomas 
observed in the colonic tissue of CD patients [192]. 
 In addition to being detected with increased frequency in human IBD patients, 
AIEC strains have also been isolated from Boxer dogs with granulomatous colitis. 
These E. coli isolates were found to have the same adherent-invasive phenotype as 
human AIEC strains. The Boxer dog isolates were also of the same phylotype (B2 
and D) and possessed similar virulence gene profiles as LF82. In contrast to the 
human AIEC strains, however, the canine AIEC strains were only isolated from 
diseased dogs and not healthy controls. Simpson and colleagues also demonstrated 
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that remission of colitis in Boxer dogs could be achieved by treatment with 
enrofloxacin, the use of which resulted in the eradication of AIEC E. coli [193]. 
 
2. d. The Microbiota and IBD  
Although no single organism has been implicated in the induction of IBD, a 
preponderance of studies indicate that the GI microbial community of IBD patients is 
different from that of healthy individuals (dysbiotic). Characteristics of a dysbiotic 
community in IBD include a reduction in numbers of organisms in the C. leptum and 
C. cocciodes clusters (members of the Firmicutes phyla and major butyrate 
producers) and an increase in numbers of Enterobacteriaceae and Bacteroidetes, 
thereby leading to a reduction in the microbial diversity of the gut. Another notable 
difference is the greater concentration of mucosa-associated bacteria in IBD patients 
as compared to healthy individuals [194-197]. Using FISH, patients with CD were 
found to have predominantly Enterobacteriaceae, γ−Proteobacteria, or 
Bacteroides/Prevotella adherent to their mucosa and present in their submucosa 
[195]. Another FISH-based analysis revealed that Bacteroides spp. were the 
dominant gut bacteria, representing up to 80 % of the total mucosa-adherent 
bacterial population in some samples. Of interest was the authors’ additional finding 
that treatment of IBD patients with mesalamine (an anti-inflammatory therapeutic 
drug) significantly reduced the numbers of mucosa-adherent bacteria [198].  
 Sample origin is an important factor to consider when interpreting data for 
microbial analyses. Stool samples are easy to obtain, but may not accurately reflect 
the microbial community in the cecum and proximal colon of patients [14]. In a 
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comparative study of the microbial populations detected in cecal versus fecal 
samples, more anaerobes and Bifidobacterium spp. were detected in fecal samples 
using culture-based methods [199]. Molecular probe hybridization revealed that 
facultative anaerobes represented by Lactobacillus, Enterococcus, and E. coli were 
higher in numbers in cecal contents, yet the number of strict anaerobes represented 
by the Bacteroides, C. leptum, and C. coccoides groups were significantly lower in 
the cecal contents. Differences in microbial composition have also been observed 
when comparing colonic biopsies versus feces [200]. Analysis of feces from 
Japanese IBD patients showed that Faecalibacterium spp. were significantly 
decreased in CD patients, while Bacteroides spp. were significantly increased only in 
patients with active IBD [201]. Based on the Shannon diversity index, this study 
demonstrated that microbial diversity was significantly reduced in CD patients both 
during active disease and remission as compared to healthy individuals. 
 Several studies have noted a specific decrease in the numbers of C. leptum 
and C. coccoides clusters present in colonic contents or feces in IBD patients [18, 
197, 202-206]. A reduction in the C. coccoides group in UC patients and C. leptum in 
CD patients has been shown using FISH probes on patient feces [202]. Another 
study employing a combination of PCR and FISH analysis of fecal samples found a 
reduced presence of both C. leptum and C. coccoides clusters in IBD patients [197]. 
Additional analyses revealed significant decreases in the concentrations of the 
SCFAs (e.g., butyric and propionic acid) in the feces of IBD patients [197]. In other 
work, high throughput sequencing demonstrated reduced numbers of 
Faecalibacterium, Ruminococcaceae, Alistipes, Collinsella, and Roseburia and 
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increased numbers of Enterobacteriaceae in a twin with ileal CD as compared to the 
healthy twin [204]. This latter study again emphasizes the involvement of the 
microbiota in the development of IBD in a genetically susceptible host, as only one 
of the twins developed disease.  
 One specific member of the C. leptum cluster, Faecalibacterium prausnitzii, 
has recently been the subject of many published studies. This organism is a major 
butyrate producer that also possesses some anti-inflammatory properties [59, 207]. 
A study by Sokol et al. described a reduction of both C. leptum and C. coccoides 
clusters in the stool of patients with active IBD along with a skewed 
Firmicutes/Bacteroidetes ratio [203]. The authors specifically identified a reduction in 
F. prausnitzii in IBD patients, confirming results obtained using biopsy samples from 
twins analyzed via qPCR [205]. In other work, denaturing gradient gel 
electrophoresis (DGGE) analysis of biopsy samples also demonstrated a significant 
decrease in Faecalibacterium spp. along with increased levels of E. coli and 
Clostridium spp. in CD patients as compared to healthy individuals [208]. Using fecal 
cylinders and 11 different FISH probes to analyze sections GIT tissue specimens, 
Swidsinski and colleagues found the presence of F. prausnitzii to be significantly 
reduced in CD patients [209]. Of special note, analysis of samples from IBD patients 
given high-dose cortisol or infliximab to reduce inflammation revealed a dramatic 
increase (>14 x109) in the levels of F. prausnitzii within days of initiating treatment. 
This increase was short-lived, however, as levels of F. prausnitzii decreased when 
the cortisol dose was reduced or the time between infliximab infusions was 
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increased. Together, these data indicate that inflammation plays a major role in 
shaping the intestinal microbiota. 
Work in murine models of colitis also demonstrates that inflammation in the 
gut, be it chemically or bacterially induced, causes an increase in the numbers of 
Enterobacteriaceae [210]. Colonization of mice with C. rodentium resulted in a 
reduction of the total number of bacteria in the colon at 7 and 14 days post-infection; 
this decrease coincided with the highest levels of both C. rodentium and intestinal 
inflammation [211]. Further analysis specifically determined that members of the 
Cytophaga-Flavobacter-Bacteroides group were decreased. Infection with C. 
rodentium infection is self-limiting, and the total bacterial levels returned to normal 
following pathogen clearance. These changes in the bacterial load were not simply 
associated with colonization of the microbial community by a new organism, as 
colonization with Campylobacter jejuni, an organism that does not cause intestinal 
inflammation in immunocompetent CONVR mice [212], induced no detectable 
changes in microbial load.  
The induction of GIT inflammation in mice via administration of dextran sulfate 
sodium (DSS) in the drinking water for seven days was associated with increased 
numbers of aerobic bacteria, specifically Entercococcus faecalis [210]. Bacteroidetes 
were eliminated from the community and the total number of bacteria was also 
decreased. A dramatic increase in the numbers of a non-pathogenic E. coli following 
DSS treatment was also observed. The authors subsequently colonized IL-10-/- mice, 
which spontaneously develop colitis [213], with this non-pathogenic E. coli. Upon the 
development of GIT inflammation, the E. coli proliferated to the same level observed 
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in DSS treated mice, but displaced the Firmicutes phylum instead of the 
Bacteroidetes. These results indicate that regardless of the source, GIT 
inflammation creates a niche that favors the colonization and population expansion 
of Enterobacteriaceae. Collectively, these data suggest that the induction of 
inflammation following colonization of the GIT by a bacterial provocateur along with 
perturbations of the microbiota together have a deleterious impact on the microbiota 
and mucosal homeostasis. 
 
2. e. Canine IBD 
In addition to affecting humans, IBD can also occur in dogs as well [214]. As 
in human IBD, the interactions among genetics, the mucosal immune system, 
inflammation, and environmental factors (i.e., diet and imbalances in the intestinal 
microbiome) all contribute to the pathogenesis of canine IBD (Figure 6) [215-217]. 
 
 
 
 
 
 
 
 
 
Figure 6 - The etiology for canine IBD involves complex interactions between host genetics, 
mucosal immunity, and the enteric microbiota. Therapeutic intervention with diet, antibiotics and 
immunosuppressive drugs is aimed at reducing inflammation and dysbiosis. 
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Mutations in innate immune receptors in German shepherd dogs (TLR5, NOD2) 
have been linked to IBD susceptibility, which in the presence of an inappropriate 
enteric microbiota may lead to upregulated pro-inflammatory cytokine production 
(e.g., IL-17, IL-22, TNF-α) and reduced bacterial clearance, thereby promoting 
chronic intestinal inflammation [218, 219]. Commensal bacterial antigens are likely to 
be important in disease pathogenesis because it has been observed that boxer dogs 
with granulomatous colitis (GC) show clinical remission following the eradication of 
mucosa-associated AIEC that share a novel adherent and invasive pathotype which 
bears phylogenetic similarity with AIEC strains recovered from patients with ileal CD 
[193, 220, 221]. Moreover, genome-wide analysis in affected boxer dogs has 
identified disease-associated single nucleotide polymorphisms (SNPs) in a gene 
(NCF2) involved with killing intracellular bacteria [222]. Still others have shown that 
CD11c+ cells are significantly decreased in the intestines of dogs with IBD 
suggesting that chronic mucosal inflammation may involve an imbalance in the 
intestinal dendritic cell population leading to aberrant immune activation [223]. 
Molecular analysis of the intestinal microbiome in different breeds of dogs with IBD 
have consistently shown that diseased tissues are enriched with members of the 
families Enterobacteriaceae and Clostridiaceae [224, 225]. These bacteria are 
believed to contribute to the pathogenesis of GIT inflammatory disease in dogs as in 
humans [187, 226]. A recent trial using high throughput 16S rDNA sequencing 
methods (i.e., 454 pyrosequencing) on intestinal biopsies of IBD dogs revealed a 
dysbiosis in the mucosa-adherent microbiota with an increase in sequences 
belonging to Proteobacteria and a decrease in Bacteroidetes, Fusobacteria, and the 
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Clostridiales [227]. Taken together, these studies suggest that chronic intestinal 
inflammation of canine IBD may be due to overly aggressive adaptive immune 
responses to enteric bacteria (or fungi) [225] in hosts with genetic defects that fail to 
properly regulate microbial killing, mucosal barrier function, or immune responses. 
As in human IBD, environmental factors (i.e., diet and microbiota imbalances) likely 
govern the onset of inflammation or reactivation and modulate genetic susceptibility 
to disease. 
 
2. e. I. Clinical and diagnostic features 
The clinical manifestations of IBD are diverse and are influenced by the 
organ(s) involved, presence of active versus inactive disease, and physiologic 
complications seen with enteric plasma protein loss and/or micronutrient (cobalamin) 
deficiency [215, 216, 228, 229]. Canine IBD is a disease that predominantly affects 
middle-aged animals. Vomiting and diarrhea are most commonly observed and are 
often accompanied by decreased appetite and weight loss. Gastric and duodenal 
inflammation is associated with vomiting and small bowel diarrhea while colonic 
involvement causes large bowel diarrhea with blood, mucus, and straining. The 
clinical course of IBD is generally cyclical and is characterized by spontaneous 
exacerbations and remissions. Importantly, the clinical signs of IBD are not disease 
specific and share numerous over-lapping features with other canine disorders. A 
diagnosis of IBD is one of exclusion and requires careful elimination of IBD mimics 
[230]. The possible causes for chronic intestinal inflammation may be excluded 
through the integration of history, physical findings, clinicopathological testing, 
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diagnostic imaging, and histopathology of intestinal biopsies. A baseline CBC, 
biochemistry profile, urinalysis, and diagnostic imaging are useful in eliminating the 
most common systemic and metabolic disorders (e.g., renal disease, hepatopathy, 
hypoadrenocorticism) causing chronic GI signs in dogs. The measure of clinical 
disease activity by means of quantifiable indices is well established in human IBD 
[231-233]. 
A canine IBD activity index (CIBDAI) used for assessment of inflammatory 
activity in dogs has been recently designed [234]. Similar to other indices, the 
magnitude of the numerical score is proportional to the degree of inflammatory 
activity. This index serves as the principal measure of response to a therapeutic 
regimen and may be used to tailor medical therapy for an individual patient’s needs 
[235]. Intestinal biopsies are required to confirm histopathological inflammation and 
to determine the extent of mucosal disease. Diagnostic endoscopy is preferred since 
this technique allows for direct assessment of mucosal abnormalities and the 
acquisition of targeted biopsy specimens. The microscopic findings in canine IBD 
consist of minimal to pronounced inflammatory cell (lymphoplasmacytic) infiltration of 
the intestinal lamina propria accompanied by varying degrees of mucosal 
architectural disruption similar to that observed in tissue from human IBD patients 
(Figure 7). 
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Unfortunately, biopsy interpretation is notoriously subjective and suffers from 
extensive intra-observer variability and the technical constraints of 
procurement/processing artifacts inherent in evaluation of endoscopic specimens 
[236]. Although several histopathological scoring schemes have been proposed 
there are no uniform grading criteria that pathologists can universally agree on. One 
small study has resulted in development of a ‘simplified model system’ for defining 
intestinal inflammation of IBD that is presently being tested in a separate clinical trial.  
 
2. e. II. Therapeutic approach 
Treatment principles for canine IBD are empirical and consist of combination 
therapy using both dietary and pharmacologic interventions. As compared to clinical 
trials evaluating the efficacy of therapy for CD and UC, only one randomized, 
controlled drug trial for canine IBD has been reported [235]. There are, however, 
abundant evidence-based observations that feeding elimination diets and 
administering corticosteroids, immunosuppressive drugs, and/or select antibiotics 
are useful in the clinical management of canine IBD. Some clinicians prefer a 
sequential approach to nutritional and drug therapy for IBD. The optimal drug or drug 
Figure 7 – Histopathological lesions of (A) crypt distortion with abscessation, (B) diffuse villous atrophy, 
and (C) mucosal ulceration seen in duodenal biopsies of dogs with IBD.  
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combinations as well as duration of therapy for induction and maintenance of 
remission of clinical signs have not been determined for most protocols [216, 230]. 
In general, the administration of corticosteroids (i.e., prednisone, prednisolone or 
budesonide), antimicrobials (i.e., metronidazole or tylosin), and immunosuppressive 
drugs (i.e., cyclosporine, chlorambucil, azathioprine) used alone or in some 
combination are effective in inducing clinical remission in most animals. Some dogs 
will require intermittent or life-long drug therapy. 
The rationale for nutritional therapy of IBD is that restricting exposure to 
antigens (i.e., dietary proteins) known to evoke sensitivity will reduce exaggerated 
host responses and attenuate intestinal inflammation. Other indications for 
specialized nutrition include the presence of decreased appetite, impaired nutrient 
absorption, or enteric plasma protein loss seen with moderate-to-severe mucosal 
inflammation. While evidence-based observations indicate that most dogs respond 
favorably to dietary intervention, the superiority of one novel protein source versus 
another or the advantage in feeding an intact protein elimination diet versus a 
hydrolyzed protein elimination diet has not been shown to date. Modifying the dietary 
n3:n6 fatty-acid ratio may also modulate inflammatory responses by reducing 
production of pro-inflammatory metabolites [237]. There is relatively sparse clinical 
data investigating prebiotic or probiotic therapy for canine IBD (see subsequent 
section on probiotics). 
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2. e. III. Future directions in canine IBD 
Canine IBD represents a common and frustrating GI disorder in veterinary 
medicine. More research is needed to unravel the mechanisms responsible for 
disease development and to translate these findings directly to human IBD. The 
primary features of IBD in humans and animals are remarkably similar (Table 1).  
 
Table 1. Comparative features of IBD in humans and dogs. 
Feature Human IBD Canine IBD 
Genetic basis Yes Likely 
Etiology Unknown but 
multifactorial 
Unknown but 
multifactorial 
Involves the microbiota Yes Yes 
Hematochezia Yes Yes 
Diarrhea Yes Yes 
Definitive Diagnosis GI biopsy GI biopsy 
Disease activity 
assessment 
Clinical indices, 
biomarkers (ASCA, 
pANCA, CRP, 
calprotectin) 
Clinical indices, 
biomarkers (pANCA, 
CRP, calprotectin ?) 
Responsive to anti-
inflammatory drugs 
Yes Yes 
Responsive to antibiotics Yes Yes 
Spontaneous GI flares Yes Yes 
 
Recent advances in clinical indices, histopathological standards, and the 
development of species-specific immunologic reagents and innovative molecular 
tools have made the dog an excellent ‘spontaneous’ animal model to study chronic 
immunologically-mediated intestinal inflammation. In addition, the dog has higher 
genomic sequence similarity to that of humans than do mice, a species traditionally 
used for comparative disease genetics [238]. However, clinical manifestations of 
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complex disease in the mouse do not compare to the human form as closely as they 
do in the dog. Furthermore, the lifespan of the dog is much shorter than that of a 
human; thus, clinical trials aimed at treatment of IBD can be carried out much 
quicker and yield results that should have relevant application to human trials [230, 
235, 239]. 
 
2. f. Treatment for Human IBD 
 Treatments for human IBD patients typically involve the use of anti-
inflammatory drugs, antibiotics, and there is a growing trend of probiotics and 
prebiotics being studied to determine their effects on disease activity. When patients 
fail to respond to treatment, the last and most drastic treatment option is surgery to 
resect sections of the inflamed bowel [240]. Most treatment options are primarily 
focused on reducing the inflammation associated with IBD. Some of these drugs 
also impact the microbiota and those will be discussed below.   
 
2. f. I. Antibiotics 
 Given the importance of the microbiota in the pathogenesis of IBD, antibiotic 
therapy may seem an obvious treatment option. A meta-analysis by Khan et al. in 
2011 reviewed randomized controlled trials utilizing antibiotics in the treatment of 
IBD [241]. Rifamycin derivatives, ciprofloxacin, and clofazamine all induced 
remission in CD patients. Rifaximin (a rifamycin derivative) is effective against both 
Gram-negative and Gram-positive anaerobes and aerobes; it is also poorly 
absorbed after oral administration, resulting in little to no systemic side effects [242, 
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243]. Analysis of the effect of the drug using an in vitro continuous culture method 
with fecal samples from CD patients revealed increases in beneficial bacteria post-
rifaximin administration [244]. Significant increases in Bifidobacterium spp., the 
Atopobium cluster, and F. prausnitzii were noted, as were increases in levels of 
lactate, acetate, and propionate as determined by 1H-NMR spectroscopy [244]. 
 Ciprofloxacin is a fluoroquinolone with broad-spectrum antibiotic activity [245]. 
In addition to having anti-bacterial properties, this drug has also been shown to have 
immunomodulatory properties as well [246]. In a TNBS mouse model of colitis, 
administration of ciprofloxacin ameliorated disease as compared to mice given 
ceftazidime (an antibacterial with a similar spectrum of activity compared to 
ciprofloxacin) [245]. Clinically, mice treated with ciprofloxacin did not lose weight and 
had reduced histopathological inflammatory scores associated with their colons. 
Ciprofloxacin treated mice also had reduced expression of IL-1β, IL-8, and TNF-α as 
measured from colonic homogenates as well as reduced expression of NF-κΒ. Since 
ceftazidime was less effective in ameliorating GIT inflammation, there appears to be 
additional benefits (i.e., anti-inflammatory) to the use of ciprofloxacin in addition to its 
spectrum of antimicrobial activity. 
Clofazamine has also been documented to significantly affect the rate of 
remission in CD patients [241]. This drug, used to treat leprosy, is similar to 
ciprofloxacin, in that it has both anti-bacterial and anti-inflammatory properties [247-
249]. It is only effective against Gram-positive organisms, and its effectiveness 
increases in anaerobic environments [250]. Its effects on the immune system include 
increasing the presence of lysosomal enzymes in macrophages [251] and increasing 
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phagocytosis by macrophages resulting in enhanced uptake and digestion of 
immune complexes [252]. Clofazamine has also been shown to inhibit TCR-
mediated IL-2 production by T cells, thereby limiting T cell activation, a component of 
the pathogenesis of IBD [253]. 
 
2. f. II. Corticosteroids 
 The most commonly used corticosteroids used are prednisolone, 
methylprednisolone, and budesonide [254]. These drugs are very effective at 
inducing remission, however, they are not without side effects. In a study comparing 
prednisolone and budesonide, both were found to be effective at inducing remission 
[255]. Patients on budesonide had reduced evidence of adrenal axis suppression 
and peripheral leucocyte counts compared to those treated with prednisolone. These 
results indicate that budesonide is a safer choice yet it is still as effective as 
prednisolone. Corticosteroids are able to prevent NFκΒ activation [256] as well as 
block infiltration of neutrophils, prevent vasodilation and enhanced vascular 
permeability and downregulate the production of pro-inflammatory cytokines [254]. 
Although it is well established that these corticosteroids have an anti-inflammatory 
effect, little research has been conducted on the effects they have on the gut 
microbiota. A study by Swidsinski et al., mentioned previously, indicated that 
administration of cortisol increased the population of F. prausnitzii in a dose 
dependent manner [209].  
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2. f. III. Immunosuppressive Therapy 
 Drugs such as methotrexate, 6-mercaptopurine (6-MP) and azathioprine (the 
prodrug of 6-MP) work by inhibiting the proliferation and activation of lymphocytes 
and decreasing the production of pro-inflammatory cytokines [254]. 6-
mercaptopurine (6-MP) and azathioprine are purine antagonists and inhibit cellular 
metabolism by interfering with DNA replication [257, 258]. Methotrexate is a folic 
acid analog that inhibits DNA synthesis and, therefore, has an anti-proliferative effect 
[259]. Antibacterial effects, including growth inhibition of MAP, have also been 
demonstrated for methotrexate and 6-MP [258]. 
 
2. f. IV. 5-Aminosalicyclic Acid (5-ASA) 
 Sulfasalazine was the first 5-ASA-type drug developed and is a combination 
of sulfapyridine (an antimicrobial) and salicyclic acid (an anti-inflammatory) to form a 
pro-drug. Upon entering the colon, this pro-drug is cleaved by colonic bacteria into 
the two separate molecules [260, 261]. Unfortunately, the frequency of 
gastrointestinal side effects was quite high due to the sulfapyridine moiety [262, 263]. 
It was later determined that the active moiety is 5-aminosalicyclic acid (5-ASA, 
mesalazine) [264]. More recently formulations of this pro-drug have eliminated the 
sulfapyridine moiety and replaced it with either a second salicyclic acid moiety 
(disodium azodisalicylate [265]) or an inert carrier (balsalazide [266]) thereby 
reducing the side effects. 
In addition to being an anti-inflammatory agent [267-270], 5-ASA also affects 
the gut microbiota. As mentioned previously, patients taking mesalamine had a 
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reduction in mucosa-adherent bacteria [198, 271]. 5-ASA has also been shown to 
inhibit the growth of MAP [272] and Bacteroides spp. [273] and moderately inhibit 
the growth of C. difficile and C. perfringens in culture [273]. This drug also effects 
bacterial gene expression, as S. Typhimurium incubated with 5-ASA had no change 
in growth but differentially expressed 110 genes [274]. Those genes characterized 
were found to be involved in invasion, metabolism, and antibiotic and stress 
resistance. In vitro assays revealed attenuation in the invasiveness of S. 
Typhimurium towards HeLa cells when pretreated with 5-ASA. These results 
indicate that in addition to inhibiting host-mediated inflammation, 5-ASA also has the 
potential to affect the intestinal microbiota. 
 
2. f. V. Anti-TNF monoclonal antibodies 
 The induction of TNF-α is most often a downstream event following the 
interaction of phlogistic microbial components with toll-like receptors (TLRs) on host 
cells. The interest in TNF-α as a therapeutic target for IBD treatment began when 
the expression and secretion of this cytokine was found to be increased in IBD 
patients [275, 276]. For example, pediatric patients with either active UC or CD 
present with elevated levels of TNF-α in their stool [275]. Additionally, the incubation 
of GIT tissue sections in culture medium has demonstrated that significantly 
elevated levels of TNF-α are spontaneously secreted from inflamed tissue of both 
UC and CD patients when compared to the amounts produced by non-inflamed 
tissue and tissue from otherwise healthy individuals [276]. The predominant cell type 
producing the TNF-α has been shown to be the macrophage [276]. Based on the 
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central role TNF-α appears to play in the pathogenesis of IBD, there was interest in 
developing a therapeutic approach to control the harmful effects of this cytokine. 
Clinically, the use of monoclonal antibodies to treat IBD patients began with 
Infliximab, an IgG1 murine-human chimeric monoclonal antibody specific for TNF-α, 
which was approved for human use in 1998 for CD [277, 278]. This monoclonal 
antibody consists of human constant regions and murine antigen binding regions 
[277]. These chimeric antibodies reduce the risk of immunoreactivity that occurs 
when murine antibodies are used. In addition to being less immunoreactive, this 
chimeric antibody had improved binding and neutralization characteristics for TNF-
α than that of the original murine antibody [277]. Another monoclonal anti-TNF 
antibody, Adalimumab, is a fully humanized IgG1 antibody that avoids the induction 
of anti-species IgG that neutralize the effectiveness of the anti-TNF-α reagent [278, 
279]. Lastly, Certolizumab is a monoclonal antibody fragment with a polyethylene 
glycol moiety (PEGylated) [278]. Certolizumab lacks the crystallizable fragment (Fc) 
portion of the immunoglobulin molecule and is an IgG4 isotype unlike Infliximab and 
Adalimumab, which are IgG1 antibodies [278, 280, 281]. In addition, the PEGylation 
increases the half-life of the antibody thereby reducing the frequency of 
administration.  
Anti-TNF-α therapy works via multi-factorial mechanisms. First, it neutralizes 
TNF-α by blocking its ability to bind to TNF receptors, thus, inhibiting the pro-
inflammatory response. Second, Anti-TNF-α binds to cell surface bound TNF-α on 
CD4+ T cells and macrophages, resulting in both complement- and antibody-
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dependent cell-mediated cytotoxicity [282]. All three monoclonal antibodies bind to 
and neutralize both soluble and membrane forms of TNF-α [281]. Infliximab and 
Adalimumab both mediate complement- and antibody-dependent cell-mediated 
cytotoxicity; however, Certolizumab only mediates complement-dependent cellular 
cytotoxicity as it lacks of an Fc region. Furthermore, Infliximab and Adalimumab 
induce apoptosis in peripheral blood lymphocytes and monocytes, as well as cause 
degranulation and loss of membrane integrity of PMNs. These activities were not 
induced with Certolizumab. Lastly, all three monoclonal antibodies inhibit the 
production of IL-1β after LPS stimulation in vitro, suggesting that there is a 
sequential production of pro-inflammatory cytokines induced by microbial 
components. Infliximab and Adalimumab both inhibit T cell proliferation in mixed 
lymphocyte reactions in vitro, again suggesting that anti-TNF-α monoclonal 
antibodies ameliorate the inflammation associated with IBD via more than one mode 
of action [283]. The impact of these therapies on the microbiota, however, is not well 
studied. As previously mentioned, treatment with Infliximab resulted in increased 
levels of F. prausnitzii after administration [209]. It is clear that the host inflammatory 
response often negatively impacts (i.e., shapes) the composition of the GIT 
microbiota, and that controlling mucosal inflammation benefits the health of the 
microbiota as well. Otherwise, there have been no specific studies performed to 
directly evaluate the role of anti-TNF-α therapies on the gut microbiota.  
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2. f. VI. Complementary and alternative therapies  
 An estimated 70 % of IBD patients have reported using complementary and 
alternative medicine (CAM) products at some time to treat their symptoms. In a 
Canadian study of IBD patients, some of the most commonly used CAM treatments 
included massage therapy, chiropractic visits, probiotics, herbs, and fish oils [284]. A 
systematic review of the literature on the use of herbal medicines reveals some anti-
inflammatory benefits associated with the administration of these herbs to both 
animals and humans [285]. It should be stressed that prior to utilizing any herbal 
remedy, which are potentially biologically active, patients need to consult their 
physician. This is especially important because the number two reason patients 
using CAM gave as to why they sought these products was that “natural therapy is 
safe” [286]. Some of the biological properties associated with CAM products include 
the reduction of pro-inflammatory cytokines, increased antioxidant production, 
inhibition of leukotriene B4, decreased NF-κΒ activation, and inhibition of platelet 
activation[285].  
 Increasing evidence supports a potential therapeutic role for prebiotic and 
probiotic therapy in human IBD [287, 288]. If IBD in dogs is indeed driven by loss of 
tolerance to components of the intestinal microbiota as it is in humans, then 
prebiotics and probiotics may also prove beneficial as primary or adjunct therapies 
with diet and drugs. Probiotics are living microorganisms that, upon ingestion in 
sufficient numbers, impart health benefits beyond those of inherent basic nutrition 
[289]. Lactobacilli and bifidobacteria have been the most commonly used human 
probiotics, but multi-strain cocktails (e.g., VSL#3), E. coli Nissle 1917, and 
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nonbacterial Saccharomyces boulardii have also been used as probiotics [226]. 
Probiotic bacteria have measurable host benefits, including the ability to improve 
epithelial barrier function, modulate the mucosal immune system, and alter the 
intestinal flora [290]. Prebiotics are non-digestible dietary carbohydrates, such as 
lactosucrose, fructo-oligosaccharides (FOS), psyllium, and bran which beneficially 
stimulate the growth and metabolism of endogenous enteric bacteria upon 
consumption [291]. Beneficial effects of prebiotics are also associated with the 
production of short chain fatty acids due to fermentation by colonic bacteria. 
Synbiotics are combinations of probiotics and prebiotics that are an emerging 
therapeutic modality. Increasing evidence supports a therapeutic role for probiotics, 
prebiotics, and synbiotics in treating gastrointestinal diseases of humans, including 
infectious diarrhea, H. pylori infection, irritable bowel syndrome, lactase deficiency, 
and IBD [84]. A comparison of prebiotic and probiotic preparations is outlined in 
Table 2. 
 
2. f. VII. Probiotics 
VSL#3 is one of the most commonly used probiotic cocktails and contains a 
very high bacterial concentration per gram of product characterized by greater 
number of different bacterial species as compared to traditional probiotic 
preparations [292]. This commercially prepared formulation consists of 450 billion 
bacteria/g of viable lyophilized bacteria comprised of eight bacterial strains 
(Lactobacillus casei, L plantarum, L. bulgaricus, L. acidolphilus, Bifidobacterium 
longum, B. breve, B. infantis and Streptococcus thermophiles). While the exact 
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mechanism of action of VSL#3 is unknown, several studies have demonstrated the 
effects of VSL#3 on epithelial barrier function and down regulation of cytokine 
secretion from immune cells. For example, Madsen [293] has shown in in vitro 
studies that epithelial barrier function could be enhanced by exposure to a soluble 
factor secreted by VSL#3 bacteria. Moreover, this same study demonstrated that 
VSL#3 did not alter the ability of the epithelial cell to activate a mucosal inflammatory 
response to a bacterial invasion. Studies with VSL#3 formulations have also been 
conducted in several animal models of colitis, inflammatory liver disease, sepsis, 
and irritable bowel syndrome (IBS). In models of experimentally-induced colitis, 
these studies demonstrated that VSL#3 normalized gut permeability and barrier 
function, and that VSL#3 modulated inflammatory and immune responses [226, 294]. 
Animal models of sepsis have also demonstrated that VSL#3 administration reduced 
bacterial translocation and significantly attenuated damage to the liver and intestinal 
mucosa [295]. The use of VSL#3 as an innovative probiotic preparation, developed 
specifically to balance the intestinal microbiota, is supported by studies in humans 
with IBD (ulcerative colitis and pouchitis) [296], and in other patients with diverse 
gastrointestinal disorders, such as IBS [297, 298]. 	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Table	  2.	  	  Basic	  Features	  of	  Probiotics	  and	  Prebiotics	  
	  
 Probiotics Prebiotics 
 
Definition 
 
Live microorganisms which, 
given in adequate amounts 
confer health benefits to the 
host  
 
 
Non-digestible carbohydrate 
which stimulate replication of 
protective enteric bacteria 
when consumed 
 
Examples 
 
E. coli Nissle 1917 
VSL#3 
Lactobacillus species 
Bifidobacterium species 
Saccharomyces boulardii 
Prostora Max® 
Forti Flora® 
Proviable-DC® 
 
 
Fructo-oligosaccharide 
(FOS) 
Galacto-oligosaccharide 
(GOS) 
Inulin 
Lactulose 
Psyllium 
Bran 
Beet pulp, pumpkin 
Resistant starch 
 
 
Protective 
Mechanisms 
 
Alters microbiota to suppress 
pathogens 
Improved intestinal barrier function 
Increased production of 
antimicrobial peptides 
Decreased expression of 
proinflammatory cytokines 
 
Stimulates replication of 
beneficial bacteria 
(Bifidobacterium) 
Enhances production of 
SCFA (butyrate) 
Improved intestinal barrier 
function 
Decreases 
proinflammatory cytokines 
 
Studies have shown VSL#3 to induce remission of inflammation in 77 % of 
adult UC patients with no adverse effects [298] and 56 % of pediatric UC patients 
[299]. These same pediatric UC patients had a reduction in disease activity index 
and sigmoidoscopy scores following VSL#3 treatment. They also had reduced levels 
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of the pro-inflammatory cytokines TNF-α and IFN-γ following therapy [299]. In vitro 
analysis of the effects of VSL#3 on Mode-K epithelial cells revealed that only one of 
the eight organisms, L. casei, inhibited TNF-induced secretion of the pro-
inflammatory chemokine IP-10 [300]. The most recent studies with VSL#3 treatment 
of UC show increased fecal concentrations of beneficial bacterial species, improved 
clinical, endoscopic and histopathological scores in most patients, and higher rates 
of remission compared to placebo [298]. VSL#3 is available without prescription and 
can be ordered via the internet or obtained locally at the pharmacy in the U.S. [301].  
Recent studies have also shown that dogs with IBD have distinctly different 
duodenal microbial communities compared to healthy dogs. Current treatments for 
IBD include the administration of nonspecific anti-inflammatory drugs which may 
confer serious side effects and do not address the underlying basis for disease, 
namely, altered microbial composition. The use of probiotics offers an attractive, 
physiologic, and non-toxic alternative to shift the balance to protective species and 
treat canine IBD. The authors (AEJ) have initiated a clinical trial to investigate the 
clinical, microbiologic, and anti-inflammatory effects of probiotic VSL#3 in the 
treatment of canine IBD. We hypothesize that VSL#3 used as an adjunct to standard 
therapy (i.e., elimination diet and prednisone) will induce a beneficial alteration of 
enteric bacteria leading to induction and maintenance of remission in dogs with IBD. 
A randomized, controlled clinical trial of eight weeks duration will assess the efficacy 
of standard therapy in conjunction with VSL#3 versus standard therapy alone in the 
management of canine IBD. There is a need for additional data to be generated to 
provide proof of efficacy in probiotic therapy before these agents can be applied to 
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widespread clinical use. These studies will also provide highly relevant insight into 
the anti-inflammatory effects of probiotics for treatment of human and canine IBD.  
Another popular probiotic is E. coli Nissle 1917 also known as Mutaflor®. This 
probiotic has been shown to be just as effective as mesalazine in achieving and 
maintaining remission of inflammation in UC patients [302-304]. It has recently been 
shown that when E. coli Nissle 1917 is genetically modified to produce the quorum-
sensing molecule AI-2, it affected the beneficial probiotic properties of this organism 
[305]. Colonization of healthy newborn infants with E. coli Nissle 1917 has shown 
that the presence of pathogenic bacteria in the gut was significantly reduced 
compared to non-colonized infants [306]. In vitro studies have shown E. coli Nissle 
1917 is able to reduce the invasive ability of multiple pathogenic organisms [307], 
and also to reduce the adherent and invasive ability of AIEC [308]. E. coli Nissle 
1917 was also shown to either inhibit the growth (49 %) or overgrowth (30 %) of 
79 % of uropathogenic organisms recovered from children with urinary tract 
infections [309]. Unlike VSL#3, Mutaflor® cannot be purchased in the U.S. due to its 
reclassification by the F.D.A. from a “medical food” (which is what VSL#3 is 
classified as) to a “biologic” [301, 310]. 
 There are few reports on the use of probiotic bacteria in dogs and cats. 
Recent in vitro studies have confirmed the capacity of a lyophilized probiotic cocktail 
(e.g., three different Lactobacillus spp. strains) to modulate the expression of 
regulatory versus pro-inflammatory cytokines in dogs with chronic enteropathies 
[311, 312]. One commercially-manufactured probiotic (FortiFlora™ – Enterococcus 
faecium SF68, Nestle Purina) is reported to potentially control diarrhea and enhance 
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immune responses in dogs and cats. Several recent trials attest to the short-term 
efficacy of probiotics in treating acute diarrhea in dogs and cats [313]. The link 
between the intestinal microbiota and gastrointestinal health in companion animals is 
now obvious. Future developments in the pharmabiotic field must include 
performance of randomized clinical trials to determine the role of probiotics and 
prebiotics in the management of canine chronic enteropathy. One large multicenter 
trial investigating the efficacy of VSL#3 in reducing inflammatory activity of canine 
IBD is presently underway. 
  
2. f. VIII. Prebiotics 
Prebiotics are substances that can be used to promote specific changes in 
the microbiota. Administration has been shown to shift the microbiota in healthy 
adults; for example, individuals who consume either soluble corn fiber or 
polydextrose had increases in F. prausnitzii and those who consumed the soluble 
corn fiber had increases in Roseburia spp. [314]. As mentioned previously, both of 
these organisms metabolically produce butyrate and F. prausnitzii also has other 
anti-inflammatory properties. In animal models, prebiotics have also shown to be 
effective. The severity of DSS-induced colitis in rats was attenuated by administering 
inulin orally as evidenced by a reduction in histopathological scores and 
myeloperioxidase accumulation in the colons [315]. In addition, the acidity of the 
colonic contents increased in rats fed inulin as well as the numbers of Lactobacillus 
spp. in the feces. In a multicenter trial feeding UC patients germinated barley 
foodstuff (GBF), patients consuming GBF had improved clinical activity index scores 
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[316]. GBF has also been shown to be effective in maintaining remission [317] and 
reducing pro-inflammatory cytokine levels in UC patients [318]. In CD patients, 
dietary supplementation with fructo-oligosaccharide (FOS) reduced their disease 
activity index, increased fecal Bifidobacterium spp. levels as well as increased 
production of IL-10 and expression of TLR-2 and TLR-4 from lamina propria 
dendritic cells [319].  
Scientific studies have also investigated the effects of dietary 
supplementation with prebiotics on the intestinal microbiota of healthy dogs and cats. 
In one study, FOS supplemented at 0.75 % dry matter produced qualitative and 
quantitative changes in the fecal flora of healthy cats [320]. Compared with samples 
from cats fed a basal diet, increased numbers of lactobacilli and Bacteroides spp. 
and decreased numbers of E. coli were associated with cats fed the FOS 
supplemented diet.  However, bacteriologic examination of the duodenal juice in 
these same cats showed wide variation in the composition of the duodenal 
microbiota, across sampling periods, which was not affected by FOS 
supplementation [321]. Moreover, healthy Beagle dogs fed a 1 % FOS diet over a 
three-month trial showed inconsistent fecal excretion of Lactobacillus spp. and 
Bifidobacterium spp. [322]. While FOS supplementation has been shown to have 
health benefits, these studies demonstrate that FOS does not have an adverse 
affect on the microbiota and suggest that it may have positive physiological benefits 
as seen in humans. This observation and the lack of significant side effects 
associated with FOS supplementation provide evidence that FOS should be 
considered as an attractive alternative or adjunct therapy for IBD in dogs and cats.  
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3. Mouse Models of IBD 
Many different mouse models have been utilized in IBD research to elucidate 
the roles that bacteria, genetics, the immune response, and environment play in the 
induction and maintenance of IBD [323]. They fall into two main categories: 
chemically-induced and genetically-engineered models. The composition of the 
microbiota in the various mouse models is also discussed. Regardless of the strain 
of mouse employed in chemically-induced or genetically-engineered models, there 
are only five options for its microbiota—conventional, specific pathogen free, 
restricted, gnotobiotic, or germ-free. Note that the word gnotobiotic (gnostos – 
“known” bios – “life”) indicates that all the organisms present, regardless of the 
numbers of species, are known and does not apply only to mice that are completely 
devoid of microbes (i.e., germfree). 
 
 
3. a. Chemically-induced models 
 
3. a. I. DSS 
 Dextran sulfate sodium (DSS) is formed by the esterification of dextran with 
chlorosulphonic acid [324].  Administered ad libtum in the drinking water, this 
compound causes enterocolitis in mice with disease severity being dependent on 
mouse strain, DSS molecular mass, and sulfur content [325-328]. Within three to 
seven days after the addition of DSS (1 to 10 % w/v) to the drinking water, mice 
exhibit loose stools, weight loss, and occult blood. Upon necropsy of mice treated 
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with DSS, cecal atrophy and colonic shortening are noted, and histopathological 
examination reveals mucosal ulceration, inflammatory infiltrate, and hyperplastic 
epithelium in the colonic mucosa. It has also been reported that glandular dropout 
occurs prior to signs of inflammation. Although the exact mechanism of action for 
DSS-induced colitis is currently not known, it is thought to manifest epithelial toxicity 
[329, 330]. Other reports indicate that DSS increases mucosal permeability within 
three days of administration (before the appearance of inflammatory infiltrate) [331]. 
Studies have also shown that DSS is taken up by macrophages in the colon and 
mesenteric lymph node and by Kupffer cells in the liver [326, 330]. When 
macrophages become laden with DSS, they have a reduced ability to perform 
normal homeostatic functions such as tissue repair and phagocytosis of bacteria 
[332]. DSS was demonstrated to be cytotoxic to Caco-2 cells, binding to their 
nucleus, causing cell cycle arrest and reduced production of reactive oxygen species 
[333].  
Microbial populations of the GIT are altered after DSS administration, with the 
microbiota of treated mice having increased numbers of Bacteroidaceae and 
Clostridium spp.  [326]. This result indicates that the changes to the microbiota may 
play a contributory role (e.g., reduction of butyrate production) in the induction of 
DSS-induced disease. However, DSS induces more severe colitis and increased 
mortality in GF mice as compared to their conventional counterparts [334, 335]. GF 
mice given either 5 % or 1 % DSS died at days three or 14, respectively, after the 
start of DSS administration [335]. Collectively, these studies indicate that the 
composition of the microbiota may influence the sensitivity of mice to DSS-induced 
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colitis as well as support the idea that the resident microbiota affords cytoprotective 
benefits for the host. 
 
3. a. II. TNBS (2,4,6, -trinitrobenzne sulfonic acid) 
 TNBS is a haptenating agent that causes a disease similar to CD when mixed 
with ethanol and administered rectally as an enema. Mice treated with TNBS 
develop a pan-colitis with the peak of clinical signs, such as diarrhea and rectal 
prolapse, occurring two to four weeks post-administration [112]. Microscopically, 
transmural inflammation is noted along with neutrophil infiltration, loss of goblet cells, 
edema, and granulomas. T cells isolated from the lamina propria secrete elevated 
levels of IFN-γ and IL-2 following stimulation with anti-CD3 and anti-CD28. However, 
administration of anti-IL-12 antibodies after induction of TNBS-induced colitis 
reduced the disease severity, and treated mice also showed reduced production of 
IFN-γ [112]. Further studies have shown that CD4+ T cells recovered from mice with 
TNBS-induced colitis could induce mild colitis when adoptively transferred into naive 
control mice; the colitic lesions were characterized by inflammatory cell infiltrate that 
produced IFN-γ [336]. In that same study, researchers found that feeding mice 
TNBS-haptenized colonic protein caused the mice to develop oral tolerance. These 
mice subsequently failed to develop colitis after TNBS administration or the transfer 
of CD4+ T cells from mice with TNBS-induced colitis. T cells from these tolerant mice 
secreted elevated amounts of TGF-β, IL-4, and IL-10 [336].  
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3. a. III. Oxazolone 
 Oxazolone is a haptenating agent that causes a disease in mice similar to UC 
when mixed with ethanol and administered rectally [337, 338]. SJL/J mice rapidly 
develop diarrhea and weight loss that peaks at day two post-administration with a 
50 % mortality rate by day four. At day two, the distal half of the colon becomes 
hemorrhagic and edematous and histologically shows signs of superficial 
inflammation. There is epithelial cell erosion, goblet cell depletion, edema, and 
inflammatory infiltrate composed of neutrophils and eosinophils. This is similar to 
what is observed microscopically in the colonic tissues of human UC patients. These 
mice also develop elevated levels of IL-4 and IL-5, but no IFN-γ, indicating that 
oxazolone induces a Th2 response. Elevated levels of TGF-β are also noted and 
may play in a role in the induction of disease in only part of the colon. The model has 
also been examined for its role in determining efficacy of IBD treatments. BALB/c 
mice given either 5-ASA or sodium prednisolone phosphate intra-rectally prior to and 
during induction of oxazolone colitis had decreased severity of disease [337]. The 
disease is self-limiting, and the mice that survive beyond day four show increased 
weight gain and are healthy by days 10-12 post-administration. 
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3. b. Genetically engineered models 
 
3. b. I. IL-10-/- 
 In 1993, Kuhn et al. discovered that mice deficient in the anti-inflammatory 
cytokine IL-10 spontaneously develop enterocolitis [213]. This model has been 
popular in IBD research and this genetic deficiency has been crossed onto many 
different genetic backgrounds of mouse [339-345]. The availability of different strains 
has highlighted the role that genetics plays in enterocolitis, as the severity of disease 
is strain dependent. The order of severity from most severe to least severe is as 
follows: C3Bir > 129 > BALB/c or NOD/Lt > C57BL/6 or C57BL/10. In addition to 
strain differences, development of enterocolitis is also dependent on the microbiota, 
as GF IL-10-/- do not develop enterocolitis and disease is attenuated after 
administration of antibiotics to IL-10-/- mice harboring a conventional microbiota [346, 
347]. The lack of IL-10 does not affect the development of the B or T cells, but its 
absence does result in a lack of regulatory T cells [213, 348]. Studies to understand 
the development of disease in these mice have shown that B cells (while present in 
high numbers in the lamina propria) are not needed for the initiation of disease, but 
that disease is mediated by CD4+ T cells [342, 349]. Transfer studies using RAG2-/- 
mice as recipients have specifically shown that naive CD4+ T cells are capable of 
inducing colitis, and CD45BRlow CD4+ T cells from IL-10-/- mice can induce disease in 
these RAG2-/- mice [348, 349]. This latter observation implicates IL-10 as a central 
mediator of regulatory T cells (CD25+ Foxp3+ CD4+ T cells). It has also been shown 
that IL-12 and IFN-γ are needed for initiation but not the continuation of colitis [342, 
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350]. The increase in the production of IL-12 and IFN-γ along with undetectable 
levels of IL-4 indicates that the enterocolitis in these mice is mediated by a Th1 
immune response, similar to that observed in humans with IBD [342, 346].  
 
3. b. II. Mdr1a-/- 
 In 1994, mice lacking the gene mdr1a were generated. This gene encodes a 
P-glycoprotein, which is a drug efflux pump, thus protecting host cells from the build-
up of toxic compounds. It was noted later that these mice spontaneously develop a 
colitis similar to human IBD and that disease can be exacerbated by colonization 
with Helicobacter bilis [351, 352]. These mdr1a-/- mice have reduced growth rates 
compared to their WT counterparts and their histological lesions begin in the 
proximal colon and proceed distally as disease severity progresses. Mdr1a-/- males 
are more susceptible to the onset of severe disease than females [353, 354].   
Mdr1a-/- mice also have increased epithelial permeability and reduced 
phosphorylation of both occludin and ZO-1, tight junction proteins, compared to WT 
counterparts [354]. They exhibit increased bacterial translocation with bacteria 
detected in both the spleen and lymph nodes that correlates with disease severity. 
Therefore, the induction of disease is associated with a defect in the epithelial barrier 
function of the GI tract. In addition to the similar disease progression found in IBD 
patients, studying these mice are of interest because the human MDR1 gene has 
been mapped on a loci that that is associated with susceptibility of IBD, although this 
relationship is under debate [355-358]. 
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3. b. III. TRUC  
  TRUC mice are both T-bet-/- and RAG-/- and spontaneously develop colitis by 
four weeks of age [359, 360]. T-bet (T-box expressed in T cells) is a transcription 
factor that aids in the development of a Th1 response [359]. These mice have 
increased permeability of their colonic epithelium that increases with age and 
increased rate of epithelial cell death. Microscopically, there is inflammatory cell 
infiltrate, goblet cell dropout, crypt loss, and the presences of ulcers. The only 
cytokine elevated in these mice is TNF-α and disease can be ameliorated using an 
anti-TNF-α antibody. The microbiota also contributes to disease in this model, as 
treatment with antibiotics was able to “cure” the mice of their colitis. Additionally, the 
TRUC colitic microbiota can be horizontally transferred to both WT and RAG-/- mice, 
and 16S rRNA analysis of feces from TRUC mice revealed that the presence of 
Klebsiella pneumoniae and Proteus mirabilis correlate with colitis. Interestingly, GF 
TRUC mice colonized with these two organisms alone do not develop colitis unless 
a more complete microbiota is present [361]. 
 
3. c. CD45RBhi CD4+ T-Cell transfer model 
C.B.-17 scid mice administered CD45RBhi CD4+ T cells develop a wasting 
disease which is not seen if CD45RBlo CD4+ T cells or CD45RBhi CD8+ T cells are 
adoptively transferred [362-364]. Disease occurs three to five weeks post-
administration and is limited to the large intestine. The mucosa, submucosa, and 
muscularis all presented with inflammatory cell infiltrates (macrophages and CD4+ T 
cells predominately), and there was also a loss of goblet cells, epithelial cell 
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hyperplasia, and deep fissure ulcers. Elevated levels of IFN-γ were present in these 
mice, and treatment with anti-IFN-γ or anti-TNF (α and β) antibodies ameliorated 
disease in these mice. However, the protection garnered by using the antibodies 
was not as great as when CD45RBlo CD4+ T cells were transferred along with 
CD45RBhi CD4+ T cells [362]. This disease type mimics CD with respect to the type 
of inflammatory response generated (Th1) and the type of intestinal inflammation 
present (transmural infiltrate of CD4+ T cells) [365]. There is also a definite microbial 
component in this model of disease, as restricted microbiota mice have less severe 
disease as compared to their SPF counterparts [364]. 
 
3. d. Bacterial-induced models 
 
3. d. I. Helicobacter spp.. 
 Although not considered a microbial cause of IBD, the presence of 
Helicobacter spp. does adjuvant or predispose mice to the onset of colitis in some 
models. In our lab, we utilize a dual hit model of colitis consisting of both 
Helicobacter bilis colonization and low-dose (1.5 %) DSS to elicit colitis, as shown in 
Figure 8 [366].  
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Individually, H. bilis colonization or 1.5 % DSS alone only induce mild typhlocolitis 
(Figure 9). However, when DSS is administered to mice colonized with H. bilis, 
severe typhlocolitis is induced [367, 368]. In this model, the colitic mice display 
diarrhea and both the cecum and colon are involved as evidenced by macroscopic 
cecal atrophy and colonic shortening. Microscopically, these mice exhibit 
inflammatory cell infiltrate, ulcerations, and loss of colonic glands (Figure 9). 
 
Multiple Hit Model of Colitis 
Defined Microbiota Mice 
(Immunocompetent C3H/HeN:Tac mice colonized with the 
Altered Schaedler Flora) 
Hit #2 
Environmental 
or Inflammatory 
Trigger 
1.5% DSS 
Colitis 
Hit #1 
Bacterial 
Colonization 
Helicobacter bilis 
Credit: Wannemuehler Lab 
Figure 8. To increase sensitivity to a colitic insult, ASF-bearing C3H/HeN:Tac 
mice were colonized with a bacterial provocateur, Helicobater bilis.  An otherwise 
non-colitic low dose of DSS is then administered resulting in colitis. 
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 It has been noted that colonization of mice with H. bilis alone can change 
mucosal gene expression and alter the immune response in C3H/HeN mice bearing 
the altered Schaedler’s flora (ASF) [366, 369]. Genes involved in T cell receptor 
signaling, the survival and activation of peripheral B cells, and chemotaxis are a few 
examples of the host genes that were upregulated by H. bilis colonization. Genes 
that were down regulated were involved in fatty acid metabolism and detoxification. 
After H. bilis colonization, serum antibodies directed at antigens derived from 
members of the ASF are induced [366, 369]. H. hepaticus colonization of A/JCr mice 
also induced changes in gene expression in the cecum, with female mice being 
more susceptible to the onset of disease [370, 371].  
Figure 9.  Mice colonized with Helicobacter bilis and subsequently administered a low dose of DSS exhibit colitis that 
is not seen with H. bilis or DSS alone.  Disease is characterized grossly by colonic shortening, edema, cecal atrophy, 
enlarged lymphoid aggregates, and blood present in the contents. Microscopically, the disease presents with 
inflammatory cell infiltrate, crypt hyperplasia, glandular dropout, and cellular erosion	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It appears that an over zealous host response to the introduction of the novel 
organism (i.e., provocateur) predisposes certain strains of mice for the onset of 
typholocoltiis following a secondary colitic insult. In a study comparing A/JCr mice 
(that develop mild inflammation) to C57BL/6 (who do not develop inflammation) mice, 
cecal gene expression profiles revealed that A/JCr mice had more genes 
differentially regulated (176) compared to C57BL/6 (80). Differentially expressed 
genes were predominantly those associated with immune response, chemotaxis, 
signal transduction, and antigen processing in the A/JCr mice while the genes in the 
C57BL/6 mice were predominately associated with immunoglobulin production.  
In the mdr1a-/- mouse, it is not simply the presence of Helicobacter that 
results in the induction of colitis but the specific species of Helicobacter influences 
the induction of a differential immune response.  In mdr1a-/- mice, H. bilis 
colonization causes colitis as early as three weeks post-infection, whereas H. 
hepaticus colonization ameliorated the severity of colitis in these mice compared to 
the uninfected control mdr1a-/- mice [352]. The disease phenotypes between 
spontaneous versus Helicobacter-induced colitis in mdr1a-/- mice were different, with 
ulcer formation not present in the Helicobacter-induced colitis. When mdr1a-/- mice 
were co-colonized with both Helicobacter species, the morbidity and mortality rate 
was between that of mice colonized by either H. bilis or H. hepaticus and the colitis 
that developed was characterized by dysplasia. H. bilis was also able to out compete 
H. hepaticus in vivo as evidenced by recovery of higher numbers of H. bilis, 
suggesting that these two species may compete for similar niches in the GIT. 
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Additionally, colonization of IL-10-/- C57BL/6 mice with Helicobacter species 
results in the induction of colitis in otherwise disease-free mice [372]. It was also 
shown that the onset and severity of colitis was species specific in relation to 
colonization by H. bilis or H. hepaticus [373]. With respect to C3Bir.129 IL-10-/- mice, 
the presence of Helicobacter spp. is required for the spontaneous onset of disease 
[339]. Further studies show that colonization of RAG1-/- mice with Helicobacter 
species fails to elicit clinical signs of disease after nine months of colonization and 
only very mild inflammation was detected at necropsy [373]. Taken together, these 
observations indicate that disease induction can be mediated by an aberrant 
adaptive immune response initiated by bacterial provocateurs entering an otherwise 
stable host-microbe environment.  
  
3. d. II. Brachyspira hyodysenteriae 
Similar to the need for the a resident microbiota in the TRUC model of colitis, 
mice colonized with Brachyspira hyodysenteriae also require the presence of a 
microbiota for the induction of typhlocolitis. B. hyodysenteriae is an anaerobic 
spirochete that is the causative agent of swine dysentery [374]. While the 
pathogenesis of B. hyodysenteriae is associated with the production of a β-
hemolysin [375], disease does not develop in the absence of a resident microbiota 
as was demonstrated by the inoculation of germfree pigs [376-378]. The importance 
of the microbiota was further demonstrated when the microbiota of C3H/HeSnJ or 
BALB/c mice was depleted by adding a cocktail of antibiotics (rifampicin, colistin, 
spectinomycin, spiramycin, and vancomycin) to their drinking water. As can be seen 
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in Figure 10, the antibiotic cocktail depleted the numbers of Gram-positive, Gram-
negative, and strict anaerobes by as much as 5 to 7 log10 (Nibbelink and 
Wannemuehler, unpublished observations). On day seven, antibiotic treated and 
sham treated mice were inoculated with 1 x 108 B. hyodysenteriae strain B204 and 
severity of disease was evaluated at 5, 10, and 15 days post-infection (DPI). As can 
be seen in Figure 11, the sham-treated mice developed severe typhlocolitis while the 
antibiotic treated mice had no lesions. At 15 DPI, the antibiotics were withdrawn from 
the drinking water of the remaining B. hyodysenteriae-infected mice to allow the 
microbiota to recover. On day 30 PI, the mice that had been treated with antibiotics 
through 15 DPI now presented with severe typhlocolitis. The presence and severity 
of typhlocolitis in these mice correlated with the presence of TNF-specific mRNA in 
the cecal tissue of the B. hyodysenteriae-infected mice (data not shown). Lastly, B. 
hyodysenteriae-induced typhlocolitis could also be prevented when the host’s 
inflammatory response was inhibited [379, 380].  Collectively, these observations 
indicate that certain bacterial provocateurs (K. pneumoniae, P. mirabilis, and B. 
hyodysenteriae) may fail to induce disease in the absence of an appropriate resident 
microbiota. As depicted in Figure 12, the etiology of colitis is complex and may 
require the presence of a microbial provocateur, the resident microbiota, and a host 
inflammatory response.    
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Figure 10. To assess the role of the 
microbiota in Brachyspira 
hyodysenteriae-induced 
typhlocolitis, C3H/HeSnJ mice were 
treated with an antibiotic cocktail to 
deplete the resident microbiota. Six 
days later, mice were infected with 
B. hyodysenteriae. The data 
indicate that there was a five to 
seven log10 reduction in the resident 
microbiota. 
 
Figure 11. Assessment of Brachyspira 
hyodysenteriae-induced typhlocolitis in 
C3H/HeSnJ mice treated with an 
antibiotic cocktail. While B. 
hyodysenteriae colonized the antibiotic-
treated mice to the same extent as it did 
the sham-treated mice, there was no 
evidence of typhlocolitis in the antibiotic 
treated mice through 15 days post-
infection (DPI). However, 15 days after 
the antibiotics were withdrawn (30 DPI), 
the mice that had been treated with the 
antibiotics had developed severe 
disease once the microbiota recovered. 
Figure 12.  The pathogenesis of 
inflammatory bowel disease is complex. 
Studies from animal models indicate that 
the etiology of disease involves the 
presence of a bacterial provocateur, the 
resident microbiota, and the host 
response. 	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3. e. Conventional mice 
 The majority of commercially available mice harbor a “conventional” 
microbiota. This simply means that the composition of the community is unknown. 
There are different types of conventionally-reared mice. For example, Taconic 
Farms maintain two types of conventional microbiota mice, restricted flora™ (RF) 
and murine pathogen free™ (PF). RF mice are not colonized by β-hemolytic 
Streptococcus species, K. pneumoniae, K. oxytoca, Pseudomonas aeruginosa, or 
Staphylococcus aureus. Mice that are PF are Helicobacter free but can contain 
organisms not found in RF mice [381].  Additionally, mice on the same background 
purchased from different vendors can harbor different microbiota, as highlighted in 
work by Ivanov and colleagues demonstrating the presence of SFB in C57BL/6 mice 
from Taconic but not Jackson Laboratories [54]. This lack of consistency in 
microbiota from mice of the same strain has even been identified at different facilities 
from the same vendor (Overstreet and Wannemuehler unpublished observation). 
Therefore, comparison of studies evaluating the microbiota of mice are difficult 
because there are hundreds of unknown bacterial species present in the murine 
microbiota and there is no standardized microbiota used by investigators. The 
advent of next-gen sequencing has helped to alleviate some of this challenge as all 
of the organisms in the gut can be sequenced. However, it still does not resolve the 
issue related to the use of disparate strains of mice from different suppliers. 
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3. f. Germfree mice 
 GF mice are completely devoid of microbial life. As mentioned previously, this 
does grossly affect the anatomy of these mice, which is most evident by the 
enlargececa being the most prominent feature [34]. The discovery that many GF 
mouse strains that carry genetic deficiencies associated with IBD (notably the        
IL-10-/-) do not develop colitis has led to the popularity of GF models to study the role 
of bacteria in the pathogenesis of IBD [346]. To determine if an organism is capable 
of initiating colitis, GF mice are monoassociated with a single bacterial species and 
then monitored for clinical signs of disease. Some of the bacterial strains used to 
date to evaluate their ability to induce disease in IL-10-/- mice are shown in Table 3. 
Although the information gathered from these studies has been useful in analyzing 
the immune response to specific organisms, trying to relate the resultant disease to 
that characteristic of IBD is marginal at best because of the differences in the 
complexities of the microbiota. IBD itself is a multi-factorial disease and it has been 
fairly well-established that the role of bacteria in IBD occurs via a shift in community 
dynamics (i.e., dysbiosis) and not the presence/absence of one particular species. A 
perfect example of this complexity is the fact that K. pneumonia and P. mirabilis fail 
to induce colitis in GF TRUC mice (Figure 12) [361]. 
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Table 3. Bacterial strains used to monoassociate GF mice to examine the ability of 
the strain to induce colitis 
Organism 
Colitis 
Severity 
Time of Disease 
Onset 
Reference 
Enterococcus faecalis Severe 10-12 weeks p.i. [382, 383] 
Escherichia coli (from WT SPF 
mouse) 
Moderate 3 weeks p.i. [382] 
Pseudomonas flourescens No disease - [382] 
Helicobacter hepaticus No disease - [384] 
Lactococcus lactis No disease - [383] 
Viridans group Streptococcus No disease - [385] 
Clostridium sordellii No disease - [385] 
Bacteroides vulgatus No disease - [385] 
Bifidobacterium animalis Mild 23 weeks p.i. [386] 
Bifidobacterium infantis No disease - [386] 
 
3. g. Defined microbiota mice  
Also referred to as gnotobiotic, defined microbiota (DM) mice have a 
microbiota in which all members are known and are housed in flexible film isolators 
to maintain this status [387]. One of the most established DM mouse models harbors 
the “Altered Schaedler Flora” (ASF). Developed by Dr. Rodger Orcutt and 
colleagues as a request from the National Cancer Institute, these eight microbial 
species were originally used to standardized the microbiota of the rodents used as 
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founders in their breeding colonies [388]. He chose to modify his mentor’s (Dr. Russ 
Schaedler) cocktail of organisms by eliminating facultative anaerobes (Escherichia 
coli var. mutabilis and Streptococcus fecalis) and the anaerobic Streptococcus and 
Clostridia spp. that formed the original “Schaedler Flora”. Dr. Orcutt added four 
additional species (see Table 4 below). This resulted in an anaerobic community 
devoid of any cocci or spore-forming blunt ended rods, which comprise the main 
isolator contaminants, making it easier to monitor for contamination of the 
gnotobiotic isolator. This new community was dubbed the “Altered Schaedler Flora” 
and was utilized in the breeding stock by major commercial mouse vendors in the 
US in that era. The ASF consists of members with different morphologies so that 
identification using fecal smears for microscopic evaluation was possible. The 
members, whose full genomes have yet to be sequenced, have had 16S rRNA 
sequencing performed to assist with the identification of the organisms [389].  
Multiple studies have demonstrated the stability of this community both when 
maintained under gnotobiotic housing conditions or when part of a conventionalized 
microbiota [390-393]. In our own lab, all eight ASF members have been stably 
maintained in our breeding colony for over 12 years, indicating the remarkable 
stability of this model microbial community over time. PCR primers have been 
developed for each of the eight ASF members as well as group-specific FISH probes 
[390, 393]. Therefore, the effects of any perturbation of the ASF, such as with 
antibiotics, inflammation, or CAM treatments can be monitored by bacterial 
abundance as well as spatial redistribution using qPCR and FISH, respectively. All 
of the organisms can be cultured and whole cell sonicates produced to measure the 
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immune response to each organism individually (something that is impossible to do 
with a conventional microbiota). Additionally, this community, although limited in 
scope, is able to synthesize all the metabolites needed by the mouse and maintains 
near normal cecal shape and size, something not possible in GF mice. It is important 
to note, however, that some of the characteristics of ASF mice are more similar to 
GF than conventional mice. Both ASF and GF mice have high fecal tryptic activity 
and possess the ability to degrade mucin and β-aspartylglycine. They also cannot 
convert bilirubin to urobilinogens or cholesterol to coprostanol [394]. Interestingly, 
this same research team compared these parameters in CD patients versus healthy 
subjects and the characteristics of the microbial metabolism associated with the 
microbiota of CD patients were very similar to those of the ASF[395]. This study 
suggests that there is benefit to the use of the ASF in mouse models of IBD.  
Other defined microbiota mouse studies have been published [396-399]. A 
study using ten bacterial species specifically chosen for their metabolic function 
were used to colonize GF mice [396]. Using microbial RNA-seq, the authors were 
able to build a model relating perturbation of the microbial community to changes in 
diet. By modeling the functional capacity of a gnotobiotic community under different 
conditions, this model and similar approaches can be used to unravel the 
operational dynamics of the gut microbiome with respect to nutrient utilization such 
that the microbiota might be manipulated to improve human and animal health [396]. 
Another study colonized mice with E. rectale and B. thetaiotamicron, and the authors 
then assessed changes in bacterial gene expression using Affymetrix GeneChips to 
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show that the cross-talk between these two organisms affected up- and down-
regulated genes in response to one another. 
 
Table 4.  Members of the altered Schaedler flora 
Strain Identity 
ASF356 Most closely related to Clostridium propionicum (92 % max 
identity) [400] 
Member of Clostridium cluster XIV  
ASF360 Lactobacillus intestinalis (99 % max identity) [401] 
ASF361 Lactobacillus murinus [400] 
ASF457 Mucispirillum schaedleri [402] 
ASF492 Eubacterium plexicaudatum [403] 
Member of Clostridium cluster XIV 
ASF500 Clostridium sp. with no known related organism in GenBank 
Database [400] 
ASF502 Most closely related to Ruminococcus gnavus (92 % max 
identity) [400] 
Member of Clostridium cluster XIV 
ASF519 Parabacteroides goldsteinii (99 % max identity) [404, 405] 
 
 
Three human commensals, E. coli, B. longum, and L. johnsonii, have also 
been used to colonize GF mice to create a gnotobiotic community [397]. This 
community was used to identify the effects that the introduction of novel organisms 
has on the community dynamic. When colonized with a second Lactobacillus sp., L. 
paracasei, it was noted that both Lactobacillus spp. were able to co-habitate 
reaching similar fecal titers. However, that was not the same when a fifth organism 
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was added, a second B. longum strain. This new strain was only maintained in the 
mouse at detectable levels for three days. Lastly, a second E. coli strain was added 
to the original community of three. This new E. coli reached the highest titer of any 
organism in the community. This addition caused the reduction of the original E. coli 
to drop to undetectable levels at day two post-addition. Later L. johnsonii also 
reached undetectable levels. B. longum decreased initially but them returned to 
normal titer levels. Lastly, when the original tri-associated mice were exposed to 
conventional mouse feces, the numbers of the original three organisms decreased. 
 In this chapter, we have discussed the three most common types of 
microbiota available for use in IBD research. Because it is clear that IBD results from 
an imbalance in the microbial community, the use of GF mice (which cannot mimic a 
“community” dynamic) may be less useful in unraveling the complexities of a 
multifactorial disease in place of defined microbiota and conventional microbiota 
mice. Ideally one would want to use a simplified community (such as the ASF) where 
the actions of all organisms can be assessed. To understand the dynamic 
interactions that occur between microbes and between the microbes and the host, it 
will be important to start with what is known in order to begin the unraveling the 
enigmatic nature of gut health and disease. 
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Abstract 
 The gastrointestinal tract harbors bacteria on which the body depends on for 
a variety of functions such as vitamin production and energy storage. This 
community is susceptible to changes from environmental factors such as antibiotics. 
The effect of the antibiotic on the microbial community lasts longer than the duration 
of treatment and in some cases the community may never fully re-establish itself. 
When the community deviates from normal it becomes dysbiotic, which may lead to 
the development of diseases such as inflammatory bowel disease. We report here 
the study of two intestinal microbial communities to identify differences in disease 
severity in response to a DSS-induced model of murine colitis. ASF and CONV mice 
were given 4 mg/mL of ampicillin for nine days. Mice were then colonized with 
Helicobacter bilis for two weeks. Then either a 1.5 % (ASF) or 2.5 % (CONV) 
dextran sulfate sodium solution was added to their drinking water for five days 
followed by a 4 day restitution period. The results of this study revealed major 
differences in the inflammatory response after the induction of colitis. The 
administration of ampicillin caused the ASF mice to gain significantly less weight 
during the study compared to their CONV counterparts. Macropscopic and 
microscopic lesions within the two communities showed no change in score when 
comparing ampicillin H. bilis DSS (AhbD) and H. bilis DSS (Hbd). Ampicillin 
administration modulated the microbiota of the ASF mice much more drastically 
compared to the CONV mice. In the ASF mice, 4 of the 8 species present in the 
community were significantly reduced at the end of the study. ASF mice produced 
significantly higher levels of pro-inflammatory cytokines compared to the CONV mice 
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and also produced significantly more antibody against members of the microbiota. 
CONV mice had an increased concentration of several diabetes biomarkers, 
something not seen in the ASF mice.  
 The results of this study reveal that the severity of the immune response to 
colitic insults is microbiota specific. Mice with a simplified microbiota had increased 
antibody responses to the microbiota and increased pro-inflammatory 
cytokine/chemokine production. CONV mice, which had only a minimal inflammatory 
response, had an increase in diabetic biomarkers indicating that these mice were 
entering into a metabolic syndrome-like state. 
 
Introduction 
 The lower gastrointestinal (GI) tract is home to 1011-1012 organisms per gram 
of colonic contents. The microbes that dwell in this intestinal ecosystem harbor 150 
times mores genes than are present in the human body [1-3]. These bacteria aid 
their host in nutrient acquisition, vitamin production, metabolism of indigestible 
foodstuffs and the development of a mature immune system [4, 5]. Therefore, it is 
obvious that the GI microbiota (i.e., the commensals), with which we share our 
bodies, provide a great service and help maintain GIT health.  
 The gut microbiota is now even being considered as a therapeutic target for 
conditions such as obesity [6]. It has been well established now that the microbiota 
of lean and obese persons differ [7-9]. Obesity has many associated complications 
such as type 2 diabetes and cardiovascular disease and also induces a low-grade 
inflammatory response [10, 11]. A study by Qin et al. revealed that those persons 
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with type 2 diabetes have an altered microbiota compared to healthy controls [12]. 
These changes include a decrease in butyrate-producing organisms and an increase 
in opportunistic pathogens. This and other studies indicate a role for the microbiota 
in these metabolic diseases [12-14]. 
  This complex microbial community maintains its composition via a delicate 
balance that can be readily altered by multiple external factors, including infections, 
dietary changes and drug treatments [4, 15, 16]. Alterations to this balance can have 
severe consequences for the host, including disruption of normal physiological 
processes and immune dysregulation [17]. We have long known that antibiotic use 
has a tremendous impact on the GI microbiota [18]. However, recent advances in 
next generation sequencing have allowed us to more fully appreciate the significant 
changes in the composition of GI microbial communities following antibiotic use. In 
some scenarios, the community never fully returns to its original state even after 
antibiotic treatment is ceased [19-21]. Antibiotic use significantly alters the 
composition of the microbiota and also enhances host susceptibility to GI infection 
and increases the predominance of antibiotic resistance genes and organisms, 
including Salmonella and adherent and invasive E. coli [21-28]. Disruption of the gut 
microbiota following antibiotic use is gaining additional attention as a predisposing 
event in the development of inflammatory bowel disease (IBD) [29-32]. The etiology 
of IBD is complex; disease is thought to develop in a genetically susceptible host 
after exposure to an environmental trigger (or triggers) that induces an aberrant 
immune response directed against and perpetuated by antigens derived from the 
resident gut microbiota [33-37]. A variety of reports, including those utilizing animal 
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models, clinical studies and epidemiological data implicate the resident microbiota, 
including GI infections, in the pathogenesis of IBD. Significant differences in the 
microbiota composition of IBD patients and healthy controls have been documented 
[38-40]. The dysbiotic community observed in IBD patients is generally characterized 
by a contraction of Firmicutes and Bacteroidetes, expansion of Proteobacteria, 
reduced microbial diversity and increased presence of mucosa-associated 
organisms [41-47]. 
Genetically engineered mice do not develop spontaneous colitis unless they 
are associated with a microbiota [48, 49]. Work by Cadwell et al. detailed the 
enhanced susceptibility of Atg16L1 deficient mice infected with a norovirus to a 
subsequent inflammatory insult administered in the form of DSS [50]. Finally, 
transient infections with pathogenic enteric organisms, such as Salmonella spp., 
Campylobacter spp. and parasites, can serve as triggers to initiate inflammatory 
responses that are perpetuated by commensal bacterial antigens [51]. Clearly, the 
composition of the gut microbiota, including the presence of GI pathogens, 
contributes to the pathogenesis of IBD. 
Previous work from our laboratory has shown that colonization of defined 
microbiota mice with Helicobacter bilis, a model mouse GI pathogen, induces host 
immune responses against antigens derived from the resident microbiota and alters 
mucosal gene expression profiles in immunocompetent mice [52-54]. We have also 
demonstrated that prior colonization with H. bilis increases host susceptibility to 
colitis following a subsequent inflammatory insult with a very low dose of the 
inflammatory trigger, dextran sulfate sodium (DSS) [55]. This dose of DSS alone is 
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not sufficient to elicit colitis. In this present study, we examine the impact of antibiotic 
pretreatment on host susceptibility to H. bilis infection and subsequent inflammatory 
insults in C3H mice with either a defined or conventional microbiota.   
In contrast to previous reports describing exacerbated disease in mice treated 
with antibiotics prior to colonization with a GI pathogen [26, 56] pretreatment of 
defined and conventional microbiota mice with ampicillin prior to H. bilis colonization 
did not enhance host susceptibility to an inflammatory insult administered in the form 
of low-dose DSS. Despite the apparent lack of differences in disease severity, 
ampicillin pretreatment enhanced local inflammation as well as the humoral 
response against the resident microbiota in defined flora mice but not in mice with a 
conventional microbiota. Ampicillin pretreatment also significantly reduced the 
density of most of the resident bacterial species in the defined flora mice. Also of 
note were elevated serum levels of several biomarkers associated with metabolic 
syndrome following the onset of disease in conventional flora but not defined 
microbiota mice. Together, these data indicate that antibiotic treatment prior to 
infection with a GI pathogen may not enhance susceptibility to a subsequent 
inflammatory insult, but it does change the nature of the host’s immune response 
and metabolism depending on the complexity of the microbiota. 
 
Materials and Methods 
Animals  
 Male and female C3H/HeN:Tac mice (6-8 weeks old) defined microbiota (DM) 
mice colonized with the altered Schaedler flora (ASF) were obtained from Taconic 
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Farms (Germantown, NY). The ASF includes ASF356, a member of the Clostridium 
cluster XIV; ASF360, Lactobacillus intestinalis [57], ASF361; Lactobacillus murinus 
[58], ASF457, Mucispirillum schaedleri [59], ASF492, Eubacterium plexicaudatum 
[60]; ASF500, a low-G+C content Gram positive bacteria; AF502, a member of the 
Clostridium cluster XIV; and ASF519, Parabacteroides goldsteinii [61, 62]. Mice 
were bred and maintained in the murine gnotobiotic facility at the College of 
Veterinary Medicine, Iowa State University. Mice were housed in flexible film 
isolators to maintain their defined status and allowed ad libitum access to an 
irradiated 2919 diet from Harlan Teklad (Madison, WI) and sterile water. One week 
prior to the start of the experiment, mice were moved to Innocage® IVC cages 
supported by an Innovive IVC rack (San Diego CA). Mice were allowed ad libitum 
access to an autoclaved 2019S diet from Harlan Teklad (Madison, WI) and sterile 
water.  
Male and female C3H/HeN (6-8 weeks old) conventional microbiota (CONV) 
mice were obtained from Harlan Laboratories (Dublin, VA). These mice were 
confirmed positive for the eight ASF members prior to purchase. Mice were 
maintained in Innocage® IVC cages supported by an Innovive IVC rack (San Diego, 
CA). Mice were allowed ad libitum access to an autoclaved 2019S diet from Harlan 
Teklad (Madison, WI) and sterile water. Throughout the study, both ASF and CONV 
mice were maintained in the same room (12:12 hours dark/light cycle) with a 
maximum of five mice per cage. All animal procedures were performed in 
accordance with the experimental protocol approved by the Iowa State University 
Institutional Animal Care and Use Committee. 
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Experimental Design 
Mice were administered either 4 mg ampicillin sodium salt/mL of sterile water 
(Sigma-Aldrich, St. Louis MO) or sterile water for nine days. Ampicillin and water 
were changed daily to ensure freshness. Cages were changed during ampicillin 
administration to prevent the mice from re-colonizing themselves via coprophagy. 
On the 9th day, mice were given sterile water and 24 hours later they were colonized 
0.3 mL of 109 organisms of Helicobacter bilis. Mice were inoculated on two 
consecutive days. On the 10th day after colonization (i.e., experimental day 20), fecal 
samples were collected to confirm H. bilis colonization via PCR analysis as 
previously described [63]. Fourteen days after colonization, mice were given either 
1.5 % (ASF) or 2.5 % (CONV) dextran sodium sulfate (DSS) (MW 36,000-50,000; 
MP Biomedicals, Solon, OH) in their drinking water for five days followed by four 
days with sterile water prior to terminating the experiment. The experiment lasted a 
total of 33 days and the timeline is shown in Figure 1. Mice that were treated with 
ampicillin, colonized with H. bilis, and treated with DSS will be referred to as AHbD 
and mice colonized with H. bilis and treated with DSS will be referred to as HbD. 
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Figure 1. Schematic diagram of the experimental plan 
 
Helicobacter bilis colonization 
 H. bilis was grown in a biphasic growth medium consisting of a Brucella agar 
base (BD, Franklin Lakes, NJ)  supplemented with 0.1 % activated charcoal (Acros 
Organics, Geel, Belgium), 20 % heat inactivated newborn calf serum (Hyclone Lab, 
Logan, UT), 2 % Vitox (Oxoid, UK) and 1.25 % agar (Fisher Scientific, Pittsburgh 
PA). A 3 ml overlay of brucella agar base supplemented with 20 % heat inactivated 
newborn calf serum, 1 % IsoVitaleX (BD, Franklin Lakes, NJ), and 1.3 % urea agar 
base (BD, Franklin Lakes, NJ) was used over the agar base and was the medium 
inoculated with the organism. Plates were incubated at 37°C in a microaerophilic 
chamber in which the atmosphere consisted of 85 % N2, 10 % CO2, and 5 % O2.  
Sample Collection and Preparation 
 Blood was collected at defined time-points via the saphenous vein. At 
necropsy, blood was collected via cardiac puncture following euthanasia via CO2 
asphyxiation. Following collection, blood samples were allowed to clot at 4°C 
	   123	  
overnight, and serum was separated by centrifugation and stored at -20 °C until 
used. The cecum was aseptically excised and contents were snap frozen in liquid 
nitrogen for DNA extraction and stored at -20°C. Cecal tissues devoid of contents 
were placed in either 10 % buffered formalin or RNAlater® (Ambion, Grand Island 
NY) for histopathological evaluation and gene expression studies. During the 
necropsy, sections of cecal tissue were placed in phosphate buffered saline to 
maintain hydration. Following the necropsy, the tissue was cut into three 1-cm 
sections and placed in wash medium (RPMI 1640 supplemented with 50 µg 
gentamicin sulfate/ml and 20,000 IU/20,000 µg of penicillin/streptomycin) and placed 
on a rocker for 30 min at 25°C. All cell culture reagents were from Cellgro, 
Manassas, VA, unless otherwise noted. At the end of the incubation period, the 
tissues were placed into 96 well plates containing explant medium (RPMI 1640 
supplemented with 20,000 IU/20,000 µg of penicillin/streptomycin, 50 µg gentamicin 
sulfate/ml, 2 mM glutamine, 50 µM 2-mercaptoethanol, and 1 mM sodium pyruvate). 
Tissues were incubated overnight at 37°C in a humidified atmosphere with 5 % CO2. 
The following day, supernatant fluids were aspirated, placed in a new 96-well plate, 
and stored at -20°C. 
Macroscopic assessment of cecal lesions 
 Macroscopic lesions of the cecum were scored, noting the presence of 
atrophy, enlarged cecal tonsil, diarrheic luminal contents, presence of fresh blood, 
gross thickening (edema) of tissue. Lesion severity scores were based on the total 
number of observable macroscopic lesions with a maximum score of 5 indicative of 
severe disease. 
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Histopathological assessment  
Fixed tissues were embedded in paraffin, sectioned and stained with 
hematoxylin and eosin (H&E) for light microscopic evaluation. Stained sections of 
each cecum were scored in a blinded fashion by a Board-certified veterinary 
pathologist (J. Hostetter) as previously described [52, 53]. The final histological 
score represented the numerical sum of 5 parameters with each parameter scored 
from 0-5 (0= no lesion, 5= maximum severity). The maximum cumulative score was 
25. Histopathologic parameters evaluated included mucosal ulceration, magnitude of 
lamina propria infiltration and character of inflammatory cells, mucosal edema, 
stromal collapse, and crypt hyperplasia.  
Cytokine/Chemokine Quantification 
 Supernatants from the cecal tissue explants were used to measure the local 
chemokine concentration using a murine multiplexed antibody array according to the 
manufacturer’s instructions (Millipore, Billerica MA). Analytes measured were: 
Eotaxin, G-CSG, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, 
IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17, IP-10, KC, LIF, LIX, MCP-1, M-CSF, 
MIG, MIP-1α , MIP-1β, MIP-2, RANTES, TNF-α, and VEGF. The mean fluorescence 
intensity (MFI) values were converted to analyte concentrations using known 
standards and commercial software (xPONET®). 
Serum Diabetes Analyte Quantification 
 Measurement of diabetes analyte concentrations in the serum of mice 
collected at necropsy was performed using a murine multiplexed antibody array 
according to the manufacturer’s instructions (Bio-Rad, Hercules, CA) and a Luminex 
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200 (Luminex Corp., Madison WI). The mean fluorescence intensity (MFI) values 
were converted to analyte concentrations using known standards and commercial 
software (xPONET®). 
Antigen-specific antibodies 
 An ELISA was performed to determine the presence of H. bilis- and ASF-
specific antibodies (total IgG H&L) in the sera as previously described [52]. 
DNA Extraction and qPCR for bacterial quantification 
Cecal DNA was extracted using an UltraClean Fecal DNA Isolation kit 
according to the manufacturer’s instructions with a few modifications (MoBio 
Laboratories Inc, Carlsbad CA). Those modifications include: adding 20 µL of 
proteinase K (20 mg/mL) to the sample along with solution S1 and the bead solution 
and heating the sample to 55ºC for 1 hour in the beginning of the procedure, using 
solution CB3 instead of S3 to bind DNA to the silica column, and rinsing the column 
twice with 70 % ethanol instead of once. After extraction, DNA was quantified using 
Quant-itTM PicoGreen® (Invitrogen, Grand Island NY) according to the manufacturer’s 
instructions. All DNA samples were diluted to 0.8678 ng/uL with nuclease free water. 
One µL was used as template in a PCR using Platinum® SYBR® Green qPCR 
SuperMix-UDG and with a final MgCl2 concentration of 4.0 mM (Invitrogen, Grand 
Island NY). All samples were run in duplicate using the primers in Table 1. The 
qPCR conditions were 2 min @ 50°C, 10 min @ 95°C, and 40 cycles of 95°C for 15 
seconds, 60°C for 60 seconds. The thermocycler was an Applied Biosystems® 5700.  
The results were compared to qPCR results from plasmid standards of the 16S 
rRNA genes to obtain final values of bacteria per gram of cecal contents. The 
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plasmids were kindly supplied by Dr. Martin Polz and the standards created as 
previously described [64].  
Table 1. ASF Primer Sequences, qPCR parameters and operon numbers 
Strain GenBank Number Species or Group Primer
A Standard Curve Operon numberB 
    Slope Intercept  
ASF356 AF157052 Clostridium sp. 
F AACGCCGCGTGAAGGAA (800) -3.33 
 
34.10 
 
5 
R ACGCTTGCCCCCTACGTATT (800) 
ASF360 AF157050 Lactobacillus sp. 
F CGGCGGATGGGTGAGTAAC (800) -3.65 
 
36.91 
 
4 
R GTATTAGCACCTGTTTCCAAGTGGTA    
(800) 
ASF361 AF157049 Lactobacillus murinus 
F GTGGCGAACGGGTGAGTAA (400) -3.26 
 
34.09 
 
6 
R GCACCTGTTTCCAAGTGTTATCC 
(400) 
ASF457 AF157057 Mucispirillum schaedleri 
F TGCAAGAATGAAACTCAAAGGAAT 
(400) -3.29 
 
33.58 
 
14 
R TAAGGTTCTTCGGTTAGCATCGA 
(400) 
ASF492 AF157054 Eubacterium plexicaudatum 
F TGGAGCATGTGGTTTAATTCGA (400) -3.44 
 
34.64 
 
4 
R TGCACCACCTGTCTGCAATG (400) 
ASF500 AF157051 
low-G+C content 
Gram positive 
bacteria 
F GCTGCTAATACCGCATGATATGTC 
(400) 
-3.27 
 
34.17 
 
11.2 
R CAGACGCGAGTCCATCTCAGA (400) 
ASF502 AF157053 Clostridium sp. 
F GCTACAATGGCGTAAACAAAGAGA 
(400) 
-3.26 
 
33.46 
 
11.2 
R TCCGAACTGAGACGTTATTTTTGA 
(400) 
ASF519 AF157056 Parabacteroides goldsteinii 
F ATTGCCGTTGAAACTGGTTGA (400) -3.46 
 
34.78 
 
5 
R CCTTCGCAATCGGAGTTCTG (400) 
A. Primers	  used	  were	  previously	  published	  by	  Alexander	  et	  al.	  [65]	  B.	  Operon	  number	  was	  previously	  determined	  by	  Sarma-­‐Rupavtarm	  et	  al.	  [64]	  Values	  in	  parenthesis	  at	  the	  end	  of	  the	  primer	  sequence	  indicate	  the	  nanomolar	  concentration	  of	  primer	  used	  
 
 
RNA Isolation and cDNA synthesis 
 Total RNA from cecal tissues was extracted using a RNeasy Mini Kit (Qiagen, 
Valencia, CA) according to the manufacturer’s instructions with the addition of an 
extra RPE wash. RNA integrity was measured using an 2100 Bioanalyzer (Agilent 
Techonologies, Santa Clara, CA). All RNA used in subsequent steps had a RIN 
number of 7 or higher. RNA was reverse transcribed to cDNA using RT2 First Strand 
Kit (Qiagen, Valencia, CA).  
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Mouse NF-κΒ Signaling Pathway 
 For pathway expression analysis, cDNA from each treatment group was 
pooled and a RT2 Profiler PCR array (Qiagen, Valencia, CA) was used according to 
the manufacturer’s instructions. The plates were run on an Applied Biosystems® 
5700 machine using the cycling conditions provided in the instructions. 
Determination of fold change differences between treatment groups was performed 
using the PCR array data analysis web portal found at 
www.SABiosciences.com/pcraraydataanalysis.php. 84 genes were analyzed and 
included: Agt, Akt1, Atf1, Atf2,Bcl10,Bcl2a1a,Bcl2l1, Bcl3, Birc3, Card10, Card11, 
Casp1, Casp8, Ccl2, Ccl5, Cd27,Cd40, Cflar, Chuk, Crebbp, Csf1, Csf2, Csf3, Egfr, 
Egr1, Eif2ak2, Elk1, F2r, Fadd, Fasl, Fos, Hmox1, Icam1, Ifng, Ikbkg, Il10, Il1a, Il1b, 
Irak1, Irak2, Irf1, Jun, Lta,Ltbr, Map3k1, Map3, Myd88, Nfkb1, Nfkb2, Nfkbia, Nod1, 
Raf1, Rel, Rela, Relb, Ripk1, Ripk2, Slc20a1, Smad3, Stat1, Tbk1, Tlr1, Tlr2, Tlr3, 
Tlr4, Tlr6, Tlr9, Tnf, Tnfaip3, Tnfrsf10b, Tnfrsf1a, Tnfrsf1b, Tnfsf10, Tnfsf14, Tollip, 
Tradd, Traf2, Traf3, Traf5, Traf6 
Fluorescence Imaging  
 To evaluate the in vivo inflammatory response, mice were intravenously 
administered 2 nmol of ProSense® 750 (Perkin Elmer, Walthem, MA) in 100 µL of 
sterile saline. ProSense® 750 is an activatable fluorescent reagent that is optically 
visible when the dye is cleaved by degradative enzymes, including cathepsin B, L, S, 
or plasminogen, that are common at sites of inflammation [66]. After 24 hours, the 
mice were euthanized by CO2 asphyxiation and the ex vivo images of excised 
tissues were captured. Images were captured using 30-second exposures with an 
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excitation filter of 730 nm and an emission filter of 790 nm. All image analysis was 
quantified using ImageJ version 1.44 [67]. Raw images were inverted and 
background subtracted via a rolling ball radius of 150 pixels. The ImageJ lookup 
table “fire” was applied to the fluorescent exposure. Composite images were 
constructed using a white light exposure (0.2 seconds) to super-impose 
fluorescence image for tissue distinction.   
Statistical Analysis 
All values were expressed as mean + SEM. ELISA, qPCR, and fluorescence 
intensity data were log transformed prior to statistical analysis to normalize the data. 
An analysis of variance (ANOVA) model was used for the qPCR, ELISA data, 
fluorescence intensity data, luminex and feed consumption and diabetes biomarker 
data with no adjustments. For the temporal ELISA, a repeated measures of analysis 
was used with treatment group, microbiota and their interaction as fixed effects. 
Non-parametric data were evaluated using a Wilcoxon Rank Sums test. P-values < 
0.05 were considered significant for all tests. SAS software (SAS Institute Inc., Cary 
NC, USA) was used for all statistical calculations.  
 
Results 
Treatment with ampicillin for nine days causes gross cecal changes  
During the experiment, a subset of mice were necropsied immediately after 
ampicillin administration to determine the effects of the antibiotic on the two 
microbial communities. As shown in Figure 2, both ASF and CONV mice treated with 
ampicillin for nine days had an increase in cecal size along with a loss of cecal 
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architecture resulting in a balloon-like appearance. The cecal contents of the 
ampicillin-treated mice had a more liquid consistency compared to that in mice given 
water alone; in addition, softer stools were observed for the mice treated with 
ampicillin. As a measure of the effect the ampicillin treatment had on the microbiota, 
cecal contents from both ASF and CONV mice were inoculated onto agar medium to 
assess the replication of aerobic bacteria; plates were incubated for 24 hours at 
37°C and no growth was noted for either group (data not shown).  
 
 
 
 
Figure 2. The administration of ampicillin for nine days cases gross changes in the  
cecal morphology. The changes include cecal enlargement and a loss of 
architecture. The result is a balloon-like sac which encloses watery cecal contents.  
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ASF and CONV mice exhibit different patterns in feed consumption and weight 
gain 
 Feed consumption in the mice was measured during the course of the nine 
day ampicillin treatment. As shown in Figure 3 A, there were no differences between 
ampicillin treated and control mice within the two different microbial communities. 
However, comparing consumption between the two microbial communities, the 
CONV mice ate significantly more than their ASF counterparts.   
The effect of the antibiotic treatment on weight gain in the mice harboring the 
two different microbial communities was recorded during the study. Mice were 
weighed at the beginning of the study, after nine days of ampicillin treatment, and at 
the termination of the experiment. Figures 3B&C show the plotted weights 
throughout the study of the CONV mice (Figure 3B) and the ASF mice (Figure 3C). 
Figure 3D shows the difference in the weights during the nine days of ampicillin 
administration. There was no difference in the amount of weight gained over the nine 
days for any group of mice. Figure 3E shows the difference in weights for the 
duration of the 33-day experiment. The ASF mice treated with ampicillin, colonized 
with H. bilis and exposed to DSS (AHbD) gained significantly (p = 0.02) less weight 
throughout the experiment compared to CONV mice that received the same 
treatment. The mice that were not treated with ampicillin had no significant change in 
weight gain over the course of the experiment regardless of microbial community.  
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Figure 3. The ASF and CONV mice exhibit different trends in weight gain and feed 
consumption. (A) CONV mice ate significantly more food during ampicillin 
administration than their ASF counterpart. There was no difference in feed 
consumption within mice harboring the same microbiota but who had different 
treatments. Figure 3B&C show the weights of the mice used in this study potted over 
time. Figure D shows the difference in the weight gained during the nine days of 
ampicillin treatment between ASF and CONV mice. Figure E shows the differences 
in weight gain during the duration of the study. All results are expressed as mean + 
SEM. An asterisk indicates p < 0.05.  
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Macroscopic cecal lesions are more severe in ASF mice compared to CONV 
mice while there is no difference in microscopic score 
 Pretreatment with ampicillin did not alter the severity of the macroscopic cecal 
lesions in either ASF or CONV mice colonized with H. bilis and exposed to DSS 
(Figure 4&5 A). Within treatment groups, the HbD ASF mice had a significantly (p = 
0.0009) higher gross score compared to the HbD CONV mice (Figure5 A). The ASF 
mice had an increased abundance of cecal atrophy, enlarged lymphoid aggregates, 
watery/mucoid contents and thickening of the cecal tissue compared to the CONV 
mice. Microscopically, there was no difference in the histopathology scores for the 
AHbD ASF compared to the AHbD CONV and the HbD ASF compared to the HbD 
CONV mice (Figure 5 B).  
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Figure 4. Both ASF and CONV mice given H. bilis and DSS exhibit typhlocolitis 
regardless of ampicillin pretreatment. This is exhibited by cecal atrophy, enlarged 
cecal tonsil with lymphoid aggregates, watery contents, and thickened cecal tissue. 
 
 
 
Figure 5. Both ASF and CONV mice given H. bilis and DSS exhibit typhlocolitis. 
 (A) ASF mice colonized with H. bilis and treated with DSS exhibited a significantly 
higher gross cecal score compared to CONV mice receiving the same treatment. 
There was no significant difference between ASF and CONV mice treated with 
ampicillin prior to H. bilis colonization and DSS treatment. (B) ASF and CONV mice 
regardless of treatment exhibit similar microscopic cecal scores. The results are 
expressed as mean + SEM. An asterisk indicates p < 0.05. 
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 Ex vivo imaging of the ceca shown in Figure 6, reveals a greater amount of 
cecal inflammation present in the AHbD ASF mice. This was confirmed quantitatively 
by measuring the mean fluorescence intensity of the cecal inflammation assessed 
using the Prosense 750 probe (Figure 7). The AHbD ASF mice had significantly 
more inflammation than their AHbD CONV counterparts (p = 0.01) or HbD ASF mice 
(p = 0.004). There was no difference in inflammation between the treatments in the 
CONV mice.  
 
 
 
Figure 6. Both ASF and CONV mice have increased inflammation when given the  
colitic insult of H. bilis and DSS. Giving ampicillin preceding the inflammatory insult 
increases inflammation in the ASF mice only. This is revealed by increased 
fluorescence intensity present only in the cecum of the ASF mice given ampicillin, 
colonized with H.bilis and treated with DSS. 
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Figure 7. ASF mice pretreated with ampicillin prior to H. bilis colonization and DSS 
administration have significantly more cecal inflammation compared to similarity 
treated CONV mice or ASF mice only colonized with H. bilis and treated with DSS. 
The results are expressed as mean + SEM. An asterisk indicates a significant p < 
0.05. MFI=mean fluorescence intensity.  
 
ASF mice develop an antibody response to the microbiota after the 
administration of DSS  
Serum samples were collected at four time-points throughout the study; 
before ampicillin administration (experimental day 0), after ampicillin administration 
(experimental day 9), before DSS (experimental day 23), and at necropsy 
(experimental day 33). Note that at the first two time-points, none of the mice were 
colonized with H. bilis, but for the last two time-points, all mice were colonized 
(Figure 8). Comparing ASF-AHbD to ASF-HbD mice, there were no significant 
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differences in total serum IgG induced to either ASF 356 or 360 at any time point. At 
necropsy (i.e., day 33), significant (p < 0.05) serum antibody specific for seven of the 
nine bacterial antigen preparations were detected in the ASF-AHbD mice compared 
to the ASF-HbD mice. The only time that the ASF-HbD mice had higher antibody 
titers compared to the ASF-AHbD mice was at day 9 and day 23 and only against 
antigen from ASF519.  
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Figure 8. The antibody response to the microbiota was measured throughout the 
experiment. The mice given ampicillin prior to H. bilis colonization and DSS 
treatment had an increased antibody response to 7 of the 9 antigens measured. The 
only antigen that had a significant response in the mice colonized with H. bilis and 
treated with DSS was ASF519. Only O.D. values greater than 0.2 were used in the 
statistical analysis. The results are expressed as mean + SEM. An asterisk indicates 
p < 0.05. 
 
ASF and CONV mice have different antibody responses after the 
administration of DSS 
 Sera collected at necropsy was used to compare the induction of antibody 
specific for whole cell lysates of each of the eight ASF members as well as to H. bilis. 
Prior to the initiation of these experiments, it was confirmed that the CONV mice 
harbored all eight members of the ASF and were not colonized with H. bilis. The 
data depicted in Figure 8 indicated that the ASF-AHbD mice had significantly greater 
antibody responses to 7 of the 9 whole cell antigen preparations measured 
compared to ASF-HbD mice. CONV-AHbD mice only developed a significant 
antibody response to H. bilis (Figure 9). The CONV-HbD mice had a significantly 
higher antibody response to ASF361 (p = 0.002), ASF457 (p = <0.0001), ASF360 (p 
= 0.005), and ASF502 (p = 0.0005) compared to ASF mice that received the same 
treatment. The ASF-AHbD mice developed a significantly higher antibody response 
to only ASF492 (p = 0.02) compared to Conv-AHbD mice. With respect to the 
antibody response to H. bilis and ASF 356, the ASF mice had significantly higher 
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antibody responses than their CONV counterpart regardless of the treatment 
regimen. 
 
 
 
Figure 9. The ASF mice had significant antibody responses to 7 of the 9 antigens 
measured between treatment groups. The CONV mice only had one antigen that 
exhibited differences between the treatment groups (H. bilis). The results are 
expressed as mean + SEM. An asterisk indicates p < 0.05.  
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ASF and CONV mice have different patterns of microbial dybiosis after 
ampicillin administration  
To identify the effect that ampicillin administration had on the cecal microbial 
community, qPCR was performed to quantify all eight ASF. Two of the ASF 
members, 360 and 492, had no significant differences within mouse microbial 
communities or within treatment groups. As shown in Figure 10, CONV-HbD mice 
had a significantly higher population of both ASF356 (p = 0.02) and 361 (p = 0.02) 
than ASF mice that received the same treatment. ASF500 and 502 shared similar 
patterns in distribution. Those organisms were significantly reduced in ASF-AHbD 
mice compared to CONV-AHbD mice. Comparing within the ASF mice, those in the 
AHbD treatment group had significantly reduced levels of ASF 500 and 502 
compared to ASF-HbD mice. The results were similar for ASF 457 with the 
exception that the CONV- AHbD mice also had significantly lower levels compared 
to CONV-HbD mice. The levels of ASF 519 were significantly reduced in both the 
ASF-AHbD and CONV-AHbD mice compared to mice in their respective 
counterparts in the HbD treatment groups. ASF 519 levels were also significantly 
higher in the ASF-HbD mice compared to the CONV-HbD mice. 
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Figure 10. The administration of ampicillin causes long term changes in the 
microbial community of the cecum in both ASF and CONV mice. The results are 
expressed as mean + SEM. An asterisk indicates a p < 0.05. 
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ASF and CONV mice have different cecal cytokine responses after ampicillin 
administration  
To identify changes in the magnitude of the mucosal inflammatory response 
induced by DSS subsequent to disrupting the microbiota with ampicillin, secretion of 
cytokines/chemokines was measured in cecal tissue collected at necropsy (day 33). 
Among the analytes measured (see Materials and Methods) three patterns emerged. 
The first pattern was exhibited by only two cytokines/chemokines (Figure 11). 
Specifically, M-CSF and IL-1β were significantly elevated ( p <0.05) in CONV-AHbD 
mice compared to CONV-HbD mice; the same was not true between ASF-AHbD and 
ASF-HbD mice. In the second response pattern (Figure 12) the 
cytokines/chemokines (IFN-γ, LIX, MCP-1, IP-10, and IL-10) were significantly (p < 
0.05) elevated in the ASF-HbD mice compared to ASF-AHbD mice. This suggests 
that the presence of antigens derived from the resident microbiota were involved in 
this response. This set of cytokines were also significantly elevated in the ASF-HbD 
mice compared to the CONV-HbD mice. 
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Figure 11. CONV mice pretreated with ampicillin prior to H. bilis colonization and 
DSS treatment exhibit increased cytokine/chemokine concentrations compared to 
ASF mice that received the same treatment and CONV mice colonized with H. bilis 
and treated with DSS. The results are expressed as mean + SEM. An asterisk 
indicates p < 0.05. 
 
 
 
 
Figure 12. ASF mice colonized with H. bilis and treated with DSS have elevated 
cytokines/chemokines concentrations compared to CONV mice given the same 
treatment or ASF mice pretreated with ampicillin prior to H. bilis colonization and 
DSS treatment. The results are expressed as mean + SEM. An asterisk indicates p 
< 0.05. 
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  With respect to the third pattern of cytokine expression (Figure 13) the 
cytokines/chemokines (Eotaxin, G-CSF, GM-CSF, IL-1α, TNF- α, MIP-1β, MIG, LIF, 
KC, IL-6, Il-12p40, and IL-12p70) were significantly (p < 0.05) elevated in only the 
ASF-HbD mice compared to the CONV-HbD mice. Since there was no significant 
difference in the concentrations of these analytes between the ASF-AHbD and ASF-
HbD, this suggests that the microbiota does not play a role in this response. 
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Figure 13. ASF mice treated with HbD have elevated cytokines/chemokines 
concentrations compared to CONV mice given the same treatment.  
The results are expressed as mean + SEM. An asterisk indicates p < 0.05. 
 
CONV mice have increased levels of diabetes biomarkers during inflammation 
compared to ASF mice  
 To identify the role that disruption of the microbiota and inflammation may 
have on the development of metabolic syndrome, eight diabetes biomarkers were 
measured at the termination of the study. The groups analyzed were HbD, AHbD, 
control, and ampicillin only (mice treated for nine days and allowed to recover 
throughout the rest of the study). Of the eight analytes measured, only leptin showed 
no significant changes between CONV and ASF mice for any of the treatment 
groups. For the other seven biomarkers only the CONV mice showed increased 
levels compared to the ASF mice (Figure 14). Inflamed CONV mice (those given 
HbD or AHbD) had significantly (p < 0.05) increased levels of GLP-1, Glucagon, 
Resistin, and Ghrelin. The CONV-AHbD mice had significantly increased levels of 
Insulin and GIP while the CONV-HbD mice had increased levels of these hormones 
that were trending towards significance compared to their ASF counterparts. Lastly, 
PAI-1 was found to be significantly  (p < 0.05) increased in all CONV mice compared 
to their ASF counterparts regardless of their treatment status.   
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Figure 14. Inflamed CONV mice have elevated levels of diabetic biomarkers in their 
sera compared ASF mice 
The results are expressed as mean + SEM. An asterisk indicates p < 0.05, a # 
indicates p < 0.1. 
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Differences in microbiota cause differences in gene expression on the host 
side 
 To determine the effects that the two types of inflammation had on the two 
microbial communities, a NF-κΒ signaling pathway superarray was used to examine 
gene expression changes in the cecum (Table 2). See materials and methods for a 
list of the genes measured.  
 
Table 2. Changes in cecal mRNA expression    
Treatment Gene Fold Change 
ASF HbD compared to CONV HbD Ccl2 +3.13 
ASF HbD compared to CONV HbD Csf3 +7.30 
ASF HbD compared to CONV HbD Il1b +4.14 
CONV AHbD compared to CONV Hbd Csf3 +4.57 
ASF AHbD compared to ASF HbD Tbk1 +3.88 
 
 
First differences between mice with different intestinal microbiota were 
examined. Comparing ASF AHbD to CONV AHbD mice revealed no changes in any 
of the 84 genes measured. ASF HbD compared to CONV HbD mice revealed three 
genes whose mRNA was up-regulated in the ASF mice. Ccl2 (MCP-1) was up-
regulated 3.13 fold which corresponded to what was seen in the luminex data. In the 
luminex data, MCP-1 was significantly elevated in the ASF HbD mice compared to 
the CONV HbD mice. It was also noted that G-CSF was up-regulated 7.3 fold in the 
ASF mice, which corresponded to what was seen in the luminex data. In the luminex 
data, G-CSF was significantly elevated in the ASF HbD mice compared to the CONV 
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HbD mice. Lastly, the IL-1β-specific mRNA expression was up-regulated 4.14 fold in 
the ASF-HbD compared to the CONV-HbD mice.  
 When comparing the two ASF groups to each other and the two CONV 
groups to each other, CONV AHbD mice had one gene whose mRNA was up-
regulated compared to CONV HbD mice. This gene G-CSF, was increased 4.57 fold 
in the superarray results. In the ASF mice, there was one gene whose mRNA was 
elevated in the AHbD mice 3.88 fold compared to the HbD mice. This gene, TANK-
binding kinase 1 has been found to activate NF-κΒ through interactions with TANK 
and TRAF2 proteins [68]. 
 
Discussion 
  The results of this study indicate that the composition of the microbiota plays 
a role in the host’s response to inflammation. The conventional mice that received 
ampicillin prior to colitic insult had no change in inflammation compared to those that 
did not. The only significant differences between those two groups were in the 
concentrations of M-CSF and IL-1β in cecal explant supernatants, antibody to H. bilis, 
and levels of ASF457 and 519 in cecal contents. Compared to the changes in 
cytokine levels and the microbiota observed between the two ASF mouse groups 
(HbD versus AHbD), the corresponding changes in the CONV mice were minor. One 
potential reason for this could be because the microbiota of the CONV mice was 
less affected by the administration of ampicillin. The microbiota of the CONV mice is 
more functionally redundant than the microbiota of the ASF mice. In the CONV mice 
a loss or decrease of one organism may not result in a loss of the microbiota's 
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functional capabilities [69]. The ASF mice had a significant reduction in 50 % of their 
microbiota members. This loss of such a significant portion of their microbiota may 
also explain the difference in weight gain between the ASF-AHbD mice and the 
CONV-AHbD mice. The ASF mice treated with ampicillin gained significantly less 
weight than the ampicillin -treated CONV mice (Figure 2E). A study by Backhed et al. 
revealed that the microbiota has a role in regulating feed intake and weight gain [70]. 
In their study, conventionalized C57BL/6J mice had 42 % more body fat compared 
to germfree (GF) controls, even though they ate 29 % less feed. Conventionalization 
of those GF mice for 14 days caused a 57% increase in their body weight even 
though they consumed 27 % less food than GF mice. This increase in weight was 
attributed to the suppression of fiaf, an inhibitor of lipoprotein lipase (LPL), which is 
responsible for the uptake of fatty acids and triglyceride accumulation. In addition, 
they found that after the mice were conventionalized, there was a significant 
increase in enzymes associated with de novo fatty acid biosynthesis [70]. The 
authors go on the suggest that this increase in fatty acids coupled with LPL leads to 
the increased weight gain seen in mice with a conventional microbiota.  
 Further work from Backhed and colleagues demonstrated that CONV mice 
fed a high fat diet gain significantly more weight than a GF cohort [71]. The GF mice 
also had increased levels of phosphorylated AMPK, which incites fatty acid oxidation. 
Additionally Ley et al. [72] has shown that the microbiota of obese and lean persons 
was significantly different; specifically, obese persons had a higher proportion of 
Firmicutes relative to Bacteroidetes as compared to lean persons. Further 
characterization revealed that the microbiota of obese persons was able to extract 
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more energy from the diet [8]. GF mice colonized with an “obese” microbiota were 
shown to gain significantly more weight than GF mice colonized with a “lean” 
microbiota, even when feed consumption was the same over 14 days. 
 A recent article describes a link between antibiotic use early in life and 
increased adiposity [73]. In our study, we found that levels of biomarkers associated 
with metabolic syndrome were significantly increased in the inflamed CONV mice. 
These markers included GIP, GLP-1, insulin, glucagon, resistin, ghrelin, and PAI-1. 
These results indicate that CONV mice, compared to the ASF mice, seem to 
develop metabolic syndrome. These mice gained more weight than the ASF mice, 
exhibited inflammation, as well as high levels of the majority of the diabetic 
biomarkers measured. GIP and GLP-1 are incretin hormones and are made by K 
and L cells, respectively, in the intestine [74]. Both of these hormones are able to 
stimulate the production of insulin, a response seen in CONV mice that received 
AHbD or HbD compared to their ASF counterparts. Glucagon has the opposite effect 
of insulin; glucose promotes insulin release and inhibits the production of glucagon 
[75, 76]. It has been reported that in diabetes mellitus, there appears to be an 
abnormal response of glucagon to the presence of glucose [77, 78]. In one study, 
patients with diabetes mellitus had elevated plasma concentrations of both insulin 
and glucagon, results that are similar to what is seen in Figure 14 [79]. Resistin has 
been found to be significantly increased in patients with type 2 diabetes (T2DM) and 
may have a role in the development of insulin resistance and cardiovascular 
inflammation [80-84]. It has also been noted that resistin may play an role in the 
inflammatory process of IBD [85]. PAI-1, GLP-1, glucagon, and insulin, markers 
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increased in the inflamed CONV mice, have found to be significantly increased in 
patients with metabolic syndrome and/or T2DM [77-79, 86-88]. High concentrations 
of PAI-1 have been shown to predict the development of diabetes [89]. Additionally, 
high PAI-1 is associated with insulin resistance as well as thrombotic vascular 
disease [90-92]. The last biomarker that was increased in the inflamed CONV mice 
was ghrelin. The role of this hormone in GI inflammation is still unclear. In some 
cases, ghrelin is able to ameliorate both DSS and TNBS-induced murine models of 
colitis [93, 94]. However, levels of ghrelin and resistin have found to be increased in 
IBD patients [95]. One of the reasons that the CONV mice developed metabolic 
syndrome and the ASF mice did not may be due to differences in the microbiota 
composition. It has been postulated that lipopolysaccharide (a component found in 
Gram negative organisms) may be a factor involved with the onset of metabolic 
diseases 96]. Of the nine organisms in the mice used in the study only three of them 
are Gram negative. The CONV mice have a much greater proportion of their 
microbial community containing LPS that could contribute to the onset of metabolic 
syndrome. 
 The results of the studies with the CONV mice reveal that administration of 
ampicillin prior to colitic insult does not change the severity of the inflammatory 
response. These mice only had significant production of total IgG H&L antibody to H. 
bilis antigen and no difference in weight gain and no change in mucosal 
inflammation based on analyses using Prosense 750 that is an inflammatory probe 
between CONV AHbD and HbD groups. The CONV mice treated with AHbD did 
have significantly reduced amounts of ASF457 and 519 and significantly elevated 
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concentrations of M-CSF and IL-1β. Additionally, these CONV mice also showed a 
pre-disposition toward metabolic syndrome and/or T2DM as indicated by the 
increased concentrations of diabetes biomarkers in the CONV mice that were 
inflamed.  
 The results in the ASF mice given AHbD compared to HbD were strikingly 
different than those found in CONV mice given the same treatments. The mice 
treated with ampicillin prior to colitic insult had greater cecal inflammation as 
indicated by the significantly elevated levels of activation of the inflammatory probe 
Prosense 750 in the cecum. However, this increase did not translate into enhanced 
microscopic evidence of disease. The histopathogical scores for all of the mice 
examined in the study ranged between 10-11.8. Compared to control mice whose 
scores were 0.2 (CONV) and 0.4 (ASF), the microscopic scores of the AHbD and 
HbD mice indicate that both groups of mice (CONV and ASF) were severely 
inflamed. There was no significant difference in histopathologic score among any of 
the treatment groups. However, when comparing inflamed ASF mice to inflamed 
CONV mice, the ASF mice produced greater amounts of pro-inflammatory 
cytokines/chemokines compared to the CONV mice. The lack of a demonstrable 
difference in the histopathological scores indicates that there must be an 
inflammatory ceiling in regards to the parameters measured. 
  Measuring the antibody response to the members of the ASF over time 
revealed that with the exception of ASF519, the only significantly elevated 
responses were found in the AHbD mice after the onset typhlocolitis. After 
administration of ampicillin, mice had significantly reduced antibody to ASF519, most 
	   152	  
likely due to a significant decrease in the organism. Previous work in our lab has 
shown that the administration of ampicillin causes a decrease in all the ASF 
organisms to undetectable levels (data not shown). That reduced antibody response 
to ASF519 was maintained even after H. bilis colonization; however, after the 
administration of the DSS, the antibody to members of the microbiota in the AHbD 
mice became significantly increased compared to the HbD mice.   
 Cytokine/chemokine levels for several of the analytes measured were higher 
in the ASF mice compared to the CONV mice, indicating that the ASF mice were 
experiencing more severe inflammation. Additionally, some of the anti-ASF antibody 
responses were increased in the ASF HbD mice compared to the ASF AHbD mice. 
This result may simply be due to a lack of antigen to produce the response in the 
AMP treated mice. The microbiota of the AMP-treated ASF mice had not returned to 
the pre-AMP levels during the duration of the experiment. At necropsy, there were 
four ASF members that had a significant reduction in numbers in the AHbD mice 
compared to the HbD mice: ASF 500, 502, 457, and 519. It has been noted that 
during an acute GI infection, CD4+ T cells will break tolerance to the commensal 
bacteria and become reactive to specific antigens derived fromresident microbiota. 
In the AHbD mice, four members of the microbiota were significantly decreased; 
consequently, there may have not been enough antigen present to stimulate the 
production of antigen-specific CD4+ T cells. Studies have shown that GF mice have 
a decreased number of CD25+ CD4+ T cells and those regulatory T cells present 
have a reduced suppressive function [97, 98]. Therefore it is possible that in the ASF 
mice, whose microbiota is not as diverse as one found in a CONV mouse, there 
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would be a decrease in these cells as well. Future studies would be needed to 
determine the quantity of Treg cells in the two groups of mice.  
Collectively, the results of this study reveal the importance of the complexity 
of the microbiota during inflammatory processes. Ampicillin pretreatment did not 
make ASF or CONV mice more susceptible to an inflammatory insult following 
colonization with H. bilis. However, ampicillin pretreatment did enhance the local 
inflammatory response as well as the humoral response against the resident 
microbiota in defined flora mice but not in mice with a conventional microbiota.  
Ampicillin pretreatment also significantly reduced the density of most of the resident 
bacterial species in the defined flora mice. CONV mice, who have a more complex 
microbiota developed a metabolic syndrome/diabetic condition when inflamed 
whereas ASF mice did not. Together, these data indicate that antibiotic treatment 
prior to infection with a GI pathogen may not enhance susceptibility to a subsequent 
inflammatory insult, but it does change the nature of the host’s immune response 
and metabolism depending on the complexity of the microbiota. 
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Abstract 
The morbidity and expense of traditional inflammatory bowel disease (IBD) 
treatments have led patients to explore alternative therapeutic options. Over 50 % of 
IBD patients have used alternative or complementary prebiotic treatments. Botanical 
supplements represent a subset of alternative therapies of potential value for IBD 
patients. Additional research is needed to identify the potential biological activity and 
safety of these products. Ethanolic extracts of the botanicals Prunella vulgaris and 
Hypericum gentianoides possess anti-inflammatory and/or anti-microbial activities; 
however, limited information exists regarding its efficacy as a treatment for IBD. 
Using mice with a defined microbiota (the altered Schaedler flora or ASF), we have 
established a colitis model that mimics human IBD and enables us to elucidate the 
roles of both the host and its microbiota in the progression of disease and the 
response to nutraceutical treatment. Despite the purported anti-inflammatory effects 
of P. vulgaris and H. gentianoides, neither extract was able to significantly lessen 
disease severity. There was no significant difference in microscopic lesion scores 
between any of the treatment groups. Use of an inflammatory probe to measure 
inflammation in situ also revealed no significant difference between the groups, but 
there was a decrease in the fluorescence intensity in mice treated with H. 
gentianoides indicating the potential for an anti-inflammatory effect with that 
botanical. Increased production of the pro-inflammatory cytokines and chemokines, 
KC, IL-5, LIX, and RANTES in mice given P. vulgaris was not observed in the mice 
treated with H. gentianoides. Mice administered H. gentianoides did have a 
substantial modulation of their gastrointestinal microbial community as H. 
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gentianoides treatment resulted in a significant decrease in four of the eight 
members of the ASF. P. vulgaris had no effect on the bacterial population. In 
summary, there was no significant amelioration of disease severity in this mouse 
model of colitis. The presented data do suggest, however, that there may be benefit 
to the use for H. gentianoides in the modulation of the gastrointestinal microbial 
community. Further studies are warranted to determine the specific compounds 
associated with this anti-bacterial activity.  
Key words: Hypericum gentianoides/Prunella vulgaris/ altered Schaedler 
flora/Helicobacter bilis 
 
Introduction 
Inflammatory bowel disease is a condition that encompasses both Crohn’s 
disease (CD) and ulcerative colitis (UC). This condition has no specific cause but is 
known to have genetic, bacterial, environmental, and immunological components [1-
3]. Although there is no cure disease, several drug therapies are designed to reduce 
the inflammation and put the patient into remission [4]. Unfortunately, many of these 
treatments are not without side effects [5]. One type of therapy that is gaining 
popularity among patients is the use of complementary and alternative medicines 
(CAM) [5, 6].  
Studies surveying the use of CAM in IBD patients have revealed that up to 
74 % of those surveyed did indeed use a CAM at some point to treat their disease [7, 
8]. Some of the reasons given for choosing to use CAM include ineffectiveness of 
conventional therapy (40 % persons surveyed), greater sense of control over the 
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disease (30 % persons surveyed), safety of therapy (28 % persons surveyed), and 
perceived adverse effects with conventional therapy (18 % persons surveyed) [7]. In 
categorizing the types of CAM utilized, Chinese herbal medicine was used by 15 % 
of those surveyed [7].  
Herbal medicines can have multiple mechanisms of action with regard to 
treatment of IBD [5, 9]. Some of these actions include the reduction of oxidative 
stress, inhibition of leukotriene B4, antimicrobial effects, and the inhibition of the pro-
inflammatory transcription factor NF-κΒ [9]. A study by Jackson et al. characterized 
the effects of an herbal remedy used by Chinese physicians to treat IBD in a DSS-
induced model of colitis [10]. This remedy consisted of a mixture of seven different 
herbs: Forsythia koreana, Corydalis saxicola, Semiaquilegia adoxoides, Taraxacum 
officinale, Chrysanthemum coronarium, Glycyrrhiza inflate, and Lonicera japonica. 
The results of this study indicated that extract treated mice had lower disease 
activity index scores, longer colons, and significantly reduced colonic ulcerations 
compared to control mice. Additionally, mice treated with the extract also had 
decreased expression of TNF-α and IL-6 in the colonic mucosa compared to the 
controls. The results of this study indicate a potential role for botanical extracts in the 
treatment of IBD [10].  
 In this present study, two different botanical extracts were used to determine 
their effects on a DDS-induced model of colitis. Prunella vulgaris, also known as 
“heal-all,” has been shown to have some anti-microbial effects as well as quorum 
sensing inhibitor activity [11]. P. vulgaris has anti-HIV properties attributable to the 
compound prunellin, a partially sulfated polysaccharide isolated from aqueous 
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extracts [12]. Another water-soluble polysaccharide isolated from the aqueous 
extract of P. vulgaris has shown to be effective against herpes simplex virus, 
possibly through inhibition of the virus particles binding to the cells [13]. Two 
phenolic acids can also be isolated from the organic fraction of P. vulgaris—caffeic 
acid and rosmarinic acid [14]. Caffeic acid has been shown to ameliorate disease in 
a DSS-induced mouse model of colitis [15]. Mice fed this phenolic acid had longer 
colons, reduced colonic myeloperoxidase activity, and reduced colonic and cecal 
microscopic lesion scores. Additionally, mRNA levels of IL-17 and iNOS were 
reduced in the mice given caffeic acid mice while CYP4B1 (cytochrome p450) 
mRNA levels were increased [15]. Rosmarinic acid, another phenolic acid found in P. 
vulgaris organic fractions, has been shown to inhibit the expression of LPS-induced 
COX-2 expression [16]. 
 The other botanical extract used in this study is from Hypericum gentianoides. 
Used by Native Americans for the treatment of multiple disorders, this relative of H. 
perforatum  (St. John’s Wart) does not contain the two major biological constituents 
of St. John’s Wart, hypericin or hyperforin[17, 18]. Using HPLC-PDA it was 
discovered that the chromatographic profile of H. gentianoides was very different 
compared to that of H. perforatum [17]. Extracts of H. gentianoides reduce the 
production of PGE2 in LPS-induced macrophages and are not cytotoxic like extracts 
of H. perforatum [19]. Additional work determined that fractions of H. gentianoides 
extracts were also able to decrease nitric oxide (NO) production Uliginosin A, a 
specific molecule discovered in one of the fractions, was found to be anti-
inflammatory by itself. Pure uliginosin A used at the same concentration found in the 
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whole extract was able to inhibit NO, TNF-α, and IL-1β production, but not PGE2 [20]. 
Anti-bacterial properties for this compound have also been reported [21]. 
 In this present study, we utilized our previously published multiple hit model of 
typhylocolitis to examine the effects of these two botanicals on disease severity [22].  
Pretreatment of H. bilis colonized mice with P. vulgaris prior to DSS treatment 
significantly increased production of the chemokines RANTES, KC, LIX and the 
cytokines IL-5 and IL-10 as compared to control H. bilis colonized mice administered 
DSS. P. vulgaris pretreated mice also had an increased IgG antibody response 
directed against ASF492, one of the eight members of the Altered Schaedler Flora. 
Pretreatment of H. bilis colonized mice with H. gentianoides prior to DSS treatment 
had a reduced antibody response against ASF519 as well as increased gross cecal 
scores as compared to mice not receiving the botanical extract. Of interest, ex vivo 
imaging using a fluorescent dye activated by cathepsins and other enzymes 
associated with inflammation revealed that H. gentianoides pretreatment tended to 
reduce cecal inflammation despite no macroscopic evidence of disease 
improvement. There was no definitive amelioration of disease following pretreatment 
with either botanical, but H. gentianoides tended to improve disease severity while P. 
vulgaris increased production of pro-inflammatory chemokines/cytokines.  
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Materials and Methods 
Animals     
 Male and female C3H/HeN:Tac mice (6-8 weeks old) mice colonized with the 
altered Schaedler flora (ASF) were obtained from Taconic Farms (Germantown, 
NY). The ASF included ASF356, a member of the Clostridium cluster XIV; ASF360, 
Lactobacillus intestinalis [23], ASF361; Lactobacillus murinus [24], ASF457, 
Mucispirillum schaedleri [25], ASF492, Eubacterium plexicaudatum [26]; ASF500, a 
low-G+C content Gram positive bacteria; AF502, a member of the Clostridium 
cluster XIV; and ASF519, Parabacteroides goldsteinii [27, 28]. Mice were bred and 
maintained in the murine gnotobiotic facility at the College of Veterinary Medicine, 
Iowa State University. Mice were housed in flexible film isolators at Iowa State 
University to maintain their defined status and allowed ad libitum access to an 
irradiated 2919 diet from Harlan Teklad (Madison, WI) and sterile water. One week 
prior to the start of the experiment, mice were moved to Innocage® IVC cages 
supported by an Innovive IVC rack (San Diego CA). Mice were allowed ad libitum 
access to an autoclaved 2019S diet from Harlan Teklad (Madison, WI) and sterile 
water. Mice were maintained in the same room (12:12 hours dark/light cycle) with a 
maximum of five mice per cage. All animal procedures were performed in 
accordance with the experimental protocol approved by the Iowa State University 
Institutional Animal Care and Use Committee. 
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Experimental Design 
Mice were colonized with 0.3 mL of 109 organisms of Helicobacter bilis on two 
consecutive days. At 10 days post-colonization, fecal samples were collected and 
PCR analysis was performed in order to confirm that the mice were colonized with H. 
bilis as previously described[29]. After 16 days of colonization, mice were orally 
gavaged with either with Prunella vulgaris (2.4 mg/day) or Hypericum gentianoides 
(4.8 mg/day) ethanolic extract for 14 days. On the 7th day of botanical gavage, the 
mice were given 1.5 % dextran sodium sulfate (DSS, MW 36,000-50,000; MP 
Biomedicals Solon, OH) in their drinking water for five days followed by four days 
with sterile water prior to terminating the experiment.  
Helicobacter bilis colonization 
 Helicobacter bilis was grown in a biphasic growth medium consisting of a 
Brucella agar base (BD, Franklin Lakes, NJ) supplemented with 0.1 % activated 
charcoal (Acros Organics, Geel Belgium), 20 % heat inactivated newborn calf serum 
(Hyclone Lab, Logan, UT), 2 % Vitox (Oxoid, UK) and 1.25 % agar (Fisher Scientific, 
Pittsburgh PA). A 3 mL overlay of brucella agar base supplemented with 20 % heat 
inactivated newborn calf serum, 1 % IsoVitaleX (BD, Franklin Lakes, NJ), and 1.3 % 
urea agar base (BD, Franklin Lakes, NJ) was used over the agar base and was the 
medium inoculated with the organism. Plates were incubated at 37°C in a 
microaerophillic chamber in which the atmosphere consisted of 85 % N2, 10 % CO2, 
and 5 % O2.  
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Extract Preparation  
The dried plant materials were kindly provided by Dr. Mark Wiederlichner at 
the USDA-ARS North Central Regional Plant Introduction Station (NCRPIS, Ames 
IA). Information about the specific provenance of P. vulgaris accession Ames 27664 
and H. gentianoides accession Ames 28015 obtained from the NCRPIS is available 
on the Germplasm Resources Information Network database at 
http://www.arsgrin.gov/npgs/acc/acc_queries.html. Arboreal portions of plants from P. 
vulgaris (Ames 27664), harvested in 2008 and H. gentianoides  (Ames 28015), 
harvested in 2009 were prepared for storage by drying for 8 days at 38°C in a 
forced-air dryer with constant humidity. The dried material was ground with a 40-
mesh screen and stored at -20°C until extraction. Extractions were made in 95 % 
ethanol (EtOH) solvent by the Soxhlet method (6 hours) [30]. Upon complete drying 
of the extract by evaporation, the weight of the extracted material was recorded; the 
residue was lyophilized and stored at -20°C until solubilized in a final working 
solution of 5 % EtOH (the lowest conentration of EtOH that would allow 
solubilization) at a final plant extract concentration of 12 mg/mL (P. vulgaris) and 24 
mg/mL (H. gentianoides). The working extract was divided into 2 mL aliquots and 
stored at -20°C until use. Extracts from NCRPIS were screened for endotoxin by 
using the Limulus Amebocyte Lysate Test (BioWhittaker, Inc., Walkersville, MD) 
according to manufacturers’ specifications for a microplate assay, and there was no 
detectable endotoxin present in the extract (data not shown). 
 
 
	   170	  
Sample Collection and Preparation 
 At necropsy, blood was collected via cardiac puncture following euthanasia 
via CO2 asphyxiation. Following collection, blood samples were allowed to clot at 
4°C overnight, serum was separated by centrifugation, and stored at -20°C until 
used. The cecum was aseptically excised and contents were snap frozen in liquid 
nitrogen for DNA extraction and stored at -20°C. Cecal tissues devoid of contents 
were placed in either 10% buffered formalin or RNAlater® (Ambion, Grand Island 
NY) for histopathological evaluation and gene expression studies. During the 
necropsy, sections of cecal tissue were placed in phosphate buffered saline to keep 
the tissues hydrated. Following the necropsy, the tissue was cut into three 1-cm 
sections and placed in wash medium (RPMI 1640 supplemented with 50 µg 
gentamicin sulfate/ml and 20,000 IU/20,000 µg of penicillin/streptomycin) and placed 
on a rocker for 30 min at 25 °C. All cell culture reagents were from Cellgro, 
Manassas VA) unless otherwise noted. At the end of the incubation period, the 
tissues were placed into 96 well plates containing explant medium (RPMI 1640 
supplemented with 20,000 IU/20,000 µg penicillin/streptomycin, 50 µg gentamicin 
sulfate/ml, 2 mM glutamine, 50 µM 2-mercaptoethanol, and 1 mM sodium pyruvate). 
Tissues were incubated overnight at 37°C in a humidified atmosphere with 5 % CO2. 
The following day, the supernatants were aspirated, placed in a new 96-well plate, 
and stored at -20°C. 
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Macroscopic assessment of cecal lesions 
 Macroscopic lesions of the cecum were scored, noting the presence of 
atrophy, enlarged cecal tonsil, diarrheic luminal contents, presence of fresh blood, 
gross thickening (edema) of tissue. Lesion severity scores were based on the total 
number of observable macroscopic lesions with a maximum score of 5 indicative of 
severe disease. 
Histopathological assessment  
Fixed tissues were embedded in paraffin, sectioned and stained with 
hematoxylin and eosin (H&E) for light microscopic evaluation. Stained sections of 
each cecum were scored in a blinded fashion by a Board-certified veterinary 
pathologist (J. Hostetter) as previously described [31, 32]. The final histological 
score represented the numerical sum of 5 parameters with each parameter scored 
from 0-5 (0= no lesion, 5= maximum severity). The maximum cumulative score was 
25. Histopathologic parameters evaluated included mucosal ulceration, magnitude of 
lamina propria infiltration and character of inflammatory cells, mucosal edema, 
stromal collapse, and crypt hyperplasia.  
Cytokine/Chemokine Quantification 
 Supernatants from the cecal tissue explants were used to measure the local 
chemokine concentration using a murine multiplexed antibody array according to the 
manufacturer’s instructions (Millipore, Billerica MA). Analytes measured were: 
Eotaxin, G-CSG, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, 
IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17, IP-10, KC, LIF, LIX, MCP-1, M-CSF, 
MIG, MIP-1α , MIP-1β, MIP-2, RANTES, TNF-α, and VEGF. The mean fluorescence 
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intensity (MFI) values were converted to analyte concentrations using known 
standards and commercial software (xPONET®). 
Antigen-specific antibodies 
 An ELISA was performed to determine the presence of H. bilis- and ASF-
specific antibodies (total IgG H&L) in the sera as previously described [32]. 
DNA Extraction and qPCR for bacterial quantification 
Cecal DNA was extracted using an UltraClean Fecal DNA Isolation kit 
according to the manufacturer’s instructions with a few modifications (MoBio 
Laboratories Inc, Carlsbad CA). Those modifications include: adding 20 µL of 
proteinase K (20 mg/mL) to the sample along with solution S1 and the bead solution 
and heating the sample to 55ºC for 1 hour in the beginning of the procedure, using 
solution CB3 instead of S3 to bind DNA to the silica column, and rinsing the column 
twice with 70% ethanol instead of once. After extraction, DNA was quantified using 
Quant-itTM PicoGreen® (Invitrogen, Grand Island NY) according to the manufacturer’s 
instructions. All DNA samples were diluted to 0.8678 ng/uL with nuclease free water. 
One µL was used as template in a PCR using Platinum® SYBR® Green qPCR 
SuperMix-UDG and with a final MgCl2 concentration of 4.0 mM (Invitrogen, Grand 
Island NY). All samples were run in duplicate using the primers in Table 1. The 
qPCR conditions were 2 min @ 50°C, 10 min @ 95°C, and 40 cycles of 95°C for 15 
seconds, 60°C for 60 seconds. The thermocycler was an Applied Biosystems® 5700.  
The results were compared to qPCR results from plasmid standards of the 16S 
rRNA genes to obtain final values of bacteria per gram of cecal contents. The 
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plasmids were kindly supplied by Dr. Martin Polz and the standards created as 
previously described [33].  
RNA Isolation and cDNA synthesis 
Total RNA from cecal tissues was extracted using an RNeasy Mini Kit 
(Qiagen, Valencia, CA) according to the manufacturer’s instructions with the addition 
of an extra RPE wash. RNA integrity was measured using a 2100 Bioanalyzer 
(Agilent Techonologies, Santa Clara, CA). All RNA used in subsequent steps had a 
RIN number of 7 or higher. RNA was reverse transcribed to cDNA using RT2 First 
Strand Kit (Qiagen, Valencia, CA).  
Mouse NFκΒ Signaling Pathway 
 For pathway expression analysis, cDNA from each treatment group was 
pooled and a RT2 Profiler PCR array (Qiagen, Valencia, CA) was used according to 
the manufacturer’s instructions. The plates were run on an Applied Biosystems® 
5700 machine using the cycling conditions provided in the instructions. 
Determination of fold change differences between treatment groups was performed 
using the PCR array data analysis web portal found at 
www.SABiosciences.com/pcraraydataanalysis.php. 84 genes were analyzed and 
included: Agt, Akt1, Atf1, Atf2,Bcl10,Bcl2a1a,Bcl2l1, Bcl3, Birc3, Card10, Card11, 
Casp1, Casp8, Ccl2, Ccl5, Cd27,Cd40, Cflar, Chuk, Crebbp, Csf1, Csf2, Csf3, Egfr, 
Egr1, Eif2ak2, Elk1, F2r, Fadd, Fasl, Fos, Hmox1, Icam1, Ifng, Ikbkg, Il10, Il1a, Il1b, 
Irak1, Irak2, Irf1, Jun, Lta,Ltbr, Map3k1, Map3, Myd88, Nfkb1, Nfkb2, Nfkbia, Nod1, 
Raf1, Rel, Rela, Relb, Ripk1, Ripk2, Slc20a1, Smad3, Stat1, Tbk1, Tlr1, Tlr2, Tlr3, 
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Tlr4, Tlr6, Tlr9, Tnf, Tnfaip3, Tnfrsf10b, Tnfrsf1a, Tnfrsf1b, Tnfsf10, Tnfsf14, Tollip, 
Tradd, Traf2, Traf3, Traf5, Traf6 
Fluorescence imaging  
 To evaluate the in vivo inflammatory response, mice were intravenously 
administered 2 nmol of ProSense® 750 (Perkin Elmer, Walthem, MA) in 100 µL of 
sterile saline. ProSense® 750 is an activatable fluorescent reagent that is optically 
visible when the dye is cleaved by degradative enzymes, including cathepsin B, L, S, 
or plasminogen, that are common at sites of inflammation [34]. After 24 hours, the 
mice were euthanized by CO2 asphyxiation and the ex vivo images of excised 
tissues were captured. Images were captured using 30-second exposures with an 
excitation filter of 730 nm and an emission filter of 790 nm. All image analysis was 
quantified using ImageJ version 1.44[35]. Raw images were inverted and 
background subtracted via a rolling ball radius of 150 pixels. The ImageJ lookup 
table “fire” was applied to the fluorescent exposure. Composite images were 
constructed using a white light exposure (0.2 seconds) to super-impose 
fluorescence image for tissue distinction.   
Statistical Analysis 
All values were expressed as mean + SEM. ELISA, qPCR, and fluorescence 
intensity data were log transformed prior to statistical analysis to normalize the data. 
An analysis of variance (ANOVA) model was used for the qPCR, ELISA data, 
fluorescence intensity data and luminex with a Tukey adjustment. Non-parametric 
data were evaluated using a Wilcoxon Rank Sums test. P-values < 0.05 were 
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considered significant for all tests. SAS software (SAS Institute Inc., Cary NC, USA) 
was used for all statistical calculations.  
 
Results 
Neither P. vulgaris nor H. gentianoides pretreatment significantly reduced 
cecal inflammation 
Subsequent to H. bilis colonization, mice were treated with either P. vulgaris 
or H. gentianoides extract via intragastric gavage for seven days prior to DSS 
administration. Pre-treatment with either botanical extract had only minimal effects 
on gross cecal pathology (Figures 1 and 2A). H. bilis colonized mice pretreated with 
H. gentianoides extract prior to receiving DSS had significantly higher gross scores 
than the H. bilis DSS mice (p = 0.032). These mice presented with more 
watery/mucoid cecal contents and cecal thickening as compared to the mice 
receiving the vehicle control. There was no difference in the macroscopic scores 
between the botanical groups. All mice treated with DSS were inflamed compared to 
naïve mice whose average score was 0.25 (data not shown). Also, there were no 
significant differences in the histopathological cecal lesion scores among any of the 
treatment groups (Figure 2B). 
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Figure 1. Photographs of gross macroscopic lesions from each treatment group. 
Treatment with H. bilis and DSS or P. vulgaris H. bilis and DSS had no effect grossly. 
The mice given H. gentianoides H. bilis and DSS did have significant gross changes 
due to the presence of water/mucoid contents and cecal thickening. 
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Figure 2. A) Mice given H. gentianoides H. bilis and DSS have significantly 
increased gross cecal scores compared to H. bilis and DSS only. B) There was no 
difference in microscopic lesion scores for any of the treatment groups. Data are 
expressed as mean + SEM. Dissimilar letters indicate p < 0.05, while similar letter 
indicate no significant difference.  
 
 Independent of extract treatment, the ceca from all H. bilis-colonized and 
DSS-treated mice were highly inflamed compared to naive mice (average score of 
1.1; data not shown). There were also no significant differences among the three 
treatment groups with regards to the mean fluorescence intensity from the 
inflammatory probe (Figure 3). 
 
A B
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Figure 3. Mice treated with botanical have no difference in cecal inflammation 
compared to H. bilis DSS mice. A) Fold increase of mean fluorescence intensity of 
treatment compared to naïve control who received no treatment. B) Ex vivo images 
of representative ceca from the three treatment groups analyzed during the study. 
Data are expressed as mean + SEM. Dissimilar letters indicate p < 0.05, while 
similar letter indicate no significant difference.  
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H. bilis colonized mice pretreated with P. vulgaris prior to DSS administration 
have increased production of chemokines and cytokines in their cecal explant 
supernatants 
Of the 32 cytokine/chemokines measured, only five were significantly 
changed in concentration among the treatment groups (Figure 4). H. bilis colonized 
mice pretreated with P. vulgaris prior to DSS administration had a significantly 
increased level (p = 0.048) of the chemokine LIX compared to vehicle control mice.  
Explant supernatants from the same mice also had increased production of IL-10 (p 
= 0.094), IL-5 (p = 0.086), KC (p = 0.071), and RANTES (p = 0.062) whose p-values 
were trending towards significance. There were no significant differences in 
cytokine/chemokines secretion when comparing vehicle treated and H. gentianoides 
pretreated mice. A comparison of the two extract treated groups to one another 
revealed that mice pretreated with P. vulgaris secreted significantly more IL-5 (p = 
0.034) and tended to produce more KC (p = 0.062) and IL-10 (p = 0.067). 
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Figure 4. Cytokine and chemokine concentrations from cecal explant supernatants. 
Treatment with P. vulgaris increased levels of pro-inflammatory cytokines compared 
to the other treatment groups. Data are expressed as mean + SEM. ** indicates p < 
0.05, ## indicates p < 0.1 
 
Pretreatment with botanical extract alters the antibody response against 
specific members of the resident microbiota  
Serum antibody responses to the eight members of the resident microbiota 
and H. bilis were measured via ELISA (Figure 5). H. bilis colonized mice pretreated 
with P. vulgaris prior to DSS administration had a significantly elevated antibody 
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response against ASF492 compared to vehicle treated H. bilis colonized mice given 
DSS (p = 0.012), and an increased anti-ASF492 antibody response compared to H. 
gentianoides pretreated mice (p = 0.083) that was trending towards significance. H. 
bilis colonized mice pretreated with H. gentianoides and DSS produced significantly 
less anti-ASF519 antibody than the vehicle treated (p = 0.003) and the P. vulgaris 
pretreated mice (p = 0.008). P. vulgaris pretreatment did not significantly alter the 
anti-ASF519 response as compared to vehicle pretreatment. Botanical extract 
treatment did not significantly alter the antibody response to any other members of 
the gut microbiota, including H. bilis (data not shown). 
 
 
 
Figure 5. Significant total IgG H&L antibody responses to specific members of the 
microbiota. P. vulgaris H. bilis DSS mice had elevated responses to antigen from 
ASF492 compared to the other treatment groups. H. gentianoides H. bilis DSS mice 
had significantly reduced responses to antigen from ASF519 compared to the other 
treatment groups. Data are expressed as mean + SEM. Dissimilar letters indicate p 
< 0.05, while similar letter indicate no significant difference. Dissimilar letters with ** 
at the end indicate p < 0.1.  
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Pretreatment with P. vulgaris and H. gentianoides extracts elicits unique host 
gene expression patterns 
 To determine the effects of the two botanical extracts on host pro-
inflammatory gene expression patterns, a NF-κΒ signaling pathway superarray was 
used to examine changes in gene expression within cecal tissues (Table 1).  
 
Table 1. Changes in cecal mRNA expression    
Treatment Gene Fold Change 
P. vulgaris compared to H. gentianoides Ccl2 -3.48 
P. vulgaris compared to H. gentianoides Il1b -3.20 
 
When comparing the H. bilis colonized mice pretreated with H. gentianoides prior to 
DSS administration to the vehicle controls, none of the 84 genes measured revealed 
any changes in mRNA expression. No changes were observed when comparing the 
P. vulgaris pretreated mice to the vehicle controls. Significant changes in host 
mRNA expression were only seen when comparing the two botanical treatments to 
one another. Pretreatment with P. vulgaris significantly decreased Ccl2 (MCP-1) 
mRNA expression 3.48 fold and decreased Il1b 3.20 fold as compared to H. 
gentianoides pretreatment. 
H. gentianoides is antibacterial to members of the ASF 
 The members of the microbiota were analyzed for changes in quantity using 
qPCR. Of the eight bacteria analyzed, four showed significant changes in quantity 
between treatment groups (Figure 6). H. bilis colonized mice pretreated with H. 
gentianoides prior to DSS treatment had significantly reduced levels of ASF356, 519, 
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360, and 361 compared to P. vulgaris pretreatment. H. gentianoides pretreatment 
significantly reduced levels of ASF356 and 519 as compared to the vehicle controls. 
There was no difference between P. vulgaris pretreatment and the vehicle controls 
for any of the bacteria measured.  
 
 
 
 
Figure 6. ASF members whose populations changed significantly during the study. 
Mice treated with H. gentianoides H. bilis and DSS had significantly reduced levels 
of ASF356,519,360 and 361. ** indicates p < 0.05. 
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Discussion 
Many IBD patients are turning to the use of CAM to help treat their symptoms; 
however, studies describing the efficacy of these therapies is lacking [30, 36]. Of the 
studies that exist, most have used rodent models of colitis to assess the efficacy 
certain plant-derived compounds [37-39]. Berberine, an isoquinoline alkaloid, 
reduces the levels of TNF, IFN-γ, IL-27 and KC in the colon and decrease colonic 
inflammatory scores in DSS-treated C57BL/6 mice [37]. Dried bilberries, rich in 
anthocyanins (AC), reduced intestinal inflammation and alleviate colitis in BALB/c 
mice administered DSS [38]. Mice feed bilberries had lower levels of IFN-γ and TNF 
during acute colitis, while feeding pure AC resulted in reduced levels of IFN-γ, TNF, 
and IL-6 in both chronic and acute colitis. In another study, polyphenols from apples 
have also been shown ameliorate DSS-induced colitis in C57BL/6 mice [39]. Mice 
treated with the polyphenols did not lose as much weight and had less severe 
microscopic inflammation scores as compared to the vehicle treated mice. 
Additionally, the colonic cytokine profile of the polyphenol treated mice was more 
similar to that of a naïve mouse than a vehicle treated mouse prior to DSS 
administration. Collectively, the results of these studies indicate that many plant-
derived compounds have anti-inflammatory potential [5].  
In this study, neither botanical investigated was able to completely ameliorate 
DSS-induced colitis in our multiple-hit model. Microscopically, the there was no 
difference in the mice pretreated with either botanical compared to the vehicle 
control mice. All the mice had a substantial increase in inflammation, (scores ranged 
from 10.2-11.6) compared to the naïve mice, whose average score was 1.1. 
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Macroscopically, the H. bilis colonized mice pretreated with H. gentianoides prior to 
DSS administration mice had significantly greater scores compared to the vehicle 
treated mice. The difference between the two was that in those mice pretreated with 
H. gentianoides, a greater proportion developed watery/mucoid contents and cecal 
thickening compared to the vehicle treated mice. However, the watery/mucoid 
contents may be a result of the antibacterial effect that H. gentianoides had on the 
ASF population. Similar results were seen when mice were treated with ampicillin to 
deplete the microbiota (Chapter 2). Although it was not significant, the H. bilis 
colonized mice pretreated with H. gentianoides prior to receiving DSS did have a 
reduced fluorescence intensity based on the in situ analysis inflammation compared 
to the other two treatment groups (Figure 3B).  
The effect of P. vulgaris administration to these mice was actually pro-
inflammatory in nature. Three chemokines were increased in the H. bilis colonized 
mice pretreated with P. vulgaris prior to receiving DSS compared to vehicle treated 
mice. Chemokines have been found to be elevated in IBD patients and are even 
being considered as a therapeutic target for treatment of the disease [40, 41]. KC 
(the mouse equivalent of IL-8) recruits neutrophils to the intestine and is elevated in 
mouse models of DSS-induced colitis and in IBD patients [42-44]. LIX, similar to 
ENA-78 found in humans, is also increased in IBD patients [45, 46]. LIX is increased 
in DSS-induced murine colitis, which can be ameliorated though the use of an 
antisense oligonucleotide [47]. Use of the antisense oligonucleotide reduced 
neutrophil recruitment and attenuated the gross macroscopic score in BALB/c mice 
given 5 % DSS. Lastly, RANTES was also significantly increased in the P. vulgaris 
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pretreated mice. This chemokine is also known to elevated in IBD patients[48]. 
RANTES is a chemoattractant for many difference types of cells, but of interest in 
this study is its importance to eosinophils [49-51]. IL-5 levels were significantly 
elevated in the P. vulgaris pretreated mice; this cytokine is necessary for the 
development of eosinophils [52]. Recent studies have shown an increase in the 
number of eosinophils present in some IBD patients [53-55].  
While P. vulgaris pretreatment was able to elicit the production of pro-
inflammatory cytokines and chemokines, H. gentianoides pretreatment was 
antibacterial to half of the ASF population. The H. bilis colonized mice pretreated 
with H. gentianoides prior to DSS administration had significantly reduced levels of 
ASF356, 519, 360, and 361 compared to P. vulgaris pretreated mice. The levels of 
ASF356 and 519 were also significantly different compared to vehicle treated mice. 
The bacteria affected by H. gentianoides were a mixture of Gram-positive and Gram-
negative, indicating that H. gentianoides may have a broad spectrum of activity. 
Although there have not been any studies published regarding the antibacterial 
activities of H. gentianoides specifically, there have been reports of the antibacterial 
effects of H. perforatum as well as of the compound uliginosin, which is found in H. 
gentianoides [21, 56].  
In summary, this study revealed that neither botanical was able to ameliorate 
the inflammation caused by the combination of H. bilis colonization and subsequent 
DSS administration. P. vuglaris, shown in many studies to have anti-inflammatory 
properties, actually induced the production of pro-inflammatory chemokines and 
cytokines in our murine model of colitis. Mice pretreated with H. gentianoides had 
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less cecal inflammation as measured in situ by the use of the inflammatory probe, 
Prosense 750. This treatment also had strong antibacterial properties as well, since 
50 % of the microbial population was significantly reduced compared to those mice 
receiving P. vuglaris. With its potential anti-inflammatory properties and substantial 
anti-bacterial properties, further studies using H. gentianoides are warranted to 
identify the specific compounds responsible for these actions.  
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Abstract 
The intestinal microbiota is centrally associated with mucosal inflammation 
and inflammatory bowel disease. However, the role played by enteric bacteria in 
initiation, progression, and/or maintenance of the gastrointestinal inflammation 
process is unclear. In the present study, pyrosequencing was used to identify 
temporal changes in the cecal microbiota associated with the onset and severity of 
colitis in IL-10-/- mice. This analysis revealed that the microbiota of the IL-10-/- mice 
contained significantly more (p ≤ 0.05) Gram-negative organisms compared to age-
matched WT mice. In the IL-10-/- mice, beneficial bacteria such as Roseburia, 
Lactococcus, and Blautia spp. significantly (p ≤ 0.05) decreased between weeks four 
and seven. Beginning at four weeks of age, the host’s inflammatory response was 
evaluated to ascertain whether changes in the microbiota correlated with the onset 
of inflammation. At four weeks of age, GM-CSF, IL-2, IFN-γ, IL-12p40, RANTES, IL-
1β, Il-13 and IP-10 were elevated in the serum of IL-10-/- mice. At 19 weeks of age, 
the IL-10-/- mice began to lose weight and this was accompanied by increased G-
CSF and IL-17 in the serum. Concomitantly, the Enterobacteriaceae family 
increased in the IL-10-/- mice comprising 9.5 % of the total cecal bacteria compared 
to 0.5 % in WT mice. These data suggest that the reduction of Gram-positive 
bacterial species along with a concomitant increase in Gram-negative organisms 
occurred as a result of chronic intestinal inflammation in C3Bir IL-10-/- mice.  
Key words: IBD/IL-10 deficient mice /microbial composition /Enterobacteriaceae/ 
pyrosequencing 
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Introduction 
The inflammatory bowel diseases (IBD), which include Crohn’s disease (CD) 
and ulcerative colitis (UC) are chronic immunologically-mediated disorders affecting 
the gastrointestinal tract. The current hypothesis for the pathogenesis of IBD 
involves a complex interplay between mucosal immunity and environmental factors 
(e.g. the enteric microbiota) in a genetically susceptible host. This allows for bacteria 
and/or their products to directly activate pathogenic CD4+ T cells that may cause 
chronic intestinal inflammation [1-7]. 
Accumulating evidence from rodent models and human IBD patients suggests 
that the pathogenesis of IBD is influenced by the composition of the enteric 
microbiota [5, 8-10]. Compared to healthy individuals, members of the 
Enterobacteriaceae are increased in IBD patients with ileal CD [11-14]. Other 
investigators have shown a decreased concentration in members of the Clostridium 
clusters IV and XIVa in humans with active IBD [15-17]. It is noteworthy that 
members of these Clostridium clusters comprise a large portion of the gut microbiota 
in healthy individuals as well as produce short chain fatty acids, such as butyrate, 
which serve as an important energy source for colonocytes. [18-21]. Butyrate also 
has an anti-inflammatory effect including the ability to reduce the expression of IL-6, 
TNF-α, and IL-1β  as well as inhibit the activation of NFκB [22-24]. It is well 
established that changes in the microbial composition occur in human IBD patients 
compared to healthy controls. However, there is a gap in our knowledge related to 
when during the disease progression a shift in the composition of the microbial 
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community occurs and whether this change precedes or follows the onset of 
intestinal inflammation [25, 26]. 
Mice deficient in IL-10 are a popular model used to study the pathogenesis of 
IBD [27]. These mice lack the anti-inflammatory cytokine, interleukin-10, which 
regulates gastrointestinal immune responses including inflammation [28]. IL-10-/- 
mice develop spontaneous enterocolitis of varying severity depending on the 
composition of the intestinal microbiota and the  genetic background of the mice. 
Compared to conventionally housed IL-10-/- mice, IL-10-/- mice housed under 
specific-pathogen free (SPF) conditions have attenuated disease and mice housed 
under germ-free conditions do not develop disease [29-31]. These studies were 
performed using IL-10-/- C3H/HeJBir mice that are predisposed to the development 
of severe IBD when housed under SPF conditions [32-34]. 
In this study, using high throughput sequencing, histological observations, 
and serum cytokine concentrations, changes in the microbial composition and in 
host immunological responses were assessed in mice 4 - 19 weeks of age. The data 
indicated that an initial inflammatory response detected at four weeks of age in IL-
10-/- mice preceded changes in microbial composition. This was characterized by a 
significant reduction in Gram-positive spp. and subsequent increase in 
Enterobacteriaceae in the IL-10-/-, but not WT mice. Over the 19 weeks of this study, 
the data indicated that there was an increase in the diversity index and the number 
of observed species a in the WT mice, but not in the IL-10-/- mice. The results from 
this study indicate that in this mouse model, the intestinal inflammation precedes the 
microbial changes. Those mice that were colitogenic had more Gram-negative 
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organisms in their microbial community which was less diverse than that of the WT 
controls.  
 
Materials and Methods 
Animals  
 Female homozygous IL-10-/- mice generated on a C3H/HeJBir background 
(C3Bir.129P2(B6)-Il10tm1Cgn/Lt) and C3H/HeJ controls were obtained from Jackson 
Laboratory (Bar Harbor, ME). At Iowa State University, animals were housed under 
SPF conditions in Innocage® IVC cages supported by an Innovive IVC rack (San 
Diego CA). All mice were maintained in the same room (12:12 hours dark/light cycle) 
with a maximum of five mice per cage. Mice were allowed ad libitum access to 
2019S diet from Harlan Teklad (Madison, WI) and acidified (pH 2.8-3.2) water. All 
provisions were autoclaved prior to administration. Upon arrival, IL-10-/- mice were 
confirmed colonized with Helicobacter spp. using the polymerase chain reaction 
(PCR) performed on fecal DNA as previously described [35]. Body weights were 
measured three times per week during the trial. Clinical signs of disease (e.g., 
weight loss, diarrhea, rectal bleeding) were recorded. All animal procedures were 
performed in accordance with the experimental protocol approved by the Iowa State 
University Institutional Animal Care and Use Committee. 
Sample Collection and Preparation 
 Randomly selected groups (n= 5-13) of female IL-10-/- mice and their WT age-
matched cohorts were necropsied at 4, 7, 10, 12, and 19 weeks of age. Blood was 
collected using cardiac puncture following euthanasia via CO2 asphyxiation. The 
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cecum was aseptically excised and tissue sections with contents were snap frozen 
in liquid nitrogen for DNA extraction and stored at -20°C. Cecal tissues devoid of 
contents were fixed in 10 % buffered formalin and processed for histopathologic 
evaluation. 
Macroscopic assessment of cecal lesions 
 Macroscopic lesions of the cecum were scored on the basis of atrophy, 
enlarged cecal tonsil, diarrheic luminal contents, presence of fresh blood, and gross 
thickening (edema) of tissue. Lesion severity scores were based on the number of 
gross lesions with a maximum score of 5, indicative of severe disease. 
Histopathological assessment  
Fixed tissues were embedded in paraffin, sectioned and stained with 
hematoxylin and eosin (H&E) for light microscope evaluation. Stained sections of 
cecum were scored in a blinded fashion by a Board-certified veterinary pathologist, 
(J. Hostetter) as previously described [36, 37]. The final histological score 
represented the numerical sum of 5 parameters with each parameter scored from 0-
5 (0= no lesion, 5= maximum severity). The maximum cumulative score was 25. 
Histopathologic parameters evaluated included: mucosal ulceration, magnitude of 
lamina propria infiltration and character of inflammatory cells, mucosal edema, 
stromal collapse, 5) crypt hyperplasia.  
Serum Cytokine/Chemokine Quantification 
 Blood collected by cardiac puncture was allowed to clot for 24 hours at 4°C. 
Serum was collected by centrifuging the blood for 10 minutes at 10,000 x G then 
stored at -20°C until analyzed. Measurement of cytokine and chemokine 
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concentrations was performed using a murine multiplexed antibody array according 
to the manufacturer’s instructions (Millipore Millierica, MA). The mean fluorescent 
intensity (MFI) values were converted to analyte concentrations using known 
standards and commercial software (xPONET®). 
Serum Amyloid A (SAA) Quantification 
 The concentration of the acute phase protein, SAA, in the serum was 
measured by a commercial ELISA kit (Tridelta Development, Ireland) according to 
the manufacturer’s instructions. After completion of the reaction, the absorbance 
was measured at 450 nm (Spectra Max 190, Molecular Devices). The concentration 
of SAA in the serum was calculated based on known concentrations of SAA 
standards, which were evaluated on the same plate as the samples. All reactions 
were performed in duplicate. 
DNA Extraction from Tissues and Contents  
Total genomic DNA was extracted from cecal tissues and their contents using 
a repeated bead beating and column extraction method [38]. Samples were 
subjected to homogenization using zirconia beads (1:3 ratio of 0.5 mm and 0.1 mm 
beads) with subsequent heating to 70°C for 15 min. This step was repeated twice. 
The DNA was purified using a QIAamp column (Qiagen, Valencia CA) and 
concentrations quantified using a Nanodrop spectrophotometer (Thermo Scientific, 
Wilmington DE). 
16S rRNA gene bacterial tag-encoded FLX amplicon pyrosequencing 
(bTEFAP) Sequencing PCR 
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The bTEFAP bacterial sequencing method was performed by the Research 
and Testing Laboratory (Lubbock, TX) as previously described with primers forward 
28F: GAGTTTGATCNTGGCTCAG and reverse 519R: GTNTTACNGCGGCKGCTG 
[39]. Raw sequence data were screened, trimmed, filtered, denoised, and chimera 
depleted with default settings using the QIIME pipeline version 1.5.0 
(http://qiime.sourceforge.net) [40] and UCHIME (http://www.drive5.com/uchime/). To 
determine the taxonomic assignment of bacterial sequences, the sequences were 
sorted such that the FASTA formatted file contained reads from longest to shortest. 
These sequences were then clustered into operational taxonomic unit (OTU) 
clusters with 96.5 % identity (3.5 % divergence) using USEARCH [41]. For each 
cluster the seed sequence was placed in a FASTA formatted sequence file. This file 
was then queried against a database of high quality sequences derived from NCBI 
using a distributed .NET algorithm that utilizes BLASTN+ (KrakenBLAST; 
www.krakenblast.com). The BLASTn+ outputs were compiled using a .NET and C# 
analysis pipeline. The data reduction analysis was performed as previously 
described [39]. 
 To account for unequal sequencing depth across samples subsequent 
analysis was performed on a randomly selected subset of 1,900 sequences per 
sample. This number was chosen to avoid exclusion of samples with lower number 
of sequence reads from further analysis. Alpha diversity (i.e., rarefaction) and beta 
diversity measures were calculated and plotted using QIIME. Differences in 
microbial communities between animal groups and time points were investigated 
using the phylogeny-based unweighted Unifrac distance metric. This analysis 
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measures the phylogenetic distance among bacterial communities in a phylogenetic 
tree, and thereby provides a measure of similarity among microbial communities 
present in different biological samples. To determine if any groups of samples 
contained significantly different bacterial communities, the analysis of similarities 
(ANOSIM) function in the statistical software package PRIMER 6 (PRIMER-E Ltd., 
Lutton, UK) was used on the unweighted UniFrac distance matrix [42]. 
Statistical Analysis 
All values were expressed as mean + SEM. Serum cytokine/chemokine data 
and SAA data were log transformed to normalize the data. A repeated measures 
analysis of variance (ANOVA) model was used, with treatment group, time and their 
interaction as fixed effects. The 454 pyrosequencing data were analyzed using a 
generalized linear mixed model, with the same fixed effects structure. T-tests were 
used to assess the differences between WT and IL-10-/- at each time point. To test 
each treatment temporally, an effect comparison of time by group was used. Tukey’s 
t-test was used for multiple pairwise comparisons among time points. Non-
parametric data were evaluated using a Wilcoxon Rank Sums test. P-values < 0.05 
were considered significant for all tests. SAS software (SAS Institute Inc., Cary NC, 
USA) was used for all statistical calculations.  
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Results 
IL-10-/- mice gain weight at a similar rate as WT mice up to week 19. 
Although IL-10-/- mice weighed slightly less than the WT mice at four weeks of 
age, both groups gained a similar amount of weight (12.0 g and 12.2 g, respectively) 
over the course of the study. However, at week 19, the IL-10-/- mice abruptly lost 
greater than 10 % of their body weight and were taken off study (Figure 1). WT mice 
showed no weight loss during this same interval (week 19). 
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Figure 1. Whole body weights of wild type (WT) and IL-10-/- (KO) mice during the 19 
week trial. Data is presented as mean + SEM. Both groups of mice gained a similar 
amount of weight between weeks 4 and 18 of age (IL-10-/- = 12.0 g, WT = 12.2 g). At 
each time point, there were equal numbers of WT and IL-10-/- mice included in the 
analysis. The number of mice used for each strain at each time point varied as 
follows: at 4 weeks of age, n = 5; at 5 weeks of age, n = 17;  at 6 weeks of age, n = 
37; at 7, 8, and 9 weeks of age, n =27; at 10 & 11 weeks of age, n=18; at 12 weeks 
of age,  n=12; at 13 to 19 weeks of age, n = 5. 
 
 
Serum pro-inflammatory/chemotactic cytokines and SAA are increased in IL-
10-/- mice versus WT mice. 
To investigate the progression of the inflammatory response of IL-10-/- mice over 
time, concentrations of pro-inflammatory cytokines and chemokines were measured 
in serum samples. Significant (p < 0.05) concentrations of IL-6, IL-1α, TNF-α and the 
neutrophil chemoattractant KC were observed in serum samples from IL-10-/- mice 
versus controls (Figure 2). 
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Figure 2. Elevation of select serum cytokines and chemokines in the serum of IL-10-
/- mice between four and 19 weeks of age. Specifically, the amounts of IL-6, IL-1α, 
TNF-α, and KC were measured in serum samples collected from wild type (white 
bars) and IL-10-/-  (black bars) mice. Data is presented as mean + SEM. *= p < 0.05 
comparing samples between WT and IL-10-/- for each time point. The number of 
mice used for each strain at each time point varied as follows: at 4 weeks of age, n = 
5; at 7 weeks of age, n = 10; at 10 weeks of age, n = 9; at 12 weeks of age, n = 13; 
at 19 weeks of age, n = 5.  
 
 
* * * * 
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Of interest, two distinct patterns of serum cytokines and chemokines were observed 
in the sera from these mice. There were increases in eight separate analytes at four 
weeks of age while two cytokines were increased at week 19. Analytes increased at 
four weeks of age included GM-CSF, IL-2, IFN-γ, IL-12p40, RANTES, IL-1β, IL-13 
and IP-10 (Figure 3), while G-CSF and IL-17 were significantly increased at week 19 
(Figure 4). This difference in cytokine expression observed in early versus late 
course enterocolitis has been previously reported in C57BL/10 IL-10-/- mice. Similar 
to our results, the study in C57BL/10 mice indicated a prominent role for IFN-γ and 
IL-12p40 in the induction of early stage enterocolitis in knockout mice [43].  
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Figure 3. Increased expression of select serum cytokines and chemokines in the 
serum of IL-10-/- mice at four weeks of age. Specifically, the amounts of GM-CSF, IL-
2, IFN-γ, IL-12(p40), RANTES, IL-1β, IL-13 and IP-10 were measured in serum 
samples collected from the IL-10-/- mice (black bars) and WT mice (white bars). Data 
is presented as mean + SEM. * = p < 0.05 comparing WT and IL-10-/- for each 
individual time point. IL-10-/- mice were also compared to each other across all time 
points. A different letter or # indicates p < 0.05 for that time point. $ indicates p < 0.1. 
The numbers of mice used for these analyses are the same as those listed in Figure 
2. 
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Figure 4. Evaluation of G-CSF and IL-17 levels in serum from WT and IL-10-/- mice 
between four and 19 weeks of age. Data is presented as mean + SEM for sera from 
IL-10-/- mice (black bars) compared to WT mice (white bars). For statistical 
comparisons * = p < 0.05 comparing WT and IL-10-/- mice for each individual time 
point. When results from IL-10-/- mice were compared across time points, a bracket 
was used to indicate the specific comparison with # = p < 0.05. The numbers of mice 
used for these analyses are the same as those listed in Figure 2. 
 
Serum amyloid A has been used as a serological marker of acute 
inflammation and is a useful biomarker in murine models of intestinal inflammation. It 
is also widely used as a biomarker in human IBD as it correlates with disease activity 
and severity of histopathological lesions [32, 44]. In this study, significantly increased 
SAA concentrations (p < 0.05) were detected in the serum of IL-10-/- compared to 
WT mice at all time points (Figure 5). These SAA increases were also accompanied 
by gross and microscopic cecal lesions in the IL-10-/- mice. One important note 
regarding the SAA sera concentrations is the biphasic response of SAA levels with 
the inflection point at week 10.  
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Figure 5. Evaluation of serum amyloid A (SAA) in the serum of WT and IL-10-/- mice 
between four and 19 weeks of age. Data is presented as mean + SEM for samples 
from IL-10-/- mice (black bars) compared to WT mice (white bars). For statistical 
comparison * = p < 0.05 when comparing IL-10-/- to WT mice within each individual 
time point. The brackets represent statistical comparison at different time points and 
# = p < 0.05 when comparing samples from IL-10-/- mice at different time points. – 
The numbers of mice used for these analyses are the same as those listed in Figure 
2. 
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Macroscopic/microscopic cecal lesions provide evidence of early onset of 
intestinal inflammation  
 The cecum of four week old mice revealed no evidence of macroscopic cecal 
lesions in either group (Figure 6A). However, IL-10-/- mice had increased 
macroscopic lesion scores compared to WT for all other time points beyond four 
weeks of age. As early as seven weeks of age, the ceca of IL-10-/- mice contained 
intraluminal blood, tissue thickening, and/or watery mucoid contents. Assessment of 
the colon revealed increased macroscopic lesion scores only at weeks 7, 10, and 12 
in the IL-10-/- mice compared to WT. There was no significant change in score 
among the groups of IL-10-/- mice evaluated at any time point (data not shown). 
 Microscopic examination of cecal tissues revealed typhlocolitis of differing 
severity present in IL-10-/- mice at all time points compared to WT mice (Figure 6B 
and 7). When temporally comparing histopathological inflammatory scores from IL-
10-/- mice, there was significantly less (p < 0.05) mucosal inflammation at week 10 
versus weeks 4 and 7. This reduction in inflammation was characterized by reduced 
edema and mucosal ulceration in the cecal tissues of the 10 week old IL-10-/- mice. 
Examination of the colon showed increased inflammation at all time points in the IL-
10-/- mice compared to WT but no change within the IL-10-/- mice at any time point 
(data not shown). 
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Figure 6. Macroscopic and microscopic evaluation of cecal tissue from WT and IL-
10-/- mice. A) Macroscopic cecal scores form IL-10-/- mice (black bars) and WT mice 
(white bars). Data is presented as mean + SEM and for statistical comparison * = p < 
0.05 when comparing WT and IL-10-/- mice at a given time point. When samples 
from different time points were compared, brackets were used to identify the 
comparisons and  # = p < 0.05. See Materials and Methods for the criteria used to 
generate the macro- and microscopic scores. The numbers of mice used for these 
analyses are the same as those listed in Figure 2. 
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Figure 7. Photomicrographs of the cecal tissue collected from IL-10-/- and wild type 
(WT) mice. Tissue samples were fixed in 10 % buffered formalin and routinely 
processed prior to staining with hematoxylin and eosin. All images were magnified 
200X.  
 
454 pyrosequencing shows increased Bacteroidetes and reduced microbial 
diversity in IL-10-/- mice compared to WT mice. 
 Culture independent molecular techniques were used to investigate 
differences in the bacterial community between IL-10-/- and WT mice between 4 and 
19 weeks of age. There were significant differences in the microbial composition of 
WT mice compared to IL-10-/- mice (Figure 8, also see Supplemental Figure S1) 
PCoA plotted by time. PCoA plots based on the unweighted UniFrac distance metric 
indicated separatism in the IL-10-/- mice between weeks 4 - 7 (ANOSIM p = 0.001) 
and 7 – 10 (p = 0.049). In the WT mice, there was clustering of the microbial 
populations between weeks 4 - 7 (p = 0.001), 7 – 10 (p = 0.023), and 12 – 19 (p = 
0.004). Analysis of the cecal samples from the WT mice revealed that there were 
increases in the number of bacterial species (Figure 9A) as well as the Shannon 
Week 4 Week 7 Week 10 Week 12 Week 19 
W
T 
IL
-1
0-
/-  
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diversity index (Figure 9B) as the mice aged compared to the IL-10-/- mice. The IL-
10-/- mice had reduced numbers of observed species, which were more tightly 
clustered over the course of the experiment compared to WT mice (Figure 10A&B).  
 
 
 
Figure 8. Principal coordinates Analysis (PCoA) of unweighted UniFrac distances of 
16S rRNA genes sequences obtained from cecal tissue and contents. The clustering 
indicates differences in the microbiota between the WT (blue circles) and IL-10-/- 
mice (red squares). 
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Figure 9. A) Rarefaction analysis and B) Shannon Diversity Index of 16 S rRNA 
sequences. Lines represent the average of each group while the error bars 
represent the standard deviations (blue= WT mice; red IL-10-/- mice)  
 
 
 
 
 
 
 
 
 
 
Figure 10. A) Rarefaction analysis and B) Shannon Diversity Index of 16 S rRNA 
sequences Lines represent the average of each group (red= 4 week, blue= 7 week, 
orange= 10 week, green= 12 week, purple= 19 week)  
A B 
A 
B 
	   213	  
Both groups had microbial communities composed predominantly of 
members from the Proteobacteria, Bacteroidetes, and Firmicutes phyla. The 
microbiota of the WT mice harbored a minor population of Bacteroidetes (<10 %) 
throughout the course of the study. The most abundant phylum in the WT mice was 
the Firmicutes, which comprised approximately 90 % of the microbial population at 
all time points (Figure 11). The only significant change observed in WT mice 
occurred in the phylum Proteobacteria. Between weeks 4 and 7 there was an 
increase (1 % to 3 %, p = 0.05) and between weeks 12 and 19 there was a decrease 
(3 % to 1 %, p = 0.03) in abundance of Proteobacteria (data not shown). The 
microbiota of the IL-10-/- mice was comprised of a greater abundance of 
Bacteroidetes but a lower abundance of Firmicutes when compared to the WT 
controls. At the phylum level, there were no significant changes in microbial 
composition of IL-10-/- mice across all time points at the phylum level. 
 
 
Phylum  
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Figure 11. 454 pyrosequencing assessing the cecal microbiota at the phylum level 
for wild type (WT) and IL-10-/- mice from four to 19 weeks of age. Panel A) The 
microbiota of the WT mice and panel B) the microbiota of the IL-10-/- mice. The data 
is presented as the relative abundance of the Firmicutes, Bacteroidetes, 
Proteobacteria and Other.  
 
 
 
 
Figure 12. 454 pyrosequencing assessing the cecal microbiota at the genus level for 
wild type (WT) and IL-10-/- mice from four to 19 weeks of age. Panel A) evaluation of 
the microbiota in cecal samples from WT mice and panel B) evaluation of the 
microbiota in cecal samples from IL-10-/- mice. The data is presented as the relative 
abundance of the bacterial genus present at levels > 1% of the total population.  
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At the genus level, the bacterial community in the ceca of the WT mice 
showed fluctuations in population percentage over time, most of which were 
increases in abundance. (Figure 13A). Those changes in microbial composition that 
occurred between weeks 4 and 7 were all increases (Figure 13C). Of the four 
genera that increased, Roseburia and Eubacterium spp. are both associated with 
the production of butyrate [18]. Between weeks 7 and 10, four additional genera 
increased. The only one that comprised >1 % of the microbial population being 
Turicibacter spp. p < 0.0001. The only genera to significantly decrease (p = 0.01) 
during this period were Lactobacillus spp. Towards the end of the study only three 
genera changed in abundance; Prevotella spp. being the only one to decrease 
significantly p = 0.0006. 
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Figure 13. Changes in the genus populations over time. Panels A and B indicate the 
changes in the microbial population over time in the WT and IL-10-/- mice, 
respectively. Panels C and D show the direction of the relative change in the 
microbial abundance (arrows) in cecal samples from WT and IL-10-/- mice, 
respectively. The p-value is represented parenthetically. Sold arrows indicate either 
a significant (p < 0.05) increase or decrease in relative abundance. Hashed arrows 
indicate a statistical trend in the corresponding direction. At 4 weeks n=5; at 7 weeks 
n=10; at 10 weeks n=9; at 12 weeks n=13; at 19 weeks n=5. 
 
 
It is well established that the microbial population in CD patients changes 
over time to a community that is less diverse than seen in a healthy controls [13, 45]. 
A similar scenario was seen in the IL-10-/- mice when compared to the WT. The most 
striking difference between mice cohorts was the prominent reduction in bacterial 
genera between weeks 4 to 7 in the IL-10-/- mice (Figure 13B). During this period, 
changes in microbial abundance were observed amongst nine different genera with 
most showing a decrease in abundance (Figure 13D). Genera that were >1 % of the 
total population prior to reduction were Lactococcus spp., Blautia spp., and 
Roseburia spp. The reduction of Roseburia spp. is especially important as they 
produce butyrate as a metabolic by-product, which is important for gut health [18].  
Between weeks 7 and 10 there were no significant changes in microbial 
composition in IL-10-/- mice. Between 10 and 12 weeks, the only genera that 
changed comprised <1 % of the population. At the final time point there was a 
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significant increase (p = 0.004) in two genera in the Enterobacteriaceae family, 
which together comprised 9.5 % of the total microbial population.   
 
Discussion 
It is widely accepted that the commensal microbiota play an important role in 
the development of experimental colitis. Germfree C57BL/6 IL-10-/- mice maintained 
for six months do not develop colitis unlike their SPF counterparts [30]. In addition, 
antibiotic administration has been shown to reduce the severity of disease in 129 
Sv/Ev IL-10-/- mice harboring a conventional microbiota [46]. Presumably a reduction 
in bacterial numbers and/or bacterial antigen reduces the phlogistic potential of the 
microbiota [46, 47]. Intestinal dysbiosis refers to an imbalance in the normal GI 
microbiota and is routinely seen in IBD patients [48]. These changes consist of a 
reduction in microbial diversity, a reduction in Firmicutes, an increase in 
Enterobacteriaceae, and an increase in Bacteroides spp. [13, 14, 17, 25, 26, 49, 50]. 
Specifically, increases in adherent and invasive E. coli (AIEC) are observed in a 
subset of CD patients, as well as in Boxer dog colitis [11, 12, 14]. Faecalibacterium 
prausnitzii, a member of the Clostridium leptum cluster (cluster IV) and a major 
butyrate producer, is often reduced in human IBD patients and therefore may have 
potential benefit as a probiotic strain [20, 51, 52]. Further evidence towards using F. 
prausnitzii as a probiotic is due to its anti-inflammatory properties [52]. A Japanese 
study noted that in addition to a reduction in Faecalibacterium spp. there was also a 
significant increase in Bacteroides spp. in patients with CD [50]. They also noted a 
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significant decrease in the microbial diversity in CD patients as measured by the 
Shannon diversity index.  
 The results presented here indicate that the weight gain of IL-10-/- mice was 
similar to that of WT mice through 18 weeks of age (Figure 1). Remarkably, this 
observation occurred in the presence of marked mucosal inflammation, which was 
noted as early as 4 weeks of age (Figure 7). In addition, increased concentrations of 
IL-6, IL-1α, TNF-α, and KC were present in sera from IL-10-/- mice compared to WT 
mice (Figure 2) and indicated active intestinal inflammation that was corroborated by 
both macroscopic and histological evaluations. Other analytes including GM-CSF, 
IL-2, IFN-γ, IL-12(p40), RANTES, IL-1β, IL-13, and IP-10 were also increased in the 
serum of four week old IL-10-/- mice (Figure 3). Increases in these 
cytokines/chemokines have been found in humans and animals with IBD [53, 54].  
 The microbiota of the IL-10-/- mice showed the greatest change in composition 
between weeks 4 and 7 with most of the changes associated with many organisms 
decreasing in abundance. Roseburia spp. was of particular interest because this 
genus decreased significantly (p < 0.0001) during this interval. Roseburia spp. are 
motile, non-spore forming, anaerobic rods which produce SCFA, including butyrate 
[55]. Roseburia species are commonly isolated from human feces and are potentially 
important bacteria for maintenance of mucosal homeostasis [56, 57]. Current 
phylogenetic analysis places these organisms in the Clostridium coccoides cluster 
(cluster XIVa) group [18, 20].   
 Recent studies show that the depletion of Roseburia/C. coccoides cluster 
organisms is a common feature of dysbiosis in human IBD. In a study evaluating IBD 
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in twins, Roseburia spp. was decreased in both the feces and ileal biopsy samples 
of patients with ileal CD compared to healthy controls [15]. A different study revealed 
that the microbiota of UC patients contained fewer mucosa-associated Roseburia 
spp. and decreased diversity of the C. coccoides cluster in feces compared to 
samples obtained from healthy controls [58]. In the mice used in this study, the 
reduction of Roseburia spp. is especially important, as they do not have appreciable 
levels of F. prausnitzii. Therefore without the redundancy in butyrate-producing 
organisms, the significant reduction in Roseburia spp. may have exacerbated 
disease development.  
 In the present study, most pro-inflammatory cytokines and chemokines were 
increased in IL-10-/- mice at four weeks of age compared to age-matched controls. 
Many of these cytokines/chemokines had their peak concentrations at four weeks of 
age and were markedly decreased in concentration through 19 weeks of age. 
Macroscopic cecal scores were significantly higher for IL-10-/- mice at seven weeks 
of age when compared to IL-10-/- mice at four weeks of age; this difference in 
severity was not seen histologically. With respect to the composition of the 
microbiota, the only significant change at the phylum level for either WT or IL-10-/- 
mice between 4 and 7 weeks of age was an increase in Proteobacteria in WT mice. 
However, the IL-10-/- mice at week four already had a skewed proportion of 
Firmicutes/Bacteroidetes, similar to what is reported in IBD patients [49]. At the 
genus level, the WT mice had increases in organisms such as Eubacterium spp., 
Ruminococcus spp., and Roseburia spp., which provide a benefit for the host, either 
through digestion of organic material or production of SCFA. Conversely, the 
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microbiota of the IL-10-/- mice showed decreased abundance in beneficial bacteria 
over the same time period. The only genera that increased in the IL-10-/- mice were 
from the Enterobacteriaceae, a family that is often associated with clinical disease in 
CD patients [13]. The IL-10-/- mice had minimal changes between 7 and 12 weeks of 
age in their intestinal microbiota. At week 10, the SAA concentration was reduced 
compared to week seven, which coincided with decreased histopathological scores 
for the cecal tissue of the IL-10-/- mice.  
The IL-10-/- mice abruptly lost >10 % of their body weight by 19 weeks of age 
and had increased levels of IL-17 and G-CSF in their serum. Mucosal IL-17 is 
increased in humans with IBD and has been associated with intestinal inflammation 
in several animal models [59, 60]. The increased IL-17 observed in the present study 
was accompanied by increased abundance of Enterobacteriaceae from (i.e. 2.5 % to 
9.5 %) at 19 weeks of age. Increased abundance of Enterobacteriaceae has been 
linked to the pathogenesis of mucosal inflammation in diverse species, including 
humans, rodents, dogs and cats [42, 49, 61-63]. The microbial diversity of IL-10-/- 
mice was also markedly altered throughout the study. The Shannon index of the WT 
mice reveals an ordered increase in diversity over time (Figure 10BA). 
Concomitantly, the number of observed species increased in an ordered fashion as 
the mice aged indicating maturation of the microbiota (Figure 10AA). In the IL-10-/- 
mice, there was no change in either the diversity or observed species over time 
(Figure 10AB and 10). This observation of reduced microbial diversity has been well 
documented in human IBD patients [49, 61]. 
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 This study demonstrated that the critical changes in microbial composition (i.e. 
dysbiosis) of IL-10-/- mice occur within the first four to seven weeks of age, after an 
increase in pro-inflammatory cytokines at week four. Intestinal inflammation eliciting 
microbial dysbiosis has also recently been reported in a 129/SvEv IL-10-/- mouse 
model of colorectal cancer [64]. In our study, changes in the microbiota developed 
prior to the onset of more severe clinical disease, which was not observed until 19 
weeks of age. These data also indicate that attenuation of mucosal inflammation 
between 7 and 10 weeks of age is associated with modulations of the host 
inflammatory response as evidenced by the reduction in serum concentrations of the 
acute phase reactant, SAA. This amelioration of the mucosal inflammation occurred 
in the absence of regulatory T cells and disease progression ensued in the absence 
of any medical intervention (e.g., antibiotics).  
In this study it was noted that these mice lacked organisms capable of 
producing butyrate. These observations identify a gap in our understanding that 
might be addressed in future studies by administering Roseburia spp. or F. 
prausnitzii as a probiotic therapy to neonatal mice to ameliorate disease in a 
genetically-susceptible host. To this end, F. prausnitzii has been shown to 
ameliorate disease in a chemically induced model of IBD [52]. Additionally, the use 
of prebiotics such as soluble fibers, used alone or in combination with a probiotic 
preparation, to promote the growth and maintenance of beneficial bacteria (e.g., 
butyrate producers) already present in the GI tract also necessitates further study. 
In conclusion, results of this study indicate that IL-10-/- mice develop intestinal 
inflammation as early as 4 weeks of age prior to the change in the microbiota 
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observed at seven weeks of age. As the WT mice aged, beneficial bacteria such as 
Eubacterium, Ruminococcus, Roseburia, and Lactococcus increased in abundance.   
In addition, there was an increase in the Shannon diversity and observed species 
present. The opposite occurred in the IL-10-/- mice, the most noticeable changes 
being a decrease in numbers of Gram-positive bacteria and an increase in numbers 
of Enterobacteriaceae that were associated with the onset of clinical disease. The 
decrease in microbial diversity suggests that there would be clinical benefits to 
treating these mice with a probiotic to create a more normal microbiota or metabolite 
profile.   
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Supplementary Figures  
 
 
 
 
 
 
Supplementary Figure 1. Principal coordinates Analysis (PCoA) of unweighted 
UniFrac distances of 16 S rRNA genes plotted by time (red= 4 week, blue= 7 week, 
orange= 10 week, green= 12 week, purple= 19 week)  
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CHAPTER 5 
Conclusions and Future Studies  
The gastrointestinal (GI) microbiota is an integral part of the body and can 
readily be considered a “virtual organ” that is vital to human and animal health. 
Members of this microbial community harbor genes not found in eukaryotic cells, 
allowing them to produce and break down substances needed by the host. In fact 
the microbiome is ≥ 150-times larger than the human genome. Moreover, GI 
bacterial community is critical for proper development of both GI tract and immune 
tissues, and for providing nutrients to host cells in the form of short chain fatty acids. 
The GI microbiota is also responsible for ensuring that the immune system is 
tolerant towards the resident microbial species as well as preventing GI colonization 
of potential pathogens.  
GI microbial communities are very dynamic, and their composition can be 
altered significantly by variety of changes (i.e., dietary patterns, antibiotic use, 
infection, etc.). Unfortunately, these alterations in the composition of function of the 
GI microbiota can have serious consequences for that host.  The microbiota has 
been implicated in many diseases, including obesity, diabetes, metabolic syndrome, 
and the disease that was the inspiration of this dissertation—inflammatory bowel 
disease (IBD). IBD is an umbrella term that encompasses both Crohn’s disease 
(CD) and ulcerative colitis (UC). First described by Dr. Crohn in 1932, IBD still has 
no cure and is of an unknown etiology.  What is known is that this disease is multi-
factorial, with environmental, genetic, bacterial, and immunological components.  
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The main focus of this dissertation was elucidating the role of the microbiota in IBD. 
One of the most consistent findings regarding the pathogensis of IBD is that the 
microbiota of IBD patients is different compared to healthy controls. The microbiota 
associated with IBD is less diverse, with an increased abundance of Proteobacteria, 
and a reduction in butyrate-producing organisms. These butyrate-producing 
organisms are capable of producing short-chain fatty acids, which are utilized as 
nutrients by the gastrointestinal epithelium.  
Environmental factors are also known to contribute to the induction of IBD; 
one of which is the association of antibiotic usage and subsequent IBD development. 
Most of the research regarding this association is through recall response surveys of 
patients indicating past antibiotic usage. In chapter 2, two groups of mice, one with a 
limited microbiota (i.e., the eight members of the altered Schaedler flora) and one 
with a conventional (i. e, hundreds of microbial species) microbiota were 
administered ampicillin to determine the effect of antibiotic usage on the severity of 
mucosal inflammation subsequent to a colitic insult. Those mice with the limited 
microbiota had increased inflammation revealed through the increased production of 
pro-inflammatory cytokines and chemokines and the increased fluorescence 
intensity measured using the inflammatory probe. The conventional mice, exhibited 
less inflammation but instead develop metabolic syndrome, which was not seen in 
the mice with the limited microbiota.  
Overall, this study revealed that having a limited microbiota (such as seen 
with IBD patients after diagnosis) causes the community to be unstable and be more 
susceptible to perturbations resulting in increased inflammation. This study also 
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implicated the presence of a normal microbiota in a host with mild inflammation can 
lead to the induction of metabolic syndrome. Future studies with this model could 
include further elucidation of the role of the microbiota in the development of 
metabolic syndrome in the conventional mice. Other parameters, such as serum 
fatty acid content, glucose levels, and insulin tolerance, should be measured to 
accurately diagnose the condition. Additional work using a restricted calorie diet as 
well as modulation of the microbiota through selected depletion of specific members  
should also be examined to identify if the mice can recover from metabolic syndrome. 
Other studies could be performed where conventional microbiota mice are fed high-
fat versus high-carbohydrate versus high-protein diets to determine the effect diet 
has on the development of the disease. Because these diabetes biomarkers were 
measured from the serum, chronological samples could be taken during the study to 
determine exactly at what point the biomarkers associated with  metabolic syndrome 
appear. Future studies capitalizing on the results from the mice with the limited 
microbiota could involve manipulation of the microbiota through the use of pro- and 
prebiotics to overcome the shortcomings that are associated with the reduced 
microbial diversity.  
One of the frustrating aspects for patients with IBD is that there is no cure. 
There are many treatment options available to help the patient achieve remission, 
but most are immunosuppressive and not without severe side effects. One facet of 
medicine that is gaining popularity is the use of complementary and alternative 
medicine (CAM), including herbal supplements. These can be purchased over the 
counter and are unfortunately not tightly regulated in regards to purity and content. 
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Patients, however use these products because they are perceived as safer than 
conventional therapies because they are natural. However, these compounds can 
have both anti-inflammatory and/or anti-bacterial properties and should be used with 
caution. The focus of chapter 3 was to identify the potential therapeutic actions of 
two botanical extracts on the severity of disease in a DSS-induced model of colitis. 
The botanicals, P. vulgaris and H. gentianoides, have been shown to possess anti-
bacterial and anti-inflammatory potential in vitro.  In the study discussed in chapter 3, 
mice with a limited microbiota were colonized with H. bilis and then orally treated 
with either botanical extract for seven days prior to the administration of DSS. At the 
end of the study, H. gentianoides exhibited anti-bacterial activities in vivo and may 
have also displayed some anti-inflammatory effects as well. P. vulgaris treatment 
correlated with the increased the production of several pro-inflammatory 
cytokines/chemokines by the host. Those that were increased are associated with 
the chemotaxis and trafficking of neutrophils and eosinophils; however, no 
differences in the macroscopic or microscopic disease scores were observed 
between mice treated with P. vulgaris versus the vehicle controls. Treatment with H. 
gentianoides significantly reduced 50 % of the microbial community compared to the 
mice given P. vulgaris and also seemed to diminish cecal inflammation as measured 
by the fluorescence intensity of the inflammatory probe. The effect of the H. 
gentianoides treatment on the microbiota was similar to what was seen in the mice 
given ampicillin. However, H. gentianoides also contained anti-inflammatory 
properties, which allowed for those mice to not have the increased severity of 
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disease seen in the limited microbiota mice given ampicillin and then given the colitic 
insult 
Future studies for this project should include identifying and isolating the 
specific compounds associated with the anti-bacterial and anti-inflammatory effects 
of H. gentianoides. The extracts used in this study were whole ethanolic extracts. 
Fractionating the extracts and then repeating the study may lead to the identification 
and isolation of the compounds responsible for the anti-bacterial and anti-
inflammatory effects associated with H. gentianoides treatment. Additionally, H. 
gentianoides may be a promising treatment for the metabolic syndrome mouse 
model described in chapter 2, as its anti-bacterial and anti-inflammatory effects may 
prevent the onset of the metabolic syndrome in mice with a conventional microbiota.  
As previously mentioned, the microbiota of IBD patients is significantly altered 
compared to healthy controls. One of the main areas of IBD research is trying to 
decipher whether this microbial change is due to the inflammation associated with 
the disease or if the change in the microbiota contributes to and accelerates the 
inflammation. This is the topic of interest in chapter 4 of this dissertation. In chapter 
4, IL-10-/- mice, which spontaneously develop colitis, were followed temporally to 
determine both inflammatory and microbial changes over time concomitantly. Initially, 
there were no clinical signs of disease, and the IL-10-/- mice gained weight in a 
similar pattern to the wild type controls up until 19 weeks of age. At that point, the IL-
10-/- mice precipitously lost weight and had to be removed from study. During the 
course of the study, mice were necropsied at predetermined time points, with the 
first time point at 4 weeks of age. At this early time point, eight pro-inflammatory 
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cytokines were significantly elevated compared to the later time points (weeks 7, 19, 
12, and 19).  The microbial community in the IL-10-/- mice at the earliest time point 
(between weeks 4 and 7) had a significant decrease in many beneficial organisms 
such as Roseburia spp., and Eubacterium spp. In the wild type mice, the opposite 
trend was observed as beneficial organisms increased in number during this time. At 
week 19, there was also another increase in pro-inflammatory cytokine secretion, 
predominantly IL-17 and G-CSF. This change was accompanied by a significant 
increase in members of the Proteobacteria. The results indicate that, in this model of 
colitis, host inflammation drives the microbial changes, decreasing the abundance of 
beneficial organisms and creating an environment that promotes the proliferation of 
Proteobacteria, which have been associated with IBD. Future studies utilizing this 
model should be aimed at correcting the microbial changes that succeed the 
inflammation. This could potentially be achieved by colonizing the mice with one of 
the beneficial bacteria found to be decreased early in the study. Roseburia spp. 
would be a good choice, as it produces butyrate, which may help to offset the 
inflammatory response of the host. Other studies could include cross fostering       
IL-10-/- pups to wild type dams and then following disease development. It is possible 
that IL-10-/- pups are being colonized with a dysbiotic microbiota from their dam, who 
likely has chronic GI inflammation. By initially colonizing these pups with a more 
diverse microbiota, the development of disease may be delayed or ameliorated. 
Lastly, an experiment where exogenous IL-10 is administered to IL-10-/- mice could 
be performed to determine if the microbiota of these mice change over time in the 
absence of inflammation.  
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In summary, the research presented in this dissertation advances our 
understanding of how the microbiota helps maintain the health of the host. 
Perturbations that disrupt the community can exacerbate the host response to 
inflammatory insults, indicating that the bacterial community of the gut exerts a 
cytoprotective effect on the host in addition to the nutritional benefits. By 
understanding exactly how these processes interconnect, future research efforts can 
be aimed at modulating the microbiota in a more favorable direction, thereby 
dampening the inflammatory process. These modulations might include dietary 
manipulations as well as feeding probiotics, prebiotics, and even botanical extracts. 
Using well designed experimental models to elucidate the dynamics of a stable 
microbial community, as the ones used in the studies outlined in this dissertation, 
may lead to the development of novel strategies and therapies that can be ultimately 
translated into treatments to improve GI health.   
 	  	  
